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Abstract 
Alterations in the genetic capacity for cobamide biosynthesis have been identified as 
potentially critical in the evolution of Mycobacterium tuberculosis from a putative 
environmental ancestor. Moreover, recent studies have implicated cobamide 
biosynthesis pathway genes in the adaptation of the bacillus to intracellular 
pathogenesis. Although mycobacteria retain essential biochemical reactions that 
require cobamides, the specific role of these co-factors during tuberculosis (TB) 
disease remains unresolved. This thesis aimed to examine the production, uptake, and 
utilization of cobamides in mycobacteria using M. smegmatis as a model. To this end, 
the genetic capacity for de novo production and uptake of cobamide in host-associated 
and environmental mycobacteria was assessed, followed by direct validation in M. 
smegmatis. A combination of genetics, gene expression analysis, live-cell time-lapse 
microscopy and targeted metabolite and protein analysis via mass spectrometry (MS) 
was then employed to investigate cobamide riboswitch-dependent regulation of 
methionine biosynthesis in M. smegmatis. Results indicated that, in wild-type M. 
smegmatis, de novo cobamide biosynthesis ensured constitutive repression of metE, 
the gene encoding the mycobacterial cobalamin-independent methionine synthase. 
Owing to this repression, metH, a gene encoding the cobalamin-dependent methionine 
synthase, was found to be conditionally essential for bacillary replication in vitro. Drug 
susceptibility testing to investigate the link between cobamides and the intrinsic 
resistance to anti-folate antibiotics confirmed novel mycobacterial vulnerabilities in 
cobamide-related methionine metabolism, indicating that the outcomes of cobamide-
dependent regulation may have relevance to mycobacterial pathogenesis and drug 
discovery. In contrast to M. tuberculosis, which was previously shown to transport 
exogenous CNCbl readily, M. smegmatis poorly assimilated exogenous co-factor 
despite the presence of multiple putative cobamide transporters. However, uptake was 
enhanced in a mutant requiring CNCbl for growth. Elucidating the factors which 
regulate cobamide biosynthesis and co-factor utilization in M. smegmatis, an 
environmental mycobacterium, might provide a lens through which to consider the 
differential regulation and utilization of cobamides in M. tuberculosis, an obligate 
pathogen with a limited host range. 
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1 General Introduction 
1.1 Tuberculosis (hereafter referred to as TB) 
Formerly known as phthisis or consumption, TB claimed nearly 1.3 million lives in 
2017, during which the estimated number of new cases of TB was 10.0 million people, 
according to the 2018 Global TB Report released by the World Health Organization 
(WHO) (World Health Organization, 2018). The same report further highlights that 
TB cases have been declining by approximately 2% since 2000, due to the use of anti-
TB drugs and systematic strategies to manage the disease. This recent reversal of TB 
trends, however, belies an ancient relationship this disease shares with humans (Comas 
et al., 2013; Bos et al., 2014; Galagan, 2014; Supply & Brosch, 2017; Brynildsrud et 
al., 2018; Gagneux, 2018). Despite this shared history, the bacterium that causes TB 
was first described only 150 years ago by Jean-Antoine Villemin, who also 
demonstrated at the time that TB was a transmissible disease (Daniel, 2015). Building 
on this work, the Robert Koch went on to confirm in 1882 that Mycobacterium 
tuberculosis, so-named because of its fungus-like appearance in liquid culture 
(forming rod-shaped heaps with protective layers), was the etiological agent of TB 
(Cambau & Drancourt, 2014; Barberis et al., 2017). A century of TB studies since 
Koch’s discovery have now revealed that this disease is caused by a group of closely 
related mycobacteria, collectively known as the M. tuberculosis complex (MTBC) 
(Tientcheu et al., 2017). In humans, TB is caused by M. tuberculosis sensu stricto and 
M. africanum, while animal TB-causing MTBC strains include M. bovis, M. microti, 
M. pinnipedii, M. orygis, M. suricattae, M. mungi, M. caprae, and a chimpanzee isolate 
(Hershberg et al., 2008; Boritsch & Brosch, 2016; Gagneux, 2018). For succinctness, 
the human TB-causing MTBC organisms are referred to as M. tuberculosis in this 
thesis, unless there is a specific need to distinguish M. africanum. 
Koch’s discoveries laid the foundation for the development of TB vaccines and four 
decades later, in 1921, the bacille Calmette-Guérin (BCG) vaccine, comprising a 
preparation of live attenuated Mycobacterium bovis, was pioneered. The BCG vaccine 
offers variable protection against TB. Nevetheless, it remains the only vaccine 
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currently approved by WHO, while a number of promising candidates are at various 
phases of clinical development (Voss et al., 2018).  
The identification of the etiological agent of TB also paved the way for rational 
treatment. Initial efforts involved quarantine-based approaches, whereby patients were 
nursed in isolated sanatoria, some located at high altitudes to provide continuous fresh 
air and abundant sunshine (Greenhalgh & Butler, 2017). The first use of antibiotics 
against TB began in the latter half of the 1940s, followed by a rapid expansion of 
effective antibiotics including streptomycin (STR), para-aminosalicylic acid (PAS), 
isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB) and rifampicin (RIF), all of 
which have different mechanisms of action. INH, PZA, EMB and RIF continue to be 
used today as first-line anti-TB drugs (World Health Organization, 2018). A 
significant obstacle to TB treatment is that the drugs must be taken in combination 
consistently over a period of six months, and preferably under direct observation by a 
health care provider. This TB control strategy, first promulgated by WHO in 1994, is 
called DOTS (directly-observed therapy, short course) (World Health Organization, 
1994). Significant gains in TB diagnosis and treatment have been made using DOTS, 
most notably in countries where health care systems are efficient (Bloom et al., 2017). 
Lapses in adherence to the relatively long treatment program undermines DOTS 
increasing the probability of undesirable outcomes such as disease recurrence, failure 
to control TB transmission and multi-drug resistance, the latter of which demands 
longer, and more complex and expensive regimens (Bloom et al., 2017; Esmail et al., 
2018). 
The emergence of multi-drug resistant M. tuberculosis strains and co-infection with 
the human immunodeficiency virus (HIV), reignited interest in anti-TB drug 
discovery, which had slowed in the 1970s (Vasava et al., 2017). The publication of the 
first complete whole-genome sequence of M. tuberculosis in 1998 (Cole et al., 1998) 
provided critical genome-based insights into the biology of the bacterium and 
mechanisms of drug-resistance, aiding in disease diagnosis and drug discovery efforts 
(Quan et al., 2018). Gradually, the number of potential drug candidates entering the 
discovery pipeline has grown, with Bedaquiline being the latest candidate to be 
approved and Delamanid undergoing clinical trials (https://www.newtbdrugs.org; 
(Esmail et al., 2018)). Although knowledge of TB infection, transmission, detection, 
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therapy and drug-resistance is accumulating, high global prevalence indicates that 
much work remains to be done to eradicate TB. Figure 1.1 shows the global map of 
TB prevalence, with the worst affected continents including Africa and Asia. 
 
Figure 1.1: Top 30 countries with the highest burden of TB, MDR-TB and HIV-TB co-
infection in 2017. The disease burden in the three categories is expressed as the absolute 
number of incident cases or in some instances, the number of incident cases per capita 
(asterisks). All of the worst-affected nations are found in Africa and Asia. The 14 countries in 
the central diamond have the highest rates in all three categories. Source: (World Health 
Organization, 2018). 
 
At the time of his discovery, Robert Koch described the aerosol transmission of M. 
tuberculosis from sick to healthy pigs (reviewed in (Cambau & Drancourt, 2014)). A 
similar model of transmission is postulated to occur in humans, whereby the key steps 
involved include (1) the exit of bacilli from the respiratory tract of an individual with 
active TB as aerosolized droplets; (2) the survival of the bacteria in aerosol form 
outside of the original host; (3) inhalation of aerosols by a new host; (4) evasion of 
immune defences, and; (5) establishment of new infection (Turner et al., 2017). 
Although this model assumes that humans are the exclusive reservoirs of M. 
tuberculosis, genomic studies suggest that the MTBC had a putative environmental 
ancestor (Supply et al., 2013). Gradually, this putative ancestor gained human 
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virulence through a possible combination of loss or acquisition of gene function and 
fixation of single nucleotide mutations (SNMs) (Supply et al., 2013). It is believed that 
these events drove the evolution of M. tuberculosis as an obligate human pathogen 
(Supply et al., 2013; Orgeur & Brosch, 2018). In the most recent review on MTBC 
evolution, Sebastien Gagneux compared genomes of MTBC and non-tuberculous 
mycobacteria (NTM) and presented evidence of step-wise loss and/or acquisition of 
genomic features that have shaped the lifestyle of M. tuberculosis as a human pathogen 
(Gagneux, 2018). It is expected that further work in this area will shed more light into 
the evolution of mycobacteria, and the specializations that make M. tuberculosis a 
successful pathogen. 
1.2 The evolution and global spread of M. tuberculosis 
The MTBC share a hypothetical most recent common ancestor (MRCA) with 
Mycobacterium canettii, a highly recombinogenic, smooth-colony-forming 
mycobacterium which was isolated in the 1960s by George Canetti from lymph nodes 
of patients from the horn of Africa (van Soolingen et al., 1997; Gutierrez et al., 2005). 
Because of their unique colony morphology, M. canettii and M. canettii-like strains 
are also known as “smooth tubercle bacilli” (STB). Some STB strains can cause fatal 
disease (Koeck et al., 2011; Blouin et al., 2014), but they show reduced persistence in 
infection models (Supply et al., 2013); moreover, to date, no human-to-human 
transmissions of STB have been reported. 
Routine applications of whole-genome sequencing (WGS) tools have now made 
possible genomic analyses of M. canettii to elucidate the molecular events that might 
have enabled M. tuberculosis to transition to humans from an environmental reservoir. 
MTBC and STB strains share approximately 3.9Mb of their genomes, with STB 
bearing on average 900 additional genes relative to M. tuberculosis (Supply et al., 
2013; Boritsch et al., 2014). Of these extra genes, only 1% are common to all STBs, 
probably due to high rates of interspecies gene acquisition by horizontal gene transfer 
(HGT), characteristic of active association with an (as-yet unknown) environmental 
reservoir (Blouin et al., 2014; Boritsch & Brosch, 2016; Gagneux, 2018). In contrast 
to the high genetic diversity of STB, a pattern of clonal expansion and little to no 
genetic recombination is observed in clinical isolates of M. tuberculosis (Comas et al., 
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2013). The extensive genetic variability of M. canettii strains relative to M. 
tuberculosis places STB at an earlier branching point before MTBC emergence. It is 
presumed that MTBC progenitor strains gradually acquired advantageous genetic 
features, including loss or acquisition of genes and the development of distinct host-
preferences, which have contributed to their pathoadaptation (Figure 1.2) (Boritsch et 
al., 2014; Orgeur & Brosch, 2018). 
One of the genes that has been lost in MTBC, but is present in STB, is the cobamide 
biosynthesis gene, cobF, encoding a precorrin-6a synthase homologue (Figure 1.2) 
(Supply et al., 2013; Blouin et al., 2014; Boritsch et al., 2014). Although there is no 
single organism in which the full set of cobamide biosynthesis genes is known or fully 
characterized, evidence put together from studies in various organisms  suggest that 
cobamide biosynthesis is energetically costly, requiring nearly 30 enzyme-catalysed 
reactions (Mattes et al., 2017). The loss of cobF might explain the lack of de novo 
cobamide biosynthesis in MTBC strains (Gopinath, Venclovas, et al., 2013) although 
it has been suggested that alternative enzymes could play compensatory roles 
(Gopinath, Moosa, et al., 2013). To date, however, there is no experimental evidence 
that any member of the MTBC produce cobamides. It is likely, therefore, that the lack 
of cobamides in MTBC strains has forced these mycobacteria to depend on their host 
for these essential co-factors. Evidence of differential production of cobamides by STB 
and MTBC would strengthen this argument and, potentially, implicate cobamide 
metabolism in the evolution of MTBC pathogenicity. 
Another important step in the evolution of MTBC virulence is speculated to have been 
the loss of the pks5 gene, encoding a polyketide synthase involved in the production 
of lipooligosaccharides (LOS), a mycobacterial glycolipid (Figure 1.2). The smooth-
colony morphology of STB is a result of the expression of Pks5, and experimental 
evidence shows that recombination events in this gene locus result in rough-colony 
morphology (Boritsch, Frigui, et al., 2016). Interestingly, Boritsch et al. also found 
that the LOS-deficient rough-colony variants had increased fitness and virulence in 
infection models compared to smooth-colony morphotypes. In addition, the surface 
modification following pks5 recombination was shown to alter MTBC recognition by 
the host’s immune system (Boritsch, Frigui, et al., 2016). Taken together, these genetic 
modifications appear to have contributed to MTBC virulence. 
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Figure 1.2: Genetic adaptations in the evolution of virulence in the M. tuberculosis 
complex. The MTBC mycobacteria share a hypothetical most recent common ancestor with 
M. canettii-like STB. The deletion of cobF (encoding a precorrin-6a synthase) and pks5 
(encoding a polyketide synthase) and insertion of pe_pgrs33 (encoding an uncharacterized PE 
family protein) are some of the key molecular events in the evolution of MTBC from a 
recombinogenic M. canettii-like ancestor. The RD9 deletion gave rise to M. africanum L5 and 
subsequently, M. africanum L6 emerged carrying deletions in RD7, RD8 and RD10. Animal-
adapted strains share a recent common ancestor with M. africanum L6. The RD9-deleted 
branch of MTBC have also accumulated mutations in phoP (encoding a two-component 
system response transcriptional positive regulator). The L1 and L7 lineages diverged before 
the emergence of modern lineages that have the M. tuberculosis-specific deletion (TbD1). The 
geographical locations where a strain is most prevalent are shown in brackets. Molecular 
events and evolutionary branching-off points are inferred from (Boritsch & Brosch, 2016; 
Gagneux, 2018; Orgeur & Brosch, 2018). CpnT – channel protein with necrosis-inducing 
toxin; RD – region of difference; mic – microti.  
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The loss of genes previously encoded by the STB ancestor is not the only feature 
marking the transition to virulence. At the time of branching from the hypothetical 
most recent common ancestor (MRCA), MTBC strains possibly also acquired MTBC-
specific genes such as the PE_PGRS33 gene, encoding an uncharacterized PE family 
protein (Figure 1.2) (Boritsch & Brosch, 2016; Boritsch, Khanna, et al., 2016). 
PE_PGRS33 belongs to a subfamily of mycobacteria-specific proteins designated as 
PE, because of a conserved Pro-Glu (PE) motif at residues 7-8 in their N-terminal 
regions, and an enriched C-terminal polymorphic GC-rich sequence (PGRS) motif 
(Bottai & Brosch, 2009). Together with the PPE proteins, which have a characteristic 
Pro-Pro-Glu (PPE) motif at residues 7-9 in the N-terminal region, the PE-PPE proteins 
collectively encode approximately 10% of the M. tuberculosis genome and 4% of the 
total proteome (Cole et al., 1998; Gey van Pittius et al., 2006). The functions of most 
PE and PPE proteins remain unknown but evidence of co-evolution with the ESX 
secretion system and surface localization has led to notion that these proteins are 
involved in virulence and immunogenicity (Gey van Pittius et al., 2006; Delogu G, 
Cole ST, 2008; Sampson, 2011; Vordermeier et al., 2012; Gröschel et al., 2016; 
Brennan, 2017). Because of its localization at the mycobacterial outer membrane, 
PE_PGRS33 is reportedly involved in mycobacterial cell wall stability and in host-
pathogen interactions (Zumbo et al., 2013). 
Another MTBC-specific gene that was acquired during evolution encodes the C-
terminal domain of CpnT, a mycobacterial channel protein with necrosis-inducing 
toxin that induces necrosis in mammalian macrophages (Danilchanka et al., 2014, 
2015; Sun et al., 2015). The N-terminal domain of CpnT is similar between STB and 
MTBC, but the C-terminal domain, which comprises the tuberculosis necrotizing 
toxin (TNT) (Sun et al., 2015), is different. This difference implies that the acquisition 
of the C-terminal domain occurred after the separation of MTBC strains (Figure 1.2). 
Apart from PE_PGRS33 and CpnT, which have been linked experimentally to 
virulence, there are three other MTBC-specific genes (encoded by homologues of 
Rv0394c, Rv2023c, and Rv3190c) that were acquired during MTBC evolution, but 
which remain to be characterized (Boritsch & Brosch, 2016).  
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As MTBC emerged, distinct host-preferences seem to have also developed, resulting 
in animal-adapted strains and human-adapted lineages (Figure 1.2) Studies have 
revealed that selected deletions in regions of difference (RD) are consistent with 
independent evolution of animal- and human-adapted MTBC (Mostowy et al., 2002; 
Pym et al., 2002; Supply et al., 2013; Blouin et al., 2014). There are seven lineages of 
the human-adapted MTBC, which are designated as lineages 1 through 7 (L1–L7) 
(Figure 1.2). Of the 7 lineages of human-adapted MTBC strains, M. africanum falls 
into L5 and L6, which are the oldest lineages. This is followed in chronological order 
by L1 and L7, which subsequently gave rise to L2 (Beijing strain), L3 and L4 (Euro-
American strain). These last three are considered the most modern M. tuberculosis 
lineages and have a characteristic M. tuberculosis-specific deletion (TbD1) (Figure 
1.2). Lineages L2 and L4 are globally widespread, while the rest of the lineages have 
remained largely geographically distinct (Brosch et al., 2002; Merker et al., 2015; 
Stucki et al., 2016). L1 is most prevalent in East Africa, South India and South East 
Asia; L2 in East Asia; L3 in North India; L4 in the Americas; L5 & L6 in West Africa; 
and L7 in East Africa. The absence of RD9 is a key distinguishing feature of M. 
africanum from the other human-adapted lineages (Figure 1.2). The RD9-deleted 
branch of the MTBC also have accumulated mutations in phoP, encoding a two-
component system response transcriptional positive regulator involved in virulence 
(Gonzalo-Asensio et al., 2014). Animal-adapted MTBC share a most recent ancestor 
with M. africanum L5 and L6, with additional deletions in RD7, RD8 and RD10 
defining the emergence of M. pinnipedii (seal), M. orygis (oryx) and Chimpanzee 
bacillus (Figure 1.2). Subsequent RD4 deletion gave rise to M. bovis (cattle), while 
M. caprae (goat) emerged independently due to the loss of RD12 and RD13. The RD1 
deletion occurred independently in M. microti (rodents), M. mungi (mongoose) and 
Dassie bacillus genomes (Figure 1.2).  
According to most recent estimates, 25% of the total world population is infected with 
TB (Houben & Dodd, 2016). The regions between Eastern Africa and South-East Asia 
are often cited as the epicentre of an outward early spread of MTBC to other parts of 
the world, in parallel with an “out-of-Africa” human dispersal hypothesis (Hershberg 
et al., 2008; Wirth et al., 2008; Comas et al., 2013; O’Neill et al., 2017). A key piece 
of evidence supporting this view is the observation that all surviving M. canettii 
strains, and all animal- and human-adapted MTBC lineages, have been found in 
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several parts of Africa (Coscolla et al., 2013; Comas et al., 2015; Nebenzahl-
Guimaraes et al., 2016). A recent analysis of lineage 4 (L4), the most widely-spread 
lineage worldwide, revealed an “out-of-Europe” global expansion corresponding to 
European colonization of Africa and the Americas (Brynildsrud et al., 2018). These 
patterns are emblematic of the intimate relationship between M. tuberculosis and 
humans. The ease of modern human movement provides opportunities for previously 
geographically distinct lineages to mix according to the human-to-human transmission 
model.  
Yet, despite increased intercontinental human migration, it is still unclear why some 
lineages are more globally spread (viz., L2 & L4) while others remain restricted. 
Interestingly, the most distantly-related members of the MTBC differ by roughly 2000 
SNMs (Coscolla & Gagneux, 2014), which when juxtaposed with the approximately 
65000-SNM difference in STB (Supply et al., 2013), indicate that MTBC are very 
closely related. Some of these SNMs, such as the phoP loss-of-function mutations in 
lineages L5, L6 and the animal-adapted strains, are associated with fitness loss 
(Gonzalo-Asensio et al., 2014). The Beijing strain (L2) has been reported to be hyper-
virulent, more transmissible and more amenable to acquiring drug resistance, although 
the molecular events underlying this phenomena are unclear (Lopez et al., 2003; Rad 
et al., 2003; Mokrousov, 2013; Merker et al., 2015; Boritsch & Brosch, 2016). 
1.3 M. tuberculosis pathogenesis 
The human-to-human transmission model of TB is anchored by three simplistic 
components: (1) an infected host, (2) a transmission route (air) and (3) a new host. The 
outcome of infection can vary depending on the immune state of the new host and 
fitness of the infecting bacillus, or a combination of these factors (Drain et al., 2018; 
Lin & Flynn, 2018). Consequently, a newly-infected individual may remain 
asymptomatic after exposure, a (presumably) noncontagious phase of disease known 
as latent M. tuberculosis infection (LTBI), which is characterized by absence of 
clinical symptoms despite a positive immunologic test (Drain et al., 2018; Lin & 
Flynn, 2018). This scenario is likely what happens in most cases of exposure because 
only a small fraction of new infections lead to active, transmissible disease (Vanderven 
et al., 2016; Lin & Flynn, 2018). The progression to active disease can be accelerated 
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in immunocompromised individuals such as those co-infected with the human 
immunodeficiency virus (HIV) and type-2 diabetes. Alcohol abuse, cigarette smoking, 
malnutrition, and repeated exposure to M. tuberculosis in overcrowded living 
conditions, may also lead to poor control of infection. 
Once inhaled, aerosolized bacilli are encountered by alveolar macrophages, which play 
a frontline role in sterilization of the invading M. tuberculosis (Figure 1.3) (Srivastava, 
Ernst & Desvignes, 2014). M. tuberculosis can also infect other cell types including 
dendritic cells, neutrophils, adipocytes, natural killer (NK) cells, and epithelial cells 
(Srivastava, Ernst & Desvignes, 2014; Randall et al., 2015). Furthermore, TB is not 
restricted to lungs; in fact, extrapulmonary TB makes up between 20–25% of notified 
new infections annually (World Health Organization, 2018). Therefore, differences 
can be expected in the metabolic interactions between bacilli and host cells in different 
microenvironments. However, the macrophage response has been most extensively 
studied and is therefore the best understood. Several mycobacterial pattern recognition 
receptors on the surface of macrophages bind mycobacterial lipids leading to 
phagocytosis, a process which captures bacilli in vacuoles called a phagosomes 
(Kaufmann, 2001). M. tuberculosis can escape or subvert host immune responses, and 
bacillary replication can occur within individual alveolar macrophages (Figure 1.3) 
(Sun et al., 2015; Uribe-Querol & Rosales, 2017). However, as more macrophages 
take up the mycobacteria, they become activated and a cascade of immune responses 
begins to slow down intracellular bacterial growth. Initially, there is an influx of trace 
metals that are toxic to mycobacteria into the phagosome (Figure 1.3). It has also been 
shown that trace elements that can be used by mycobacteria as micronutrients are 
sequestered (Neyrolles et al., 2015). As the macrophage matures, it fuses with a 
lysosome, causing the internal pH to shift from around pH 6.5 to pH 4.5 (Figure 1.3). 
M. tuberculosis, however, can block normal acidification of phagosomes by 
preventing fusion with lysosomes (Vergne et al., 2005), which maintains the pH at 
levels that are permissive to mycobacterial replication. 
The macrophage maturation process is also accompanied by a superoxide burst, which 
further slows down M. tuberculosis replication (Russell, 2011). Still, bacilli can 
continue to replicate within the macrophage while resisting the oxidative stress (Ehrt 
& Schnappinger, 2009). In addition to macrophage activation, lymphocytes and lipid-
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rich foamy macrophages are recruited, forming the granuloma, a mass of cells which 
encase the infected macrophage cell (Figure 1.3) (Guirado & Schlesinger, 2013). 
Ultimately, the granuloma develops a necrotic core and traps M. tuberculosis in a 
hypoxic, lipid-rich environment. At this point, M. tuberculosis can enter a 
metabolically “quiescent” state characterized by slowed replication (Tailleux et al., 
2008). If M. tuberculosis survives this onslaught of immune responses,  bacilli can 
ultimately break out of the caseous granuloma into the respiratory cavity, where they 
can be expelled and transmitted within aerosols (Figure 1.3) (Rhee et al., 2011; Gouzy 
et al., 2014). Evidently, this model oversimplifies granuloma behaviour by implying 
that the granulomatous response is either sterilizing or permissive, leading to LTBI. 
However, recent studies suggest a much more complex interaction between bacilli and 
macrophage, characterized by a high degree of diversity of responses depending on 
the lineage and sterilization efficacy of individual granulomas (Lin et al., 2014; Huang 
et al., 2018; Hunter, 2018). 
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Figure 1.3: A schematic of M. tuberculosis pathogenesis. 1. Aerosolized bacilli inhaled by a 
new host are recognized by pattern recognition receptors (PRR) on the surfaces of alveolar 
macrophages and phagocytosed. The phagosome then undergoes a process of maturation 
which includes acidification, fusion with lysosomes, accumulation of toxic trace metals, and 
release of reactive nitrogen intermediates (RNI) and reactive oxygen species (ROS) that slow 
down growth and kill invading bacilli. M. tuberculosis can counter host immune responses at 
various steps of this process, including blocking phagosomal maturation, endosome-
phagosome fusion, and phagolysosome fusion. 2. Granuloma formation includes the 
recruitment of foamy cells and neutrophils to the site of infection. 3. Granuloma maturation 
leads to caseation, trapping bacilli inside a lipid-rich centre. 4. Disease reactivation due to the 
breaking-out of bacilli into the respiratory passage, where they are expelled as aerosolized 
droplets and transmitted to new hosts. 
 
1.4 Cobamide-related metabolism in TB disease 
In the context of TB disease, bacilli and the host cells require energy for normal 
metabolic functions and are often pitted against one another for the same resources in 
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discrete niches of infection. For the purposes of this thesis, only those aspects relating 
to cobamide metabolism are briefly highlighted in this section.  
As the primary environment for M. tuberculosis, the granuloma is rich in high-energy 
fatty acids and cholesterol, which are broken down by bacilli to generate energy and 
precursors for polyketides and phospholipids (Van der Geize et al., 2007; Peyron et 
al., 2008; Daniel et al., 2011; Beste et al., 2013; Lee et al., 2013; Quadri, 2014; 
Lovewell, Sassetti & VanderVen, 2016). M. tuberculosis expresses two enzymes that 
are required to utilize acetyl-CoA derived from fatty acids: isocitrate lyase (ICL) and 
phosphoenolpyruvate carboxykinase (PEPCK) (Muñoz-Elías et al., 2006; Marrero et 
al., 2010; Eoh & Rhee, 2014). The consumption of cholesterol yields propionyl 
coenzyme A (PrP-CoA), which is converted by 2-methylcitrate synthase (PrpC; EC 
2.3.3.1), to 2-methylcitrate, a noxious intermediate that inhibits gluconeogenesis 
(Horswill, Dudding & Escalante-Semerena, 2001; Rocco & Escalante-Semerena, 
2010). The toxicity of 2-methylcitrate is resolved by converting this intermediate to 
pyruvate and succinate, which enter the tricarboxylic acid (TCA) cycle via the 
glyoxylate shunt (McKinney et al., 2000; Eoh & Rhee, 2014). Alternatively, PrP-CoA 
is first converted to methylmalonyl coenzyme A (MM-CoA) , which is further 
converted to succinyl coenzyme A via the MM-CoA pathway. The MM-CoA route 
involves the cobalamin-dependent enzyme, (R)-methylmalonyl-CoA mutase (MCM; 
EC 5.4.99.2) (Savvi et al., 2008). Another way in which cells protect against 2-
methylcitrate toxicity is by utilizing PrP-CoA and acetyl coenzyme A as building 
blocks for cell envelope components: phthiocerol dimycocerosates (PDIM), 
polyacylated trehaloses (PATS) and sulfolipids (SL), which are associated with 
mycobacterial virulence (Russell et al., 2010; Lee et al., 2013; Lovewell, Sassetti & 
VanderVen, 2016). In one study using a mouse infection model, M. tuberculosis 
mutants in which the 2-methylcitrate pathway was disabled were able to establish 
infection, presumably by engaging the MM-CoA pathway to overcome 2-
methylcitrate toxicity (Muñoz-Elías et al., 2006). These findings raised the possibility 
that bacilli could use host-derived cobamides to enable activity of the MCM enzyme.  
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1.5 Cobamide chemical structure 
Cobamides are complex cyclic tetrapyrrolidine that contains a centrally-chelated 
cobalt ion coordinated equatorially by four nitrogens donated by the nitrogen atom of 
each pyrrole ring and axially by an upper and a lower nitrogenous or phenolic base 
(Figure 1.4A). The upper axial face is occupied by an alkyl ligand, represented as an 
“R-group,” (Figure 1.4A) from which the corresponding cobamide form derives its 
common name. If “R” is a cyano group, the cobamide is referred to as cyanocobamide 
(CNCba); if a deoxyadenosine group, then adenosylcobamide (AdoCba); if a methyl 
group, then methylcobamide (MeCba); and if a hydroxyl group, then  
hydroxycobamide (HOCba). AdoCba is one of two biologically functional cobamide 
forms and is involved in radical chemistry reactions such as carbon rearrangements, 
dehydrations and deaminations (Halpern, 1985). The other biologically functional 
cobamide form is Co(I)cobamide, in which the cobalt ion is in the +1 state (Co+). 
Co(I)cobamide is involved in methyl transfers and dehalogenation reactions (Koutmos 
et al., 2009; Dassanayake, Cabelli & Brasch, 2013; Payne et al., 2015; Dowling et al., 
2016). Cobalamin is the only cobamide that contains 5,6-dimethylbenzimidazole 
(DMB) as the lower base. The identity of the “R” group also determines the type of 
cobalamin form, whereby the alkyl group is a cyano in cyanocablamin (CNCbl; also 
known as vitamin B12); an adenosyl in adenosylcobalamin (AdoCbl; also known as 
coenzyme B12); a methyl in methylcobalamin (MeCbl) and a hydroxyl in 
hydroxycobalamin (HOCbl). When the nitrogen of DMB is coordinated to the cobalt 
ion, it is referred to as a “base-on” (i.e., DMB-on) configuration (Figure 1.4B). When 
cobalamin-binding proteins interact with the co-factor, they also do so either in the 
“base-on” configuration or in a “base-off” conformation in which DMB has been 
displaced by an amino acid residue. If a histidine is the coordinating residue, the 
interaction is “base-off,” “His-on,” but if a different amino acid is involved, then the 
coordination “base-off,” “His-off” (Figure 1.4B) (Drennan et al., 1994).  
The Co–C bond between the cobalt ion and a coordinating carbon of the R-group 
determines the catalytic reactivity of the cobamide. The Co–C bond undergoes 
different types of cleavage, which alters the oxidation states of cobalt, enabling 
cobamides to act as co-factors in a variety of reactions. For example, in rearrangement 
reactions, homolytic cleavage is required to form reactive, but transient, 
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deoxyadenosyl radical species. In methyl transfer reactions, heterolytic cleavage 
cycles the oxidation state of cobalt between Co3+ and Co+ (Giedyk, Goliszewska & 
Gryko, 2015). The Co–C bond is usually inert in the absence of light but, when excited 
by light, photolysis occurs relatively easily (Weissbach et al., 1960; Jones, 2017; 
Padmanabhan et al., 2017). The versatility of the coordination states between 
cobalamin and proteins and the lability of the Co–C illustrate the broad spectrum of 
cobalamin biochemistry (Parks et al., 2013; Bridwell-Rabb, Grell & Drennan, 2018).  
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Figure 1.4: The chemical structure of a cobamide. A. Cobalamin structure: a corrin ring 
surrounds a centrally-chelated cobalt ion. The cobalt ion is coordinated by an alkyl upper 
ligand (R-group) and 5,6-dimethylbenzimidazole (DMB). The R-group can be occupied by 
cyano- (cyanocobamide), adenosyl- (adenosylcobamide), methyl- (methylcobamide) or 
hydroxyl- (hydroxycobamide) groups. B. On-base/off-base configurations of lower ligand 
coordination. 
 
1.6 Cobamide biosynthesis in mycobacteria 
Although cobamides are required by cells in all domains of life (Nielsen et al., 2012), 
de novo biosynthesis of these molecules is restricted to some bacteria and archaea 
(Zhang et al., 2009; Doxey et al., 2015). Mycobacteria possess most of the genes 
involved in de novo cobamide biosynthesis, except for members of the MTBC which 
are missing cobF as previously discussed in section 1.2 of this chapter. However, the 
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loss of cobF is not the only deficiency in cobamide biosynthetic capacity in the RD9-
deleted lineages (L5, L6). This deletion caused a 5’ truncation of cobL, which occurs 
in an operon with cobM and cobK (Brosch et al., 2002), potentially disrupting function 
of all three genes. It has also been observed that in many clinical isolates of M. 
tuberculosis, potentially inactivating SNMs occur in cobN (Young, Comas & de 
Carvalho, 2015). Interestingly, M. leprae, which has a reduced genome owing to 
extensive decay (Cole et al., 2001), is predicted to either contain pseudogenes or 
entirely lack certain cobamide biosynthetic genes (Rodionov et al., 2003; Zhang et al., 
2009; Gopinath, Moosa, et al., 2013). These genomic insights suggest that M. 
tuberculosis and other pathogenic mycobacteria might have lost the ability to produce 
cobamides and have come to rely on the host for these compounds. 
Aerobic and anaerobic routes exist for the biosynthesis of cobamides, which are 
distinguished by their requirements for molecular oxygen, the timing of the cobalt 
insertion step (which occurs early in anaerobic biosynthesis, and late in aerobic 
biosynthesis), and the mechanism of ring contraction (Warren et al., 2002). As a 
convention, the prefix “cob” designates genes involved in the oxygen-dependent 
process, while “cbi” denotes genes in the oxygen-independent route. It is an 
acknowledged fact that there is confusion regarding the use of these gene prefixes. For 
example, all cobamide biosynthesis genes are prefixed “cob” in P. denitrificans 
whereas in S. typhimurium the prefix “cbi” is used to distinguish genes required to 
synthesise cobinamide, the precursor of cobalamin, from the genes required to convert 
cobinamide to cobalamin, which are prefixed “cob” (Blanche et al., 1995; Raux et al., 
1998; Warren et al., 2002; Mattes et al., 2017). In this thesis, the “cob” prefix is used 
to designate the aerobic pathway, and to differentiate those genes used in the anaerobic 
pathway, the prefix “cbi” is used. The cobalt-containing intermediates of the anaerobic 
pathway are distinguished by the prefix “Co-”; for example, Co-Precorin-6A. Either 
route can be divided into two major steps. The first is corrin ring synthesis while the 
second is the assembly and attachment of the lower base. 
Like siroheme, co-factor F430 and chlorophyll, cobamides are derived from the 
general tetrapyrrole precursor, 5-aminolevulinic acid (ALA), a product of the C-5 
glutamate pathway (Oh-hama, Stolowich & Scott, 1988; Kang et al., 2012). ALA 
undergoes condensation, polymerization, rearrangement and cyclization to form 
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uroporphyrinogen III. Committed cobamide biosynthesis begins when 
uroporphyrinogen III is methylated at C-2 and C-7 to form precorrin-2 (Lawrence et 
al., 1995). This step is catalysed by CysG, a multifunctional S-adenosyl-L-
methionine:uroporphyrinogen III methyltransferase (SUMT). CobA, a smaller SUMT 
sharing structural homology with the catalytically relevant C-terminus of CysG is 
encoded in M. smegmatis. CysG also acts as a precorrin-2 oxidase and a ferrochelatase. 
Another protein, HemD, can also catalyse Uroporphyrin III methylation. M. 
tuberculosis expresses cysG and hemD, both of which have been identified in 
transposon (Tn) mutagenesis screens as independently essential for in vitro growth 
(Griffin et al., 2011; Dejesus et al., 2017). This is likely because in addition to the 
cobamide pathway, the products of the reactions catalysed by the two enzymes are also 
precursors for siroheme and co-factor F430. 
Corrin ring synthesis begins after precorrin-2, and these steps occur differently under 
aerobic and anaerobic conditions. In the aerobic pathway, CobG initiates the ring 
contraction before late-stage cobalt insertion by CobNST, a cobalt chelatase complex 
formed by three enzymes: CobN, CobS and CobT. In the absence of oxygen, CbiX or 
CbiK first catalyse the cobalt insertion step (Moore & Warren, 2012). The two routes 
reunite at the corrinoid adenosylation step which produces cob(II)yrinate a,c,-diamide 
(Warren et al., 2002). The second stage of cobamide biosynthesis, the assembly of 
DMB, can also occur either aerobically or anaerobically (Renz, 1970; Keck, Munder 
& Renz, 1998; Warren et al., 2002; Hazra et al., 2015). Mycobacterial cobamide 
production is discussed in more detail in Chapter 3 of this thesis. 
1.7 Cobamide transport in mycobacteria 
Studies show that treatment outcomes worsened in TB patients suffering from 
pernicious anaemia when regimens that included vitamin B12 supplements were 
prescribed (Ramagopalan et al., 2013). These clinical cases suggest that pathogenic 
mycobacteria might have specialized mechanisms to access cobamides and/or 
precursors as a cost-effective alternative to de novo biosynthesis. 
Accumulating evidence indicates that M. tuberculosis transports cobamides when 
cultured in vitro (Warner et al., 2007; Savvi et al., 2008; Griffin et al., 2012; Lee et 
al., 2013; Boot et al., 2016). This transport is mediated by BacA, an ATP-binding 
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cassette transporter protein encoded by the Rv1819c gene which has also been 
implicated in drug efflux (Gopinath, Venclovas, et al., 2013), hinting that cobamide 
uptake in mycobacteria is unlike that of Gram-negative bacteria which rely on a well-
characterized system consisting of the outer membrane protein, BtuB, the 
transmembrane proteins TonB, ExbB and ExbD, the periplasmic protein, BtuF, and 
the inner membrane complex, BtuCD (Cadieux et al., 2002; Locher, Lee & Rees, 2002; 
Noinaj et al., 2010; Korkhov et al., 2014). Thus, extracellular cobamides are carried 
as precious cargo from one protein to another, into the bacterial cytosol. Hovever, a 
cobamide delivery system inside the bacterial cytosol has not been described and it is 
unknown how cobamide-dependent enzymes find the co-factor. In mammals, an in 
vitro model for the multistep shuttling of food-derived cobamides across intestinal cell 
membranes and delivery to cobamide-dependent enzymes, in which at least 15 proteins 
carry the co-factor to cytosolic and mitochondrial sites, has been proposed (Banerjee, 
2006; Padovani et al., 2008; Banerjee, Gherasim & Padovani, 2009; Nielsen et al., 
2012).  
Evidently, cobamide uptake is complex and a complete characterization of this process 
in mycobacteria is made all the more difficult by the fact that unlike Gram negative 
bacteria, mycobacteria have an unusual and notoriously complex cell envelope 
(Niederweis et al., 2010). This highly hydrophobic envelope presents a formidable 
barrier to passive diffusion of large water-soluble compounds such as cobamides, 
strongly suggesting that a distinct active transport mechanism exists for this molecule. 
However, given the long generation time for most pathogenic mycobacteria, the 
requirement for fast uptake of small molecules might not be strict, and passive 
transport may be all that it takes to achieve the necessary amount of the co-factor inside 
cells. However, the possibility of passive diffusion of cobamides is very low, as a 
cobamide would be fully protonated at the optimal pH for bacterial growth, which 
would require active transport. Therefore, the identification of cobamide chaperones 
could contribute significantly to understanding the role of cobamides in mycobacterial 
physiology and pathogenesis. 
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1.8 Riboswitch regulation of mycobacterial cobamide metabolism 
In mycobacteria, there are only three known cobamide-related metabolic processes: 
biosynthesis of methionine, ribonucleotide reduction, and propionyl CoA catabolism 
via the methylmalonyl pathway. Interestingly, each of the three metabolic processes 
has cobamide-dependent and -independent enzymes (Young, Comas & de Carvalho, 
2015). Of the cobamide-independent enzymes, only the cobalamin-independent 
methionine synthase, MetE (5-methyltetrahydropteroyltriglutamate-homocysteine 
methyltransferase, EC  2.1.1.13), has been experimentally shown to be under direct 
control by a cobalamin riboswitch (Warner et al., 2007). Apart from the metE 
riboswitch, comparative genomics have identified other cobalamin riboswitches in the 
5’ untranslated region (5’ UTR) of putative operons comprising putative ABC-type 
cobamide transporters found only in environmental mycobacteria. In addition, these 
environmental organisms also have other predicted cobalamin riboswitches in front of 
putative operons containing predicted cobalt transporters (Novichkov et al., 2013). In 
pathogenic strains, the only other riboswitch (i.e., apart from the metE riboswitch) 
occurs in the 5’ UTR of a three-gene operon cosisting of a putative cobalt transport 
gene ppe2, and cobamide biosynthesis genes cobQ1 and cobU (Rodionov et al., 2003).  
Riboswitches are conserved non-coding RNA secondary structures usually located in 
the 5’ UTRs of the messenger RNA (mRNA) of the genes under their control (Nahvi, 
Barrick & Breaker, 2004). These RNA elements sense and bind a variety of specific 
ligands including coenzymes, metal ions, nucleobases, tRNAs, sugars, amino acids, or 
toxic metabolites (Ignatov & Johansson, 2017). They can also act as thermo- or pH-
switches to control gene expression in response to temperature or pH changes 
(Nechooshtan et al., 2009; Ignatov & Johansson, 2017). It is classically understood 
that ligand binding or stimulus sensing triggers conformational changes in the mRNA, 
which block or permit transcription and/or translation (Breaker, 2012). Transcription 
control is achieved by the formation of a terminator structure while the sequestration 
of the ribosome binding sites (RBS) leads to inhibition of translation (Lussier et al., 
2015). Riboswitches typically comprise two parts: a highly conserved RNA aptamer 
and an expression platform, which usually is made of less conserved sequences 
(Figure 1.5) (Haller, Soulière & Micura, 2011). The aptamer domain tightly binds a 
ligand, inducing allosteric changes in the riboswitch structure, which occludes the 
 21 
 
transcription start codon or RBS (Figure 1.5). These rearrangements control the 
expression of the adjacent gene or operon (Sherwood & Henkin, 2016).  
Even before the use of the term ‘riboswitch’ to refer to ligand-sensing RNA, the 
regulation of gene and protein expression by cobalamin had been demonstrated in E. 
coli and S. typhimurium, in which cobalamin controlled BtuB expression by RBS 
sequestration in both organisms (Ravnum & Andersson, 1997; Nou & Kadner, 2000). 
Advances in structural biology have now made available high-resolution X-ray 
structures of the cobalamin riboswitches in E. coli, providing further insights into the 
riboswitch mechanism. The aptamer domain of the cobalamin riboswitch is a common 
core surrounded by four peripheral extensions (P), also known as stems (Figure 1.5) 
(Johnson Jr et al., 2012; Peselis & Serganov, 2012). The stems are connected by loops 
(L) and junctions (J). Another common element of this riboswitch is a tertiary structure 
called the “kissing loop,” which is formed by an interaction of L5 and L13 (Figure 
1.5). The kissing loop is a peculiar feature of cobalamin riboswitches which has been 
shown to improve ligand binding efficiency although it is not essential for ligand 
binding (Lussier et al., 2015). This tertiary structure, however, has been found to fold 
more slowly than secondary structures (Soulière et al., 2013), a mechanistic problem 
which is solved by the presence of three strategic regulatory pause sites that coordinate 
independent folding of the aptamer and expression platform domains (Perdrizet et al., 
2012). The L13/P13 structure (Figure 1.5) acts as the anti-terminator or anti-sequester 
for transcriptional regulation or translational control, respectively. 
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Figure 1.5: A schematic of the consensus structure of the cobalamin riboswitch. A. Ligand-
bound conformation of a translationally-controlling cobalamin riboswitch. A conserved, 
centrally situated aptamer core lies at the intersection of a four-way junction of P3-P6. P5 and 
P13 interact to form the kissing loop tertiary structure. The L13/P13 structure contains the 
anti-terminator or anti-sequester. In this configuration, the ribosome binding site (RBS) 
associates with the anti-RBS sequences. In this schematic (based on (Johnson Jr et al., 2012; 
Peselis & Serganov, 2012)), AdoCbl (red oval) is bound to the aptamer. B. Schematic showing 
the expression platform in transcriptional (left schematic) and translational (right schematic) 
riboswitches in the absence of cobalamin. The anti-terminator and anti-RBS domains associate 
with P1-derived anti-anti-terminator and anti-anti-RBS sequences, respectively. AUG – start 
codon. 
There is considerable diversity among riboswitches because they have high ligand 
specificity. Subtle alterations in their structure can inactivate ligand-binding or 
completely change the type of ligand engaged. For example, among purine 
riboswitches, the guanine and adenine riboswitches are distinguished by only one 
nucleotide difference (Serganov et al., 2004). Similarly, cobalamin riboswitches can 
discriminate between AdoCbl, MeCbl and HOCbl (Johnson Jr et al., 2012; Perdrizet 
et al., 2012; Peselis & Serganov, 2012; Soulière et al., 2013; Polaski et al., 2017). 
AdoCbl riboswitches differ from MeCbl and HOCbl riboswitches by the presence of 
an extension of the P6 stem that forms a peripheral extension comprising P8–P11 
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helices (Figure 1.5), which are missing in the MeCbl and HOCbl riboswitches. The 
specificity of riboswitches implies that, potentially, each has a unique mechanism of 
action. Riboswitches, therefore, represent an underexplored frontier with potential to 
complement current knowledge in mycobacterial biology and possibly, provide novel 
targets for antimycobacterial therapy.  
The basic mechanism of regulation by a riboswitch involves two mutually exclusive 
states: an “ON” state that allows gene expression and an “OFF” state that suppresses 
gene expression. In general, “ON” riboswitches detect toxic or overabundant 
metabolites and turn on the expression of genes that eliminate those metabolites (Baker 
et al., 2012; Furukawa et al., 2015). Conversely, “OFF” riboswitches turn genes off in 
response to metabolite availability and, typically, regulate biosynthesis or transport. 
Experimental evidence shows, however, that the precise process by which 
riboswitches regulate gene expression is not simply the flipping “ON” or “OFF” of a 
switch, but involves complex mechanics of ligand-induced signalling, speed of 
transcription, and the kinetics and thermodynamics of RNA folding. (Haller, Soulière 
& Micura, 2011). 
1.9 Methionine biosynthesis in mycobacteria 
Methionine is an essential amino acid required for initiating protein biosynthesis, DNA 
methylation and cysteine biosynthesis. There are at least three possible pathways for 
the synthesis of methionine in mycobacteria. In one pathway, O-acylated L-
homoserine undergoes trans-sulphuration with L-cysteine to form L-cystathionine, 
which is then cleaved to L-homocysteine. L-homocysteine is subsequently methylated 
to produce L-methionine (Figure 1.6A). Alternatively, O-acetyl-L-homoserine reacts 
with hydrogen sulphide to produce L-homocysteine, bypassing L-cystathionine 
(Figure 1.6A). In another route, L-homoserine is first esterified by succinyl-CoA to 
form O-succinyl-L-homoserine, which can be converted directly to L-homocysteine or 
indirectly via L-cystathionine (Figure 1.6A). All the genes involved in mycobacterial 
methionine biosynthesis are known, except those required for the esterification of L-
homoserine. The methylation of L-homocysteine is catalysed either by the cobalamin-
independent MetE or MetH (5-methyltetrahydrofolate-homocysteine 
methyltransferase, EC  2.1.1.14), which requires cobalamin as a co-factor. Both 
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enzymes have a mutual requirement for zinc to activate homocysteine (Matthews & 
Goulding, 1997). In general, organisms that are capable of synthesizing or assimilating 
cobamides encode MetH, while those that cannot synthesize or salvage cobamides 
encode only MetE. 
 
Figure 1.6: Methionine biosynthesis and S-adenosyl methionine recycling in 
mycobacteria. A. Possible routes to de novo methionine in mycobacteria. The first step is the 
esterification of L-homoserine by acetyl-CoA (green line) or by succinyl-CoA (red line) Trans-
sulphuration of the O-acylated L-homoserine with L-cysteine (black solid lines) forms L-
cystathionine which is reduced to L-homocysteine. O-acetyl-L-homoserine can undergo direct 
sulphuration to L-homocysteine (black dashed line). The enzyme catalysing the esterification 
of L-homoserine by succinyl-CoA is unknown. B. Methylation of homocysteine. The transfer 
of a methyl group from 5-methyltetrahydrofolate (Me-THF) to homocysteine is carried out by 
MetE or MetH. In pathogenic mycobacteria, MmuM is predicted to catalyse the transfer of a 
methyl group from SAM to L-homocysteine. SAH – S-adenosyl-L-homocysteine. Enzyme 
annotations are based on M. tuberculosis H37Rv.  
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Although the net reaction catalysed by MetE and MetH is essentially the same, 
comprising the transfer of a methyl group from 5-methyltetrahydrofolate (5-MTHF) 
to homocysteine, there are catalytic features unique to each of the two enzymes. For 
example, MetE uses the triglutamylated derivative of 5-MTHF, whereas MetH can 
accept monoglutamylated 5-MTHF (Gonzalez et al., 1992). Furthermore, while MetE 
catalyses the direct transfer of the methyl species from 5-MTHF, using a catalytic 
cysteine residue as an intermediate methyl acceptor, MetH first transfers the methyl 
group to Co(I)cobalamin (Gonzalez et al., 1992). Interestingly, the measured rate of 
turnover of MetH is reportedly 100-fold higher than that of MetE, implying that the 
direct methylation strategy employed by MetE is less efficient.  
Protein structures of the mycobacterial methionine synthases have not been resolved, 
but useful deductions can be made by examining the crystal structures in E. coli, T. 
maritima, N. crassa, C. albicans and A. thaliana (Dixon et al., 1996; Ferrer et al., 
2004; Pejchal & Ludwig, 2005; Fu et al., 2011; Ubhi et al., 2014; Wheatley, Ng & 
Kapoor, 2016). Sequence alignments revealed that unlike MetE, which shares 
homology with that of other bacteria, a MetH variant specific to actinobacteria is found 
in mycobacteria (Young, Comas & de Carvalho, 2015). Interestingly, a conserved 
hypothetical protein, Rv3015c, often annotated as a MetE homologue, is also found in 
M. tuberculosis. Rv3015c has about 44% sequence overlap with the conserved, 
catalytic C-terminal domain of MetE from C. reinhardtii, but the zinc ion-binding and 
homocysteine activation motifs are inactive, making it unlikely that this single-domain 
protein is functional (Warner et al., 2007). 
A comparison of MetH and MetE in non-mycobacterial models reveals important 
structural differences between the two enzymes. For instance, MetH has four distinct 
domains, each performing separate catalytic functions (Goulding, Postigo & 
Matthews, 1997), whereas MetE has two domains linked by a catalytic groove (Ferrer 
et al., 2004; Pejchal & Ludwig, 2005). The four domains of MetH comprising the 
homocysteine, 5-MTHF, cobamide, and S-adenosylmethionine (SAM) binding and 
activation domains, form a modular structure orientated in the N- to C- terminal 
direction along the protein sequence (Figure 1.7) (Goulding, Postigo & Matthews, 
1997). By contrast, the MetE structure is a dual ()8 barrel structure connected by an 
inter-domain linker, with N- and C-terminal domains that share substantial sequence 
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and structural homology (Figure 1.7) (Pejchal & Ludwig, 2005), possibly due to a 
primordial gene duplication event. The zinc binding domains of both enzymes occur 
in a conserved region but, in MetE, the binding site is in the C-terminal domain 
whereas in MetH this site is found in the N-terminal region (Figure 1.7). In the 
unbound state, the zinc ion is coordinated in a tetrahedral structure by one histidine, 
one glutamate and two cysteine residues in MetE. In contrast, this coordination is 
achieved by three cysteines and one asparagine in the unbound MetH. However, in the 
bound state, the zinc ligand undergoes inversion, during which the coordinating 
glutamate in MetE and asparagine in MetH are replaced by the sulphur of 
homocysteine (Koutmos et al., 2008; Ubhi et al., 2014; Ubhi & Robertus, 2015; 
Wheatley, Ng & Kapoor, 2016). 
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Figure 1.7: Schematic of inferred structures of mycobacterial methionine synthases. 
Protein sequences of M. tuberculosis MetH, MetE, MmuM and Rv3015c were scanned for 
conserved domains against the InterPro database (Jones et al., 2014) to find domain 
architectures. There are four domains in MetH, with distinct binding motifs for homocysteine 
(Hcy), the pterin group derived from 5-methyl tetrahydrofolate (5-MTHF), cobalamin (B12) 
and SAM, which binds the C-terminal activation domain. MetE is organized into N- and C-
terminal domains, while the putative methyltransferases MmuM and Rv3015c are single-
domain proteins. Rv3015c shares homology with the C-terminal domain of MetE. Numbers 
above each module indicate the coordinates of the residues that define each domain. 
 
In addition to MetH and MetE, several mycobacteria also encode a probable 
cobalamin-independent homocysteine S-methyltransferase, MmuM, which can 
catalyse the methylation of L-homocysteine using S-methylmethionine (SMM), a 
SAM derivative, as a methyl donor (Ying et al., 2015). MmuM is widespread among 
clinically relevant mycobacteria which encode this gene in their chromosomes or on 
plasmids; in contrast, M. smegmatis and the fish mycobacterium, M. marinum, lack 
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MmuM homologues (Ying et al., 2015). MmuM shares sequence and functional 
homology with the human betaine-homocysteine S-methyltransferase 2 (BHMT2; EC  
2.1.1.10), which catalyses the conversion of betaine into dimethyl glycine and the 
methylation of homocysteine (Li et al., 2016). Recently, the overall structure of 
MmuM from E. coli was resolved, revealing some similarities with the homocysteine-
binding domain of T. maritima MetH (Li et al., 2016). Like MetH, MmuM has an N-
terminal zinc ion-binding domain of its ()8 TIM-barrel structure (Figure 1.7). Three 
cysteines and a tyrosine coordinate the zinc ion, and like MetE and MetH, a zinc 
inversion mechanism is predicted for binding with homocysteine. In E. coli, the 
absence of MetE and MetH can be compensated by MmuM, provided SAM is included 
in growth media (Thanbichler, Neuhierl & Böck, 1999). However, experimental 
evidence suggest that production of methionine via MmuM is inadequate to 
compensate for the lack of MetE and MetH activities in M. tuberculosis (Warner et 
al., 2007; Berney et al., 2015). Therefore, although MmuM provides a plausible way 
to recycle SAM and other metabolites of the methionine pathway, its role in 
mycobacterial metabolism remains unclear. 
1.10 The intersection of cobalamin, methionine and folate metabolism 
Cobalamin, methionine and folate metabolism share a unique intersection at the 
methylation of L-homocysteine by MetH. In the one-carbon pool by folate, 5-MTHF 
is generated by an irreversible conversion of 5,10-methylenetetrahydrofolate (Blanco, 
Coque & Martin, 1998). In the absence of cobalamin and, consequently, lack of MetH 
activity, cellular 5-MTHF accumulates, leading to a phenomenon called the “methyl 
folate trap.” In humans, the methyl folate trap is associated with 
hyperhomocysteinemia and the onset of megaloblastic anaemia (Palmer et al., 2017). 
Originally thought to exist in eukaryotes only, the methyl folate trap was recently 
described in prokaryotes, including mycobacteria (Guzzo et al., 2016). When induced 
in the presence of drugs targeting the folate pathway, this phenomenon is lethal in the 
absence of cobalamin.  
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1.11 Aims and objectives 
The overall goal of this thesis was to examine cobamide production, uptake and 
regulation of mycobacterial methionine metabolism using M. smegmatis as a proxy 
and where appropriate, making comparisons with pathogenic mycobacteria. After 
initiating the experimental work, it became clear that, while M. smegmatis was a useful 
model organism, a direct comparison with M. tuberculosis could not be made with 
respect to the acquisition of this co-factor. Unexpectedly, differences in cobamide-
related metabolism between the two mycobacteria were revealed, as described in later 
chapters. These chapters have been organized to describe systematically the specific 
aims and objectives of this work, the research methodology, results and discussion. 
Chapter 2 contains the details of the experimental methods and in Chapter 3, an 
evaluation of the genetic capacity for cobamide biosynthesis and transport in 
mycobacteria is presented. This is followed by an experimental validation of cobamide 
production and functionality of the riboswitch controlling metE in M. smegmatis in 
Chapter 4. Chapter 5 describes how the interaction between cobalamin and the metE 
riboswitch underlies the essentiality of metH in M. smegmatis. The question of how 
the regulation of methionine biosynthesis by cobalamin mediate susceptibility of M. 
smegmatis to drugs targeting the folate pathway is also addressed. In Chapter 6, 
concluding remarks are made, situating this dissertation within a series of studies 
emanating from both the Molecular Mycobacterial Research Unit (MMRU), and other 
research groups, that address fundamental questions regarding cobamide-related 
metabolism and its inferred relevance to mycobacterial pathogenesis. It is expected 
that these investigations will yield key insights into the utility of targeting cobamide 
biosynthesis or cobamide-dependent regulation for anti-TB drug development.  
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2 Materials and Methods 
2.1 Downloads of genomes and visualization of phylogenetic distances 
A modified version of the procedure for detecting cobamide biosynthesis and salvage 
genes (Shelton et al., 2018) was followed. The names, metadata and unique identifiers 
for 1111 publicly available Mycobacteriaceae family genomes classified as either 
“finished” or “permanent draft” were downloaded from the Joint Genome Institute’s 
Integrated Microbial Genomes with Expert Review (JGI/IMG ER, 
https://img.jgi.doe.gov/) database (Markowitz et al., 2012) (accessed July-Aug, 2018). 
The JGI/IMG ER database was selected because of its unique comparative genomics 
tools, including built-in annotation profiles for KEGG classifications and protein 
family databases such as Pfam (El-Gebali et al., 2018). The JGI/IMG ER database also 
offered user-friendly access to multiple reference datasets allowing comparative 
phylogenetic analyses and assessments of metabolic potential of individuals. The list 
of 1111 genomes was manually inspected to remove duplicates and a refined list of 
1069 genomes was obtained (Table S1, Supplementary information online). The 
gene count of Mycobacterium leprae Br4923 (gene count = 1654) was chosen as the 
minimum cut-off for genome size. Each unique genome name was considered a 
distinct strain. 16S-based phylogenetic distances between the genomes in the refined 
list were computed under the “Compare Genomes” functionality in JGI/IMG ER with 
BLAST percent identity set at 30+%. A precomputed Newick file for all genomes in 
the refined list was downloaded and displayed using FigTree v1.4.3 
(http://tree.bio.ed.ac.uk/software/figtree). The tree was rooted on Hoyosella sublava 
as an outgroup species. 
2.2 Detection of de novo cobamide biosynthesis and salvage genes in 
mycobacterial genomes 
To find genes involved in the de novo cobamide biosynthesis and salvage pathways, 
the “Find Functions” tool in JGI/IMG ER was used to search for enzymes by the 
enzyme commission (EC) number (Table S2, Supplementary information online) 
(Ogata et al., 1999). The KEGG Porphyrin and chlorophyll metabolism and the KEGG 
Riboflavin metabolism pathways were used as references for cobamide and DMB 
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biosynthesis respectively. The genes were matched with genomes using the “function 
profile: functions vs genomes” functionality and gene hits were downloaded as a list 
of unique EC numbers, enzyme names and genome names. Output Excel sheets were 
combined into one master Excel file which was used as input for an R script that 
interpreted the absence or presence of genes to assess the intactness of de novo 
cobamide biosynthesis. To identify enzymes involved in the salvage pathway, the 
canonical E. coli corrinoid transporter complex BtuFCD (EC  3.6.3.33) (Cadieux et 
al., 2002) and the atypical M. tuberculosis cobamide transporter, which is orthologous 
to BacA (Gopinath, Venclovas, et al., 2013), were matched against the genomes using 
the “function profile: functions vs genomes” functionality. For convenience, the 
pathway was analysed in segments representing the synthesis of: (1) the 5-
aminolevulinic acid (ALA) and uroporphyrinogen III biosynthesis (Uro’ III), (2) 
aerobic and anaerobic corrin ring contraction, and (3) cobinamide-phosphate (Cbi-P) 
and DMB assembly. The P. denitrificans gene nomenclature (Blanche et al., 1995) 
was used.The prefix “cob” was used to designate genes or enzymes of the aerobic 
corrin ring synthesis pathway  and “cbi” to designate those of the anaerobic corrin ring 
synthesis pathway.  
2.3 Identification of cobamide biosynthetic genes in M. smegmatis 
Genes encoding the cobamide biosynthetic and salvage enzymes as listed in Table 3.2 
of Chapter 3 and M. smegmatis orthologs of the M. tuberculosis cobamide 
biosynthetic genes described in (Gopinath, Moosa, et al., 2013) were retrieved using 
the search function in the Mycobrowser portal (Kapopoulou, Lew & Cole, 2011). 
2.4 Bacterial strains and growth conditions 
The bacterial strains and plasmids used in this study are described in Table 2.1. Unless 
specified, M. smegmatis mc2155 was grown in either Middlebrook (Difco) 7H9 
supplemented with 10% Oleic Albumin Dextrose Catalase (OADC) (Becton 
Dickinson) and 0.05% Tween 80 or on Middlebrook (Difco) 7H10 supplemented with 
10% OADC. When used in mycobacterial cultures, kanamycin (Km) was added at a 
final concentration of 25g/ml and hygromycin (Hyg) at a final concentration of 
50g/ml. E. coli was grown in lysogeny broth (LB) or lysogeny agar (LA) with 
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50g/ml Km or 200g/ml Hyg, where appropriate. All cultures were incubated at 37C 
unless indicated otherwise. Unless specified, growth curves were generated by seeding 
bacterial cells in clear round-bottom 96-well culture plates (Greiner Bio-One) and 
taking absorbance measurements every 1.5h, over a period of 30h, in a FLUOstar 
OPTIMA microplate reader (BMG Labtech). 
Table 2.1: Strains and plasmids used in this study 
Strain or plasmid Description References 
Mycobacterium smegmatis 
mc2155 High-frequency transformation 
mutant of M. smegmatis ATCC 607 
(Snapper et al., 1990) 
cobK cobK knockout in mc2155 This study 
cobKmetH metH knockout in cobK This study 
metE metE knockout in mc2155 Dawes, unpublished 
metEcobK::hyg metE knockout in cobK::hyg 
background 
Dawes, unpublished 
metH KD M. smegmatis metH knockdown 
strain 
This study 
Plasmids 
p2NIL Suicide plasmid; KmR (Parish & Stoker, 
2000) 
pGOAL17 Cassette plasmid; AmpR (Parish & Stoker, 
2000) 
pGOAL19 Cassette plasmid; AmpR (Parish & Stoker, 
2000) 
p3875K M. smegmatis cobK vector; KmR This study 
p3875K19 M. smegmatis cobK vector 
containing PacI cassette from 
pGOAL19; KmR, HygR, SucS 
This study 
p4185K M. smegmatis metH vector; KmR This study 
p4185K19 M. smegmatis metH vector 
containing PacI cassette from 
pGOAL19; KmR, HygR, SucS 
This study 
p4185K17 M. smegmatis metH::hyg vector 
containing PacI cassette from 
pGOAL19; KmR, HygR, SucS 
This study 
PLJR962 CRISPRi backbone for M. 
smegmatis 
(Rock et al., 2017) 
PLJR962_metH1 M. smegmatis metH knockdown 
construct with sgRNA1 oligo 
This study 
PLJR962_metH2 M. smegmatis metH knockdown 
construct with sgRNA2 oligo 
This study 
PLJR962_metH3 M. smegmatis metH knockdown 
construct with sgRNA3 oligo 
This study 
PLJR962_metH4 M. smegmatis metH knockdown 
construct with sgRNA4 oligo 
This study 
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Strain or plasmid Description References 
PLJR962_metH5 M. smegmatis metH knockdown 
construct with sgRNA5 oligo 
This study 
PLJR962_metH6 M. smegmatis metH knockdown 
construct with sgRNA6 oligo 
This study 
PLJR962_metH7 M. smegmatis metH knockdown 
construct with sgRNA7 oligo 
This study 
PLJR962_metH8 M. smegmatis metH knockdown 
construct with sgRNA8 oligo 
This study 
PLJR962_metH9 M. smegmatis metH knockdown 
construct with sgRNA9 oligo 
This study 
PLJR962_metH10 M. smegmatis metH knockdown 
construct with sgRNA10 oligo 
This study 
PLJR962_metH11 M. smegmatis metH knockdown 
construct with sgRNA11 oligo 
This study 
PLJR962_metH12 M. smegmatis metH knockdown 
construct with sgRNA12 oligo 
This study 
PLJR962_metH15 M. smegmatis metH knockdown 
construct with sgRNA15 oligo 
This study 
PLJR962_mmpL3 M. smegmatis mmpL3 knockdown 
construct 
This study 
 
2.5 Cloning 
The oligonucleotides (oligos) used for cloning and PCR are listed in Table 2.2. The 
p2NIL backbone (Addgene plasmid #20188; (Parish & Stoker, 2000)) was used to 
generate the suicide vector while pGOAL19 (Addgene plasmid #20190; (Parish & 
Stoker, 2000)) was used to generate the counter-selection cassette. An in-frame, 
unmarked deletion in M. smegmatis cobK (MSMEG_3875) was generated by 
amplifying a 912bp fragment (FR1) containing 40bp of the 5’ end of cobK plus 872bp 
of upstream flanking sequence and a 923bp fragment (FR2) containing 107bp of the 
3’ end of cobK plus 816bp fragment of the downstream flanking sequence. The two 
fragments were joined in a three-way ligation reaction with p2NIL using Asp718I, 
BglII, and HindIII restriction, resulting in the p3875K vector carrying a deleted cobK 
allele of 120bp size. A counter-selection fragment carrying the lacZ, hyg, and sacB 
genes was excised from pGOAL19 and cloned at the PacI site of p3875K to generate 
the suicide vector p3875K19 that was then electroporated into competent M. 
smegmatis cells.  
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To generate an in-frame, unmarked deletion in M. smegmatis metH (MSMEG_4185), 
an amplicon (FR1) containing the 1524bp of the 5’ coding sequence of metH and 
another 1480bp amplicon (FR2) containing 354bp of the 3’ end of metH plus the 
downstream flanking sequence were amplified by PCR. FR1 was subjected to 
restriction with Asp718I and BglII and FR2 was digested with HindIII and BglII and 
the two digested fragments were then joined in a three-way ligation reaction with 
p2NIL to produce the p4185K vector with an 1848bp truncated metH allele. A counter-
selection fragment carrying the lacZ, hyg, and sacB genes was excised from pGOAL19 
and cloned at the PacI site of p4185K to generate the suicide vector p4185K19 that 
was used in electroporation. To generate the hyg-marked suicide vector p4185K17, a 
hyg cassette was cloned into the BglII site of p4185K before inserting the counter-
selection cassette derived from pGOAL17 (Addgene plasmid #20189) (Parish & 
Stoker, 2000). Constructs were validated using restriction enzyme mapping and 
Sanger sequencing using the primers listed in Table 2.3. 
Table 2.2: Oligos used for cloning, screening and gene expression analysis using ddPCR 
Oligo ID 5’ → 3’ sequence Description 
3875F1 CTCAGAAAGCTTGAAAGGCGGCGATT Forward primer 
for FR1 cobK; 
HindIII 
3875R1 GCAGCAGAACTCGCAGATCTATCGTC  Reverse primer 
for FR1 cobK; 
BglII 
3875F2 TGGCGGAGATCTTGATCATGGTGGAC Forward primer 
for FR2 cobK; 
BglII 
3875R2 GGTCCGAGCATGCGGTACCGTTCTA  Reverse primer 
for FR2 cobK; 
Asp718I 
4185F1 GAGACGTTGGTACCGAACAT Forward primer 
for FR1 metH; 
Asp718I 
4185R1 GCGCCCGCAGATCTGCTT Reverse primer 
for FR1 metH; 
BglII 
4185F2 GCACCGAGATCTGGGCGT Forward primer 
for FR2 metH; 
BglII 
4185R2 GGTGTCGAAGCTTACCGGA Reverse primer 
for FR2 metH; 
HindIII 
3875_KO_F GGTGCGTATCGGAGGATT 
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Oligo ID 5’ → 3’ sequence Description 
3875_KO_R GTTCGCCCTCGTAGTCAT Internal primers 
cobK 
3875_F CAACATCGTCCCCCAACTGA  Flanking primers 
cobK 3875_R CGACATCACGCTCGACAAAC 
4185-KO-F GTTCCTGTTCCACGCCAT Internal primers 
metH 4185-KO-R CTGTCAGCCACTTCTCCT 
4185_F CAACATGGACGAGGGCATGA Flanking primers 
metH 4185_R    GACTGCGGGTGCGAGAAATA 
6638_F GGTTCATCGCCTCGTGGAAT Flanking primers 
metE 6638_R GTCAACTTGTCAGGGCTGCT 
TB_metH_F CGACGGTGTTGTGCAGTT Flanking primers 
PPE37-metH 
locus inn M. tb 
TB_metH_R CGTCGTTGGATTCGTGCT 
3875_ProbeF GGGTGCACAGCGTCACCA Primers 
generating 
562bp probe for 
southern blot on 
cobK 
3875_ProbeR CCGACATCACGCTCGACA 
rt_metE_Fwd GGAGCGCAACGACATGGT Sequence 
detection 
primers for metE 
gene expression 
by ddPCR  
rt_metE_Rev TCTCGGTCGCGAAGAAACC 
rt_4185_Fwd TCGACGAGGATTCGCTGTTC Sequence 
detection 
primers for metH 
gene expression 
by ddPCR 
rt_4185_Rev GGCCGATCCGGTGATGT 
rt_sigA_Fwd GCCCGCACCATCCGTAT Sequence 
detection primer 
for sigA gene 
expression by 
ddPCR 
rt_sigA_Rev ATACGGCCGAGCTTGTTGAT Sequence 
detection primer 
for sigA gene 
expression by 
ddPCR 
rt_metE_probe TATTTCGCCGAACAGC Taqman 
hydrolysis probe 
for metE  
rt_4185_probe CATCGGTGAGCGCAC Taqman 
hydrolysis probe 
for metH 
rt_sigA_probe CCGGTGCACATGGT Taqman 
hydrolysis probe 
for SigA 
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Table 2.3: Primers used for Sanger sequencing 
Primer ID Sequence (5’ → 3’) 
MSMcobK_SeqKF1 CAAGGCATGACGGTCTAC 
MSMcobK_SeqKF2 ACGCCAAGGTGATCGACA 
MSMcobK_SeqKF3 CAACATCGTCCCCCAACT 
MSMcobK_SeqKF4 GGGGTCGAAGAGCATGTT 
MSMcobK_SeqKR1 CGCCGAGTACAGGTAACT 
MSMcobK_SeqKR2 ATGATGGTGGTGATGGCG 
MSMcobK_SeqKR3 GAGACCTGTTGGCGCGAT 
MSMcobK_SeqKR4 CGACATCACGCTCGACAA 
MSMcobK_SeqKR5 CGGTGAGGGAGCAGATTT 
MSMmetHKO_SeqF1 CGATCGTTGTCAGAAGTA 
MSMmetHKO_SeqR1 GAAACAGCCCACCGGATA 
MSMmetHKO_SeqF2 GCAGGAGAGTGATACCGAT 
MSMmetHKO_SeqR2 GTCGACTCCGAAAAGCTGT 
MSMmetHKO_SeqF3 CCCGACGCTTTAGTCACA 
MSMmetHKO_SeqR3 CAGTACTTCGTCGTCGGCA 
MSMmetHKO_SeqF4 CTTGAACAACGTGGCCTT 
MSMmetHKO_SeqR4 CAAGGTCGTGGAGGGCAAA 
MSMmetHKO_SeqF5 CGATCCGGTGATGTTGGT 
MSMmetHKO_SeqR5 GAATACAGCACCCCGGACA 
MSMmetHKO_SeqF6 GTTGAGGGTGTCGAAGAT 
MSMmetHKO_SeqF7 GGGTTGAGTGTTGTTCCA 
MSMmetHKO_SeqR6 GGGTTCCGATTTAGTGCT 
 
2.6 Electroporation and screening 
To make competent cells for electroporation, 50ml M. smegmatis cultures were grown 
to exponential phase cells (OD600nm of 0.6–0.8) and harvested by centrifugation at 4000 
× g for 10min. Following this, cells were subjected to three successive washes in 40ml, 
30ml, and 20ml ice-cold 10% glycerol. After the third wash, cell pellets were re-
suspended in 1ml ice-cold 10% glycerol and used immediately or stored at -80C until 
needed. Electroporation was done in a GenePulser XcellTM electroporator (Bio-Rad) 
using the time constant settings (1200V; 5ms time constant; 1mm cuvette). A total of 
100l competent cells were incubated with 1–8g DNA for 20min on ice prior to 
pulsing. Single crossover (SCO) transformants were selected with Km and Hyg on 
7H10-OADC plates. As colonies became visible on the plates, 50l of 2% (w/v) 5-
bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal) was underlain in each plate for the 
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blue/white screening of SCOs. PCR was used to confirm the SCOs, which were then 
cultured in antibiotic-free 7H9-OADC, followed by serial dilution and plating on 
7H10-OADC containing 2% (w/v) sucrose. For the cobK strain, double crossover 
recombinants (DCOs) were screened by PCR and confirmed with Southern blotting. 
In addition to PCR, M. smegmatis metH strains were validated by Sanger sequencing 
using the primers in Table 2.3. 
2.7 Extraction of M. smegmatis genomic DNA 
Genomic DNA was isolated from 5ml of cultures at OD600nm = 1 using the 
cetyltrimethylammonium bromide (CTAB) method (van Helden et al., 2001) as 
follows. The cell suspension was divided into 1ml aliquots, pelleted and re-suspended 
in 500l 1x TE (10mM Tris, pH 8.0; 1mM EDTA, pH 8.0). To each aliquot, 50l of 
10mg/ml lysozyme was added, followed by an overnight incubation at 37°C. Next, the 
cells were chemically lysed with 70l of 10% SDS and 7l of 10mg/ml proteinase K, 
with shaking at 400 rpm in a thermomixer at 65C for 2h. This was followed by the 
addition of 100l of 5M NaCl and 80l CTAB, with further shaking at 65C for 10min. 
To harvest the DNA, 700l of 24:1 (v/v) chloroform: isoamyl alcohol was added and 
the tubes left to stand for 10min standing at room temperature, followed by 
centrifuging at 14000 × g for 10min. The aqueous phase was mixed with 700l of ice-
cold isopropanol and frozen for 30min at -80C to precipitate the DNA. The DNA 
precipitate was pelleted by centrifugation at 14000 × g for 10min, washed in 70% 
ethanol and dried in a vacuum. 
2.8 Southern blotting 
For Southern blotting, 2–3g DNA was digested overnight with StyI and separated on 
1% agarose gel at 80V. The DNA was then transferred onto a HydrobondTM N+ 
membrane (Amersham) by overnight capillary transfer. DNA was then fixed on the 
membrane by microwaving for 2min on high setting. Next, the membrane was 
hybridized at 42C overnight with target-specific PCR-generated probes (Table 2.2). 
Probe labelling and detection was done using the ECL Direct Nucleic Acid Labelling 
and Detection Systems (Amersham). The target DNA fragments were visualized on 
hypersensitive X-ray films. 
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2.9 Extraction of cobamides 
Wild-type and mutant M. smegmatis strains were cultured until stationary phase 
(OD600nm ≥2) in 50ml 7H9-OADC supplemented with 3g/ml (23M) cobalt 
chloride. Cells were harvested by centrifugation at 4000 × g for 10min at 4C. Cell 
pellets were then re-suspended in 8ml of 50mM sodium acetate buffer, pH4.5, and 
stored at -80C until needed. Once thawed, the cells were lysed by 5min of sonication 
using a microtip sonicator with the following settings: 30 amplitude; 15sec pulse; 
15sec cooling. Next, 16l of a solution of 100mM KCN was added to the lysed cells. 
Then, the extraction tube was tightly closed and incubated in a chemical fume hood 
for 30min at room temperature, followed by boiling at 90C for 45min inside the hood. 
The tube was then cooled on ice briefly and centrifuged at 4C at 4000 x g for 10min. 
The supernatant was filtered through a 0.22m filter and loaded onto a Sep-Pak C18 
Plus Light Cartridge (Waters), which had been washed with 5ml 75% (v/v) ethanol 
and conditioned with 10ml sterile water. Following loading of the supernatant, the 
cartridge was washed with 10ml of water and eluted with 75% ethanol, collecting 
about 15 drops. The eluent was analysed immediately by liquid chromatography 
tandem mass spectrometry (LC-MS/MS) or stored in -20C until needed. Prior to LC-
MS/MS analysis, the cell extract was centrifuged at 14000 × g for 10min on a bench-
top centrifuge, followed by a chloroform purification step. 
2.10 Analysis of cobamides by LC-MS/MS 
Eluents were analysed using LC-MS/MS in a positive ionization mode. Quantification 
was accomplished using the following multiple reaction monitoring (MRM) 
parameters: (m/z, 678→359 and m/z, 678→147). Chromatographic separation was 
performed through a HPLC reverse phase column (Phenomenex SynergiTM Polar-RP 
100Å, 50 x 2mm (Separations)) using an Agilent 1200 Rapid Resolution HPLC system 
equipped with a binary pump, degasser, and auto sampler, coupled to an AB Sciex 
4000 QTRAP hybrid triple quadrupole linear ion-trap spectrometer. Mobile phases 
were 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B), and the 
following gradients were run: 0-2min, 95% A; 2-4, 5% A; 4-6min, 95% A; 6-8min, 
95% A. The flow rate was maintained at 400µl/min. The MS analysis was performed 
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on an AB Sciex 4000 QTRAP LC mass spectrometer using the following parameters: 
Curtain gas (25.00); IS (5500.00); Temperature (200.00C); GS1 (80.00); GS2 
(55.00); EP (12.0). Data processing was done using the SCIEX Analyst® software. 
2.11 RNA extraction and cDNA preparation 
Total RNA was extracted using the FastRNA® Pro Blue kit (MP Biomedicals) from 
cell pellets of exponentially growing (OD600nm = 0.4) or stationary phase (OD600nm = 
1.5) mycobacterial cultures. To remove residual contaminating genomic DNA, the 
isolated RNA was digested with TURBO DNAse (Ambion) after which 0.5g of the 
DNase-treated RNA was used as template for cDNA synthesis, using the High 
Capacity RNA to cDNA kit (Thermofisher).  
2.12 Quantitative gene expression analysis by ddPCR 
Droplet digital PCR (ddPCR) and data analysis was performed as described (Singh et 
al., 2015). Primers and minor groove binder (MGB) Taqman probes (Table 2.2) were 
designed using Primer Express 3.0 (Applied Biosystems). TaqMan MGB probes 
homologous to the target genes were labelled with 2'-chloro-7'-phenyl-1, 4-dichloro-
6-carboxyfluorescein (VIC) whereas the reference gene, sigA, was labelled with 6-
carboxyfluorescein (FAM), to allow duplexing. The ddPCR reaction mixtures (20l) 
containing 1x ddPCR Supermix for Probes, no dUTP (Bio-Rad), 375nM primers, 
250nM VIC- or FAM-labelled probes and 1-10ng of cDNA template were emulsified 
in an Automated Droplet Generator (AutoDG) (Bio-Rad), and partitioned into 
approximately 20000 droplets. PCR was performed in a QX100 Thermal Cycler (Bio-
Rad) with the following cycling conditions: 1 (95C for 10min ); 40 (94C for 30 
sec, 60C for 1min ; 2C/s ramp rate); 1 (98C for 10min ; 2C/s ramp rate); 1 (4C 
infinite hold; 2C/s ramp rate). Following amplification, droplets were quantified 
using the QX200 droplet reader (BioRAD). Three technical replicates were run for 
each target gene for each biological replicate. The absolute quantities of gene copies 
were determined using the QuantaSoft Analysis Pro (Bio-Rad) software. Poisson 
statistics were applied to the fraction of endpoint population of positive droplets to 
analyse the fluorescence data from each well. The absolute transcript levels of target 
genes were computed in copies/l and normalized to sigA. The ratios of normalized 
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transcript count in mutant strains relative to the wild-type strain was used to assess 
expression differences. 
2.13 Whole genome sequencing, genome assembly and variant detection 
Genomic DNA was extracted using the CTAB method (van Helden et al., 2001) as 
described above, from exponential phase cultures grown from single colonies. 
Genomic libraries prepared using the TruSeq Nano DNA (Illumina) sample 
preparation kit according to the manufacturer’s instructions, were sequenced using a 
150bp paired-end strategy on an Illumina HiSeq 4000 instrument. Trimmomatic v0.35 
(Bolger, Lohse & Usadel, 2014) was used to remove adapters, leading or trailing bases 
with a quality score < 3, reads shorter than 36bp in length, and bases with an average 
quality score of < 15 based on a 4-base sliding window. BWA v0.7.12 (Li & Durbin, 
2009, 2010) was then used to map paired-end reads to the M. smegmatis mc2155 
reference genome (CP000480.1) (Fleischmann et al., 2006). SAMtools v0.1.2 (Li et 
al., 2009) was used to call bases. Sites that had Phred scores lower than 20 or coverage 
below 10-fold were removed from further analysis. SNPeff v4.1 (Cingolani et al., 
2012), using the M. smegmatis mc2155 (uid57701) database, was used to annotate 
variant positions. 
2.14 Cell fractionation for protein quantification 
Triplicate cultures of M. smegmatis were grown to OD600nm ~ 1.2 in 7H9-OADC with 
or without 10g/ml CNCbl. Cell lysis, fractionation and filter-assisted sample 
preparation (FASP) was done as described (Hermann et al., 2018). Cells were 
harvested by centrifugation at 3500  g for 10min and washed three times with 
phosphate-buffered saline (PBS, pH 7.4) containing 1 cOmpleteTM protease inhibitor 
(Roche). Cells were lysed by 3min of sonication with a microtip sonicator using the 
settings: 30 amplitude; 15sec pulse; 15sec cooling. The cell lysate was centrifuged for 
10min at 8000  g to collect the cytosolic fraction (supernatant) and membrane fraction 
(pellet). The pellet was washed with PBS, re-suspended with 100mM Tris (pH 8.0), 
4% SDS and 100mM DTT, and boiled in a water bath at 95C for 30min. Urea was 
then mixed with the boiled pellet to a final concentration of 8M, with rocking for 
30min at room temperature. The supernatant fraction and the dissolved pellet were 
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filtered through a 0.22m filter, snap-frozen in liquid nitrogen and stored at -80C 
until needed. Protein concentration was determined by the RCDC assay (BioRAD) as 
per manufacturer’s protocol. 
2.15 Filter-assisted sample preparation 
Tryptic peptides were generated using the FASP protocol as described (Hermann et 
al., 2018). Briefly, sequence-grade Trypsin (NEB) was added at 1:100 enzyme to 
protein ratio and incubated for 18h at 37C in a wet chamber. Trypsin was quenched 
with 0.1% formic acid. Tryptic peptides were eluted with three rounds of buffer 
exchange with ABC buffer and desalted with homemade STAGE-tips containing 
Empore Octadecyl C18 solid-phase extraction discs (Supelco). C18 discs were 
conditioned with three washes with solvent B (80% acetonitrile (ACN); 0.1% formic 
acid (FA)) and three washes with solvent A (2% ACN; 0.1% FA). 20g peptides were 
then eluted with solvent C (60% ACN; 0.1% FA), dried in a vacuum and re-suspended 
with solvent A to a concentration of 200ng/l. 
2.16 Selected Reaction Monitoring (SRM) assay development and LCMS 
analysis 
SRM assays were developed in Skyline (version 4.1) using a spectral library generated 
from previous discovery MS data (Hermann et al., 2018) with a cut-off score of 0.9. 
Skyline was set up to select two peptides per input protein, with the highest picked 
MS1 intensity in the discovery data, and then the top 5 most intense fragment ions for 
each of those peptides. A transition list was then generated for the Thermo Scientific 
triple stage quadrupole (TSQ) Vantage mass spectrometer. Samples were separated 
using a Thermo Accella LC system on a 10cm monolithic C18 column (Phenomenex) 
with a 4.6mm ID with a mobile phase that comprised a mixture of solvent A (water + 
0.1% formic acid) and solvent B (HPLC-grade acetonitrile + 0.1% formic acid). The 
method was 45min in total, and the flow rate was 300l/min. The gradient program 
began with 3% B, followed by a gradient from 8%–45% B from 5–25min, then an 
increase to 80% B at 30min for a 5-minute wash, before returning to 3% B for the 
remainder of the method. The LC system was run in-line into a Thermo TSQ Vantage 
through a heated electrospray ionisation (HESI) source. The source voltage was 
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+3500V, with a capillary temperature of 300°C, a vaporiser temperature of 200°C, 
sheath gas of 30, and aux gas of 10. 
2.17 Retention time calculation and method refinement and scheduling 
To determine the retention time for each peptide, methods were generated for the TSQ 
Vantage with a maximum of 20 transitions monitored per method. Therefore, since the 
original list contained 5 transitions, a total of 8 unscheduled methods was generated, 
with a cycle time of 5sec to maximise the amount of signal, a collision gas pressure of 
1.5 mTorr, a Q1 peak width (FWHM) of 0.7, and collision energies as determined by 
Skyline. These unscheduled methods were then run with consecutive 2l injections of 
a reference sample to further refine the list of transitions and determine the retention 
time for each peptide. The reference sample was generated by pooling all samples. The 
unscheduled runs were analysed in Skyline to determine the retention times for each 
peptide. Any transitions with no intensity or those with background-level intensity, 
interference, or ambiguous signal were removed from the method, with a minimum of 
3 transitions per peptide remaining in the final list. The spectral library was used to 
further refine the assays, with any peptides with a dotp score lower than 0.7 removed 
from the final list. 
2.18 Gene silencing of M. smegmatis metH by CRISPRi 
Transcriptional knockdown (KD) of target genes using the clustered randomly 
interspaced short palindromic repeats interference (CRISPRi) approach was carried 
out as described (Rock et al., 2017). Short guide RNAs (sgRNAs) were designed as 
described (de Wet et al., 2018), and 13 sgRNA oligo pairs– top oligo (forward primer) 
and bottom oligo (reverse primer) – targeting metH were synthesised (Table 2.4). The 
top and bottom oligos were annealed to generate an sgRNA, which was then cloned 
into the PLJR962 plasmid (Rock et al., 2017) using BsmBI restriction. The ligation 
reaction was done overnight in a 10l reaction using T4 DNA ligase (NEB) and the 
entire ligation mix from each reaction was transformed into 50l electrocompetent E. 
coli DH5 to make thirteen independent transformations. Transformants were selected 
on LB plates with 50g/ml Km. For each transformation, plasmid DNA was extracted 
from single colonies and sequenced with primer 1834 (Table 2.4) to verify the metH 
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KD constructs. As a positive control, a mmpL3 KD construct was also generated. 
Competent M. smegmatis cells were transformed by electroporation with 200ng of the 
metH KD or mmpL3 KD constructs. Each independent electroporation was selected on 
7H10-OADC containing 25g/ml Km. To induce gene silencing by CRISPRi, 
100ng/ml anhydrotetracycline (ATc) was included in the selection plates. For 
uninduced controls, plates did not include ATc. 
Table 2.4: Oligos used to generate sgRNAs targeting M. smegmatis metH 
sgRNA Oligo 5' → 3' Sequence 
1 F1 GGGAAAGTACTGCGACTGCGGGTG 
R1 AAACCACCCGCAGTCGCAGTACTT 
2 F2 GGGAGTCGTCACCGACGGCGTTGGC 
R2 AAACGCCAACGCCGTCGGTGACGAC 
3 F3 GGGAGTCACCGACGGCGTTGGCCGG 
R3 AAACCCGGCCAACGCCGTCGGTGAC 
4 F4 GGGAGCCGGGTTGTTGAGGATGTC 
R4 AAACGACATCCTCAACAACCCGGC 
5 F5 GGGAGCCCTTCATCTCCCACGCGTT 
R5 AAACAACGCGTGGGAGATGAAGGGC 
6 F6 GGGAGCTTCTTCTCGGCCTCGATGT 
R6 AAACACATCGAGGCCGAGAAGAAGC 
7 F7 GGGAGCGGACTTCACGACCTGCGG 
R7 AAACCCGCAGGTCGTGAAGTCCGC 
8 F8 GGGAGTGCGTGATGCGTTCGCGCA 
R8 AAACTGCGCGAACGCATCACGCAC 
9 F9 GGGAGTCCAGGCCGGCCTTGATGGC 
R9 AAACGCCATCAAGGCCGGCCTGGAC 
10 F10 GGGAGCCGGCCTTGATGGCGTGGAA 
R10 AAACTTCCACGCCATCAAGGCCGGC 
11 F11 GGGAGCCTCCCGCACCGGGTTGTTGCC 
R11 AAACGGCAACAACCCGGTGCGGGAGGC 
12 F12 GGGAACCGGGTTGTTGCCGCGGAA 
R12 AAACTTCCGCGGCAACAACCCGGT 
15 F15 GGGAGCTGGGCGTGCCGGATCGAGTT 
R15 AAACAACTCGATCCGGCACGCCCAGC 
mmpL3 L3F GGGAACAGACTGGCTGCCCTCGTC 
L3R AAACGACGAGGGCAGCCAGTCTGT 
P1834  TTCCTGTGAAGAGCCATTGATAATG 
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2.19 Single cell microfluidics and time-lapse microscopy 
To perform single-cell analyses using microfluidics, a 100l suspension of 2.0 x 106 
bacterial cells/ml was prepared and loaded on the four-chambered CellASIC ONIX 
B04A-03 microfluidic platform (Merck) kept at 37C throughout the experiment. Cells 
were trapped with the following pressure and flow time settings: channel A8 at 13.8 
kPa for 15 seconds; channel A6 at 27.6kPa for 15 seconds. Channel A6 was then rinsed 
at 6.9kPa for 30 seconds. Untrapped cells were washed out by flowing inlet solution 
at 34.5kPa for 5min Prior to trapping, cells at OD600nm = 1 was diluted to OD600nm = 
0.1 in 10ml 7H9-OADC with or without 100ng/ml of ATc and incubated in a shaking 
incubator for 6h at 37C. ATc-containing media was perfused continuously in 
channels loaded with cells that had been pre-exposed to ATc and for cells that were 
not pre-exposed to ATc, only 7H9-OADC was perfused. The experiment was run for 
43h. Live-cell imaging was performed on a Zeiss AxioObserver using a 100X, 1.4NA 
Objective with Phase Contrast and Colibri.7 fluorescent illumination system. Images 
were captured every 15min using a Zeiss Axiocam 503 and processed using FIJI 
software (https://fiji.sc/). 
2.20 Determination of SULFAs MIC90 using the microplate alamar blue assays 
(MABA) 
M. smegmatis strains were grown to OD600nm 0.2–0.5 and diluted 1:1000 in 7H9-
OADC. Then, 50l of this diluted culture was added to 50l 7H9-OADC containing 
2-fold serial dilutions of sulfamethoxazole (Sigma-Aldrich®), sulfathiazole (Sigma-
Aldrich®) or sulfadiazine (Sigma-Aldrich®) in clear round-bottom 96-well culture 
plates (Greiner Bio-One). Where applicable, 10g/ml CNCbl was included in each 
well. Plates were incubated overnight at 37C, after which 10l of 100g/ml resazurin 
was added to each well. The plates were incubated for an additional 5h at 37C before 
fluorescence intensity measurements were taken using a FLUOstar OPTIMA 
microplate reader (BMG Labtech). The data were exported and analysed with 
GraphPad Prism 5. 
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3 Phylogenomics analysis predicts that de novo cobamide 
biosynthesis in mycobacteria is biased toward environmental 
species  
3.1 Overview 
Environmental and pathogenic species of mycobacteria colonize vastly different 
niches and, as a result, these microorganisms might be expected to exhibit phenotypic 
and metabolic diversity. For example, M. smegmatis, a saprophyte frequently used as 
a model for the general study of mycobacteria (Barry, 2001; Reyrat & Kahn, 2001), is 
a fast grower with doubling times of approximately 3h. On the other hand, M. 
tuberculosis is an obligate human pathogen which doubles roughly every 24h in 
standard liquid medium. The causative agent of leprosy, M. leprae, has a notoriously 
long generation time of two weeks, and is impossible to grow in axenic culture. 
Instead, M. leprae  proliferates in footpads of mice, armadillos and macaques 
(Shepard, 1960; Sasaki et al., 2001). Various annotated mycobacterial genomes are 
now available in several up-to-date, publicly accessible databases such as the 
Mycobrowser portal (Kapopoulou, Lew & Cole, 2011), the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG) (Ogata et al., 1999), and the Joint Genome Institute’s 
Integrated Microbial Genomes with Expert Review (JGI/IMG ER) (Markowitz et al., 
2012). These repositories enable genomic comparisons of various mycobacterial 
species to define key phylogenetic and metabolic differences between pathogens and 
non-pathogens. As reviewed in chapter 1, cobamide production has been implicated 
in the evolution of mycobacterial pathogenesis, whereby specific deletions or 
inactivation of genes in the de novo cobamide biosynthetic pathway have been 
observed in some pathogenic strains (Orgeur & Brosch, 2018). Consequently, these 
organisms might have become dependent, at least partially, on their hosts for 
cobamides or their precursors. In this chapter, the genetic capacity of mycobacteria for 
cobamide biosynthesis and salvage is analysed and discussed. 
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3.2 Results 
3.2.1 Mycobacterial genomes dataset and phylogenetic tree 
Publicly available, complete (designated as “finished”) or nearly complete 
(“permanent draft”) genome assemblies belonging to the taxonomic family 
Mycobacteriaceae were surveyed to assess the genetic potential for cobamide 
biosynthesis and salvage. After filtering to remove duplications or entries with fewer 
genes than M. leprae, which is known to have the most reduced mycobacterial genome 
(Cole et al., 2001), 42 entries were discarded from the original 1111 genomes, 
resulting in a working dataset of 1069 genomes (Table S1, Supplementary 
information online). Information about ecosystem associated with the genomes was 
available for 872 records (81.6%), with human hosts contributing 837 (96%) of these 
(Table 3.1). These included isolates of human and animal adapted strains of the MTBC 
which were sequenced at different centres around the world, the M. abscessus 
complex, and opportunistic non-tuberculous mycobacteria such as M. fortuitum, M. 
neonaurum, M. xenopi, M. kansasii, M. avium, M. marinum and M. smegmatis. There 
were 179 genomes that did not have associated ecosystem information, 18 genomes of 
environmental organisms which were not associated with animal or human hosts, and 
5 genomes from engineered microbiomes (Table 3.1). On average, the genomes of 
host-associated mycobacteria were smaller (average genome size = 4.8Mb) compared 
to those of environmental mycobacteria (average genome size = 5.9Mb) (Table 3.1), 
consistent with host adaptation. There were no genomes associated with mycobacteria 
that infect small mammals such as meerkats (M. suricattae), voles (M. microti) and 
dassies (Dassie bacilli). It is possible their genomes might have been among those in 
the unclassified category (average genome size = 4.7Mb) (Table 3.1). M. leprae TN 
had the smallest genome (3.3Mb) and encoded 2750 genes, of which 1086 were 
pseudogenes (Table S1, Supplementary information online). 
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Table 3.1: Summary of mycobacterial genomes and ecosystem metadata 
Ecosystem/Host Number of genomes Average genome size (Mb) 
Bison 1 4.6 
Water buffalo 1 5.0 
Asian Elephant 1 5.3 
Oryx 1 4.8 
Camel 2 4.7 
Goat 2 4.8 
Wild boar 2 5.2 
Birds 4 4.8 
Deer 4 4.8 
Sheep 4 4.7 
Engineered microbiome 5 5.7 
Cattle 9 4.1 
Environmental 18 5.9 
Unclassified 179 4.7 
Human 836 4.5 
 
The JGI/IMG ER database provided a functionality for computing the phylogenetic 
distances between genomes based on 16S rRNA sequencing (Markowitz et al., 2012). 
The tree was rooted on H. sublava, once grouped with the Mycobacteriaceae family 
but recently reclassified into the genus Hoyosella (Hamada et al., 2016). Two primary 
clusters of genomes were observed which, on inspection, revealed a dichotomy 
between host-associated genomes and environmental mycobacteria (Figure 3.1). 
Although the available data were insufficient to infer ancestry, other investigators have 
demonstrated that environmental species are ancestral to host-associated 
mycobacteria, an evolution which accompanied a transition to pathogenicity (Supply 
et al., 2013). 
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Figure 3.1: Phylogenetic distance tree of mycobacterial genomes based on 16S rRNA 
alignment. Genomes for which ecosystem and host metadata were available are highlighted 
in colour while those lacking these metadata are shown in black. Red indicates host-associated 
organisms, blue indicates environmental species and purple are genomes of engineered 
microbiomes. Some genomes of M. tuberculosis clinical isolates and of the M. avium and M. 
abscessus complexes are collapsed by tips (triangles) for easy visualization. H. sublava is the 
outgroup species. 
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3.2.2 Mycobacterial genomes encode variable capacity for corrin ring 
biosynthesis via the aerobic pathway 
To determine the completeness of de novo cobamide biosynthesis in mycobacterial 
genomes, the pathway was segmented into three parts for analysis (Table 3.2) The 
first part grouped together enzymes involved in the synthesis of the tetrapyrrole 
precursors ALA and Uro’ III. The second segment comprised enzymes catalysing the 
ring contraction steps, which were subdivided into aerobic and anaerobic pathways, 
and the last part grouped enzymes involved in the synthesis of Cbi-P and DMB (Table 
3.2). More than 98% of mycobacterial genomes encoded at least one copy of the genes 
involved in the synthesis of ALA and Uro’ III (Table 3.2). Except for cobF and cobB, 
which were found in 18% and 78% of the genomes, respectively, the genes involved 
in the aerobic corrin ring synthesis pathway were encoded by more than 98% of the 
mycobacterial genomes (Table 3.2). However, there were no hits for genes encoding 
the anaerobic corrin ring biosynthetic pathway except cbiF, cbiJ, and cbiC, which were 
contained in 99% of the genomes and cbiA, found in 78% of the genomes (Table 3.2). 
The annotations of these genes in representative mycobacteria were queried in the 
KEGG database (Ogata et al., 1999), and were found to correspond to CobM (CbiF), 
CobK (CbiJ), CobH (CbiC), and CobB (CbiA). Amino acid sequences of these “Cob” 
enzymes were then analysed for protein domain architecture with Pfam (El-Gebali et 
al., 2018). This analysis revealed “Cbi” family motifs in the “Cob” enzymes, which 
explained their being detected in the anaerobic corrin ring synthesis step.  
Table3.2: Distribution of de novo cobamide biosynthetic and salvage pathway enzymes in 
mycobacteria. 
Symbol EC# Synthesis step % Genomes 
GltX EC 6.1.1.17 ALA and Uro’ III synthesis 100.00% 
ProS EC 6.1.1.15 ALA and Uro’ III synthesis 100.00% 
HemA EC 1.2.1.70 ALA and Uro’ III synthesis 100.00% 
HemL EC 5.4.3.8 ALA and Uro’ III synthesis 99.00% 
HemB EC 4.2.1.24 ALA and Uro’ III synthesis 100.00% 
HemC EC 2.5.1.61 ALA and Uro’ III synthesis 100.00% 
HemD EC 4.2.1.75 ALA and Uro’ III synthesis 100.00% 
CobA_CysG EC 2.1.1.107 ALA and Uro’ III synthesis 100.00% 
CysG EC 1.3.1.76 ALA and Uro’ III synthesis 98.00% 
CobI EC 2.1.1.130 Corrin ring synthesis (aerobic) 99.00% 
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Symbol EC# Synthesis step % Genomes 
CobG EC 1.14.13.83 Corrin ring synthesis (aerobic) 99.00% 
CobJ EC 2.1.1.131 Corrin ring synthesis (aerobic) 99.00% 
CobM EC 2.1.1.133 Corrin ring synthesis (aerobic) 99.00% 
CobF EC 2.1.1.152 Corrin ring synthesis (aerobic) 18.00% 
CobK EC 1.3.1.54 Corrin ring synthesis (aerobic) 99.00% 
CobL EC 2.1.1.132 Corrin ring synthesis (aerobic) 99.00% 
CobH EC 5.4.99.61 Corrin ring synthesis (aerobic) 98.00% 
CobB EC 6.3.5.9 Corrin ring synthesis (aerobic) 78.00% 
CobNST EC 6.6.1.2 Corrin ring synthesis (aerobic) 99.00% 
CbiK_CbiX EC 4.99.1.3 Corrin ring synthesis (anaerobic) 0.00% 
CbiL EC 2.1.1.151 Corrin ring synthesis (anaerobic) 0.00% 
CbiH EC 2.1.1.272 Corrin ring synthesis (anaerobic) 0.00% 
CbiF EC 2.1.1.271 Corrin ring synthesis (anaerobic) 99.00% 
CbiG EC 3.7.1.12 Corrin ring synthesis (anaerobic) 0.00% 
CbiD EC 2.1.1.195 Corrin ring synthesis (anaerobic) 0.00% 
CbiJ EC 1.3.1.106 Corrin ring synthesis (anaerobic) 99.00% 
CbiT EC 2.1.1.196 Corrin ring synthesis (anaerobic) 0.00% 
CbiE EC 2.1.1.289 Corrin ring synthesis (anaerobic) 0.00% 
CbiC EC 5.4.99.60 Corrin ring synthesis (anaerobic) 98.00% 
CbiA EC 6.3.5.11 Corrin ring synthesis (anaerobic) 78.00% 
CobR EC 1.16.8.1 Cbi-P synthesis 0.00% 
CobO_PduO EC 2.5.1.17 Cbi-P synthesis 100.00% 
CobQ EC 6.3.5.10 Cbi-P synthesis 99.00% 
CobC_CobD_protein 
 
EC 6.3.1.10 Cbi-P synthesis 99.00% 
CbiZ EC 3.5.1.90 Cbi-P synthesis 0.00% 
CobU_CobP EC 2.7.1.156 Cbi-P synthesis 99.00% 
CobU_CobP EC 2.7.7.62 Cbi-P synthesis 99.00% 
RibF EC 2.7.1.26 DMB synthesis  99.00% 
Fre EC 1.5.1.38 DMB synthesis  0.03% 
BluB EC 1.13.11.79 DMB synthesis  99.00% 
CobU_CobT EC 2.4.2.21 DMB attachment 99.00% 
CobC EC 3.1.3.73 DMB attachment 0.00% 
CobS_CobV EC 2.7.8.26 DMB attachment 97.00% 
BtuFCD EC 3.6.3.33 Corrinoid uptake 0.00% 
BacA not assigned Corrinoid uptake 99.00% 
 
The variability in the intactness of the corrin ring synthesis step among the 1069 
mycobacterial genomes was represented graphically on a binary heat map generated 
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in “R,” where functionality was inferred as the presence of at least one gene copy for 
each enzyme-catalysed step (Figure 3.2). This functional profile revealed that most 
genomes that lacked cobF belonged to host-associated mycobacteria. Interestingly, a 
large proportion of the genomes missing cobF also lacked cobB (Figure 3.2). The 
genomes of M. leprae (genome size = 3.3Mb) and M. mucogenicum (genome size = 
3.4Mb) were missing all corrin ring biosynthesis enzymes (Figure 3.2). There was a 
high degree of variability in the presence of genes encoding the corrin ring synthesis 
step in genomes belonging to the M. avium complex (MAC) (Figure 3.2). A functional 
heat map for the MAC showed that this variability prevailed throughout the de novo 
cobamide biosynthesis pathway (Figure 3.3). 
 52 
 
 
Figure 3.2: A binary heat map showing the distribution of genes involved in corrin ring 
synthesis step of the de novo cobamide pathway in mycobacteria. The presence or absence 
of at least one gene copy in the corrin ring synthesis step was assigned the value 1 or 0, 
respectively, and clustered by species in “R.” Hits are indicated in blue while the absence of 
genes is displayed in white. The aerobic pathway was intact for environmental species (ENV) 
but species of the MTBC were missing cobF. Some of the MTBC genomes also lacked cobB. 
Anaerobic pathway genes were not found but cobM, cobK, cobH and cobB were detected as 
hits for cbiF, cbiJ, cbiC and cbiA, respectively. A high variability in corrin ring coding capacity 
was observed in the M. avium complex (MAC). MAB – M. abscessus. 
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Figure 3.3: Heat map showing the distribution of de novo cobamide biosynthesis genes in 
the M. avium complex genomes. A matrix of copy numbers for genes involved in de novo 
cobamide biosynthesis and corrinoid salvage in the MAC genomes was displayed graphically 
in “R.” The MAC genomes displayed a high degree of variation both in the presence of at least 
one gene copy per enzyme step, and in the number of gene copies per step. 
 
3.2.3 De novo Cbi-P and DMB synthesis steps are conserved in mycobacteria 
The step immediately following corrin ring synthesis is the reduction of cob(II)yrinate 
a,c diamide by CobR, a predicted cob(II)yrinate a,c diamide reductase (Lawrence et 
al., 2008). In this analysis, no homologues of the gene encoding this enzyme were 
found in any genome (Table 3.2). However, BluB, which also catalyses the formation 
of DMB, has been proposed as an alternative cob(II)yrinate a,c diamide reductase 
based on sequence homology to CobR  (Gopinath, Moosa, et al., 2013). The BluB 
enzyme was present in more than 99% of the genomes analysed (Table 3.2). The 
enzymes which catalyse the subsequent reactions leading up to Cbi-P were also found 
in more than 99% of the genomes (Table 3.2). The gene encoding CobO (EC 2.5.1.17), 
involved in the adenosylation of the cobalt ion to form adenosylcobyrinate a,c-diamide 
were also found in 99% of the genomes in this analysis (Table 3.2). Moreover, genes 
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encoding aminopropanol biosynthesis enzymes CobC/CobD (EC 6.3.1.10), which, 
together with the as-yet-unidentified protein , form an enzyme complex that 
catalayses the attachment of aminopropanol to adenosylcobyrinate, were also detected 
in 99% of genomes analysed (Table 3.2). Genes encoding CobU/CobT (EC 2.4.2.21) 
and CobS/CobV (EC 2.7.8.26), involved in the attachment of DMB to Cbi-P were also 
found in 97% of the genomes in this analysis (Table 3.2). However, no homologue of 
the gene encoding CobC (EC 3.1.3.73), an adenosylcobalamin 5’-phosphatase 
involved in the final step of adenosylcobalamin biosynthesis, was detected in any 
genome (Table 3.2). In addition to BluB, the riboflavin kinase RibF, and a flavin 
mononucleotide (FMN) reductase are also required for DMB synthesis in prokaryotes 
that use the aerobic pathway. More than 99% of the genomes encoded RibF but the 
FMN reductase was found in only 31 genomes (0.03%) (Table 3.2), of which 28 were 
genomes belonging to environmental organisms and 3 were genomes belonging to 
host-associated mycobacteria (M. xenopi; 2 genomes, and M. avium; 1 genome). Apart 
from participating in the de novo cobamide biosynthesis pathway, CobO and PduO are 
also predicted to be involved in the salvage of cobamides (Gopinath, Venclovas, et al., 
2013). However, previous genetic screens conducted in the MMRU identified an 
atypical transporter, BacA, which was consistent with the fact that no mycobacterial 
genomes encoded homologues of the canonical BtuFCD transporter complex found in 
Gram negative bacteria (Gopinath, Venclovas, et al., 2013). In the present analysis, 
none of the genomes encoded the BtuFCD transporter complex but more than 99% of 
the genomes encoded at least one copy of BacA or CobO/PduO enzymes (Table 3.2). 
3.3 Discussion 
Cobamides are required by cells in all domains of life (Nielsen et al., 2012) yet de 
novo biosynthesis of this co-factor is restricted to some bacteria and archaea (Zhang et 
al., 2009; Doxey et al., 2015). In this chapter, a comparative analysis of over 1000 
mycobacterial genomes from the publicly accessible JGI/IMG ER database 
(Markowitz et al., 2012) is presented. Phylogenetic clustering based on 16S alignments 
separated the genomes into two primary groups of environmental and host-associated 
mycobacteria. This analysis revealed that environmental mycobacteria encode a 
complete pathway for de novo cobamide biosynthesis via the aerobic route while 
pathogenic strains lack at least one enzyme in the pathway, CobF being the most 
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notably absent among the MTBC strains. The activity of CobF is presumed to have 
been lost during evolution of MTBC from a non-pathogenic environmental ancestor 
(Orgeur & Brosch, 2018). The detection of CobO/PduO enzyme classes and BacA in 
more than 99% the genomes further suggested that mycobacteria have a conserved 
genetic capacity to bypass de novo biosynthesis if exogenous cobamides available. 
Interestingly, genomes of the M. avium complex, which cause opportunistic diseases 
in humans, showed highly variable genetic capacity for de novo cobamide synthesis. 
This was not surprising, however, given that high frequency of genetic variability is 
associated with this complex (Rindi & Garzelli, 2014; Imperiale et al., 2017). The 
overall preservation of genes involved in either de novo cobamide biosynthesis or 
salvage among mycobacteria signal the indispensability of this co-factor in these 
organisms irrespective of their habitat and pathogenicity.  
In M. leprae, only those genes related to the synthesis of the general tetrapyrrole 
precursors appeared intact. However, it was also observed that the draft genome of M. 
mucogenicum, a rapidly growing NTM associated with opportunistic infections related 
to contaminated water systems and hospital equipment (Springer et al., 1995), was 
also unexpectedly small. However, recent whole-genome resequencing of M. 
mucogenicum estimated that the number of genes it encoded was 6003 (Asmar et al., 
2015) as opposed to 3125 reported in the JGI/IMG ER database, implying that 
occasional errors may be found with genome drafts in this database, necessitating 
manual curation of data.  
Although the absence of CobF is assumed to have disrupted de novo cobamide 
production, a putative replacement for this enzyme (Rv2067c) has been suggested, 
implying a possibility of recovering cobamide from M. tuberculosis (Gopinath, 
Moosa, et al., 2013). Interestingly, most organisms that lacked CobF also lacked 
CobB, which catalyses the amidation of the corrin ring prior to the cobalt chelation 
step. In M. leprae, cobB is a pseudogene, and in the analysis conducted here, it 
appeared as “missing.” It is likely, therefore, that this was also the case in those 
genomes where cobB was marked as absent, instead of its being completely “missing.” 
Ongoing studies in the MMRU have failed to provide direct proof of cobamide 
production in M. tuberculosis (Dr. Gabriel Mashabela, personal communication), 
despite the presence of putative cobF substitutes, encoded by Rv2067c and Rv0391 
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(Gopinath, Moosa, et al., 2013). It is unclear how loss-of-function CobB mutations 
alone (assuming putative replacement enzymes for CobF are present in some 
mycobacteria) would affect cobamide biosynthesis in those organisms.  
The natural loss of the cobB gene has not been reported in the literature for any other 
organism. Recently, however, relatively frequent frameshift mutations affecting the 3’ 
region of cobB were discovered in clinical isolates of M. tuberculosis, a finding that 
suggests that this gene might also be involved in adapting to pressures within the host 
(Minias, Minias & Dziadek, 2018). In transposon mutagenesis screens, it has been 
shown that the loss of cobamide biosynthesis genes including cobB is associated with 
decreased production of PDIM, a mycobacterial lipid associated with virulence 
(Russell et al., 2010; Lee et al., 2013; Lovewell, Sassetti & VanderVen, 2016) and 
with increased fitness in Acanthamoeba (Weerdenburg et al., 2015; Boot et al., 2016). 
In light of these reports, it is tempting to speculate that the seemingly parallel loss of 
cobF and cobB represents an ongoing evolutionary event in pathogenic mycobacteria, 
in agreement with the theory that the evolution of mycobacterial pathogenesis is 
associated with genome decay (Gagneux, 2018; Orgeur & Brosch, 2018). Minias and 
colleagues also found that several other de novo cobamide biosynthesis genes in M. 
tuberculosis clinical isolates appear to be undergoing purifying selection (Minias, 
Minias & Dziadek, 2018). While their findings pointed to the possibility of cobamide 
production in M. tuberculosis, the lack of experimental evidence of cobalamin 
production in this organism suggests that the negative selection pressure acting on 
these genes might be an adaptation to host-induced stressors, antimycobacterial 
treatment or a combination of these pressures rather than in response to the limited 
access to cobamides in the host. 
Among the mycobacterial genomes studied, none expressed any anaerobic “Cbi” 
enzymes, which was expected as mycobacteria typically inhabit oxygenated 
environments. However, four “Cob” enzymes (CobB/H/K/M) were detected as “Cbi” 
enzymes (CbiA/C/J/F), catalysing the corresponding corrin ring synthesis steps in the 
anaerobic pathway. This observation suggested possible enzymatic dexterity in this 
part of the cobamide biosynthetic pathway, whereby reaction steps of the aerobic and 
anaerobic routes can be catalysed by enzymes of either pathway. This view is 
supported by observations that P. aeruginosa, an aerobic bacterium which lacks an 
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identifiable CobF but expresses the corresponding enzymes CbiG and CbiD, is capable 
of de novo cobamide production (Crespo, Blanco-Cabra & Torrents, 2018). The 
discovery of Rv0259c as a possible homologue of the sirohydrochlorin 
cobaltochelatase CbiX/CbiK in M. tuberculosis implies that mycobacteria might also 
be able, at least partially, to use the anaerobic pathway (Gopinath, Moosa, et al., 2013). 
In a previous study in the MMRU, two non-homologous de novo cobamide 
biosynthesis pathway enzymes, CobO (a homologue of the Salmonella CobA, the most 
extensively studied adenosyltransferase (Escalante-Semerena, Suh & Roth, 1990)) and 
PduO (a homologue of the Salmonella PduO (Johnson et al., 2001)), were implicated 
in corrinoid assimilation, although only the latter was shown to be required in vitro for 
the assimilation of dicyanocobinamide (CN)2Cbi (Gopinath, Venclovas, et al., 2013). 
There is ample experimental evidence (reviewed in-depth in (Mattes et al., 2017)) that 
the Salmonella CobA is also involved in de novo synthesis of the corrin ring and the 
nucleotide loop. Given that CobO was widespread in mycobacterial genomes analysed 
in this study it would not be surprising that in mycobacteria, this protein functions in 
the same manner as the Salmonella CobA. Other bacteria and some archaea encode an 
adenosylcobinamide hydrolase, named CbiZ (EC 3.5.1.90), that is used to remodel 
adenosylcobamide by hydrolyzing the amide bond between aminopropanol and the 
ring, yielding adenosylcobyrinate, which can then be converted to a cobamide that the 
bacterium can use through the incorporation of a base other than DMB (Woodson & 
Escalante-Semerena, 2004). A homologue of this enzyme was not found in any 
mycobacterial genome analysed in this study (Table 3.2), hinting that this remodelling 
might not exist and that the final product in the pathway is an adenosylated cobamide. 
The genes involved in Cbi-P synthesis, and in the assembly and attachment of DMB 
were highly conserved in the mycobacterial genomes used in this analysis. The gene 
encoding BluB, which catalyses the oxygen-dependent conversion of reduced FMN 
(FMNH2) to DMB (Campbell et al., 2006; Gray & Escalante-Semerena, 2007), was 
widespread in mycobacterial genomes. FMNH2 is the product of NADPH-dependent 
FMN reductase, but the enzyme catalysing this reaction was detected in only a few 
genomes of environmental organisms. Recently, one research group presented 
experimental evidence that anaerobic bacteria such as Eubacterium limosum encode 
bzaABCDE genes required for a four-step reaction leading to DMB, starting with 5-
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aminoimidazole ribotide (AIR), a precursor for thiamine (vitamin B6) biosynthesis 
(Hazra et al., 2015). In their paper, these authors hypothesized that DMB could be 
assembled anaerobically using methionine, glycine, formic acid and erythrose as 
building blocks (Renz, 1970). It is unknown, however, whether mycobacteria encode 
the enzymes that would be involved in recycling these metabolites. Subsequent 
comparative genomics by the same investigators did not find identifiable homologs of 
any bza genes in mycobacteria, suggesting that anaerobic DMB biosynthesis in 
mycobacteria is unlikely (Shelton et al., 2018).  
The question of how mycobacteria accomplish cobamide transport continues to be a 
challenging puzzle. Several lines of indirect evidence suggest that, although 
mycobacteria lack the classical bacterial cobamide transporter complex BtuFCD, they 
can salvage cobamides using the BacA, an efflux protein implicated in drug resistance 
(Warner et al., 2007; Savvi et al., 2008; Gopinath, Venclovas, et al., 2013; Guzzo et 
al., 2016; Lawrence et al., 2018). The fact that the BtuFCD complex was absent in 
mycobacteria implies that the canonical mechanism of cobamide transport found in 
Gram negative bacteria (Lewinson et al., 2010) might not be at play in mycobacteria. 
The reason behind this could be that, unlike Gram negative bacteria, mycobacteria are 
characterized by a highly complex cell envelope (Niederweis et al., 2010), which 
provides a unique barrier to small molecule transport in these organisms. The current 
model of mycobacterial cobamide transport situates BacA in the cytoplasmic 
membrane (Gopinath, Venclovas, et al., 2013). Therefore, the array of proteins that 
would deliver cobamide through the mycobacterial outer cell membrane and 
periplasmic space remain unknown. In summary, mycobacteria encode a variable 
capacity for cobamide biosynthesis. Moreover, there is a strong impetus to develop 
mycobacteria as distinct models these organisms as they do not conform to classic 
models of cobamide biosynthesis and metabolism.  
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4 Production of cobamides by M. smegmatis strain mc2 155 
4.1 Overview 
Cobamides are fascinating co-factors that have a rich scientific history marked by 
intensive efforts to characterise their biosynthesis. Because of their complex chemical 
structure, sophisticated machinery is required to shuttle cobamides between cellular 
microenvironments or across the interfaces of pathogens or symbionts and their hosts 
(Croft et al., 2005; Nielsen et al., 2012; Fang, Kang & Zhang, 2017). Despite the fact 
that cells in all domains of life require this co-factor, only a small group of prokaryotes 
can synthesise cobamides via an energetically-expensive process requiring nearly 30 
enzyme-catalysed steps (Smith, Warren & Refsum, 2018). The catalytic efficiencies 
of cobamide-dependent enzymes seemingly subsidize the costs of de novo production, 
implying there is strong evolutionary pressure to keep these enzymes in all living 
systems. Only plants appear to have dispensed with their dependence on cobamides, 
although recent studies reveal that certain herbs can accumulate exogenous co-factor 
(Lawrence et al., 2018).  
In mycobacteria, cobamide-dependent enzymes catalyse the biosynthesis of 
methionine and deoxyribonucleotides and the catabolism of propionate and 
ethanolamine (Young, Comas & de Carvalho, 2015). Knowledge about the roles 
played by cobamide in mycobacterial physiology and during disease has remained 
limited, partly because mycobacterial pathogens are challenging to study. For instance, 
the risk of exposure to M. tuberculosis is a serious threat to researchers and 
experiments requiring the use of this organism must be handled in costly, specialized 
biosafety level 3 (BSL3) facilities. Moreover, M. tuberculosis has a long generation 
time of 24h in nutrient-rich broth and takes more than 3 weeks to form colonies on 
solid media (James, Williams & Marsh, 2000). To circumvent these challenges, 
various aspects of mycobacterial physiology, metabolism and pathogenesis have been 
studied using non-pathogenic mycobacterial models such as M. smegmatis and 
attenuated strains such as engineered auxotrophs and M. bovis BCG (Shiloh & 
DiGiuseppe Champion, 2010). M. smegmatis is a particularly convenient model 
because it is amenable to tractable genetic manipulation, safe to handle in biosafety 
level 2 (BSL2) laboratories and has a relatively fast doubling time of only 3–4h.  
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Previous studies in the MMRU established that CNCbl uptake pathways are intact M. 
tuberculosis but de novo cobamide biosynthesis appears to be absent (Warner et al., 
2007). Subsequently, CNCbl transport in M. tuberculosis was validated 
experimentally and BacA (Rv1819c) was discovered as a non-canonical cobamide 
transporter (Gopinath, Venclovas, et al., 2013). In this chapter, direct evidence of de 
novo cobalamin production in M. smegmatis is presented. The regulation of 
methionine biosynthesis by cobalamin in this bacterium is also described. Lastly, the 
uptake of exogenous CNCbl and dicyanocobanimade ((CN)2Cbi), is examined and 
findings are compared with current knowledge about corrinoid transport in M. 
tuberculosis.  
4.2 Results 
4.2.1 The de novo cobamide biosynthetic pathway of M. smegmatis is functional  
Multiple comparative genomics studies have predicted that mycobacteria can make or 
utilize cobamides (Rodionov et al., 2003; Vitreschak et al., 2003; Zhang et al., 2009; 
Gopinath, Moosa, et al., 2013; Minias, Minias & Dziadek, 2018; Shelton et al., 2018). 
Here, the cobamide biosynthetic genes in M. smegmatis were identified by querying 
the Mycobrowser portal (Kapopoulou, Lew & Cole, 2011) for orthologs of the 
identified M. tuberculosis genes. Hits from this ortholog search indicated that M. 
smegmatis encodes all enzymes required for de novo cobamide biosynthesis (Table 
4.1). Enzymes catalysing the anaerobic pathway were missing, although CobB/H/K/M 
were found to be hypothetical replacements for CbiA/C/J/F, respectively (Table 4.1). 
Two paralogous genes, MSMEG_0431 and MSMEG_4529, encoded putative CbiX 
replacements (Table4.1). Genes encoding corrinoid salvage and DMB synthesis and 
attachment were also found. 
Besides these, M. smegmatis encoded four other proteins (MSMEG_1123, 
MSMEG_6048, MSMEG_6069, and MSMEG_2607) for which enzymatic functions 
have not been assigned, although their predicted gene annotations implicated them in 
cobamide biosynthesis. MSMEG_1123/6048/6069 share homology with CobW 
protein of proteobacteria, which has been suggested to participate in cobalt chelation 
due to its proximity to CobNST cobalt-chelatase complex (Rodionov et al., 2003). In 
M. smegmatis, the putative CobW proteins were not proximal to CobNST. 
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MSMEG_2607 was annotated as CbiM, which is a predicted cobalt transporter 
(Rodionov et al., 2003). In sum, this analysis revealed that M. smegmatis has the full 
genetic capacity for the de novo biosynthesis of cobamides via the aerobic pathway. 
Table 4.1: De novo cobamide biosynthetic genes in M. smegmatis 
Symbol EC# Synthesis 
step 
M. smegmatis gene number 
GltX EC 6.1.1.17 ALA and 
Uro’ III  
MSMEG_2383/MSMEG_6306 
ProS EC 6.1.1.15 ALA and 
Uro’ III  
MSMEG_2621 
HemA EC 1.2.1.70 ALA and 
Uro’ III  
MSMEG_0952/MSMEG_0661 
HemL EC 5.4.3.8 ALA and 
Uro’ III  
MSMEG_0969/MSMEG_5970 
HemB EC 4.2.1.24 ALA and 
Uro’ III  
MSMEG_0956 
HemC EC 2.5.1.61 ALA and 
Uro’ III  
MSMEG_0953 
HemD EC 4.2.1.75 ALA and 
Uro’ III  
MSMEG_0432/MSMEG_0954 
CobA_CysG EC 2.1.1.107 ALA and 
Uro’ III  
MSMEG_2618 
CysG EC 1.3.1.76 ALA and 
Uro’ III  
MSMEG_2618 
CobI EC 2.1.1.130 Corrin ring 
(aerobic) 
MSMEG_3873 
CobG EC 1.14.13.83 Corrin ring 
(aerobic) 
MSMEG_3871 
CobJ EC 2.1.1.131 Corrin ring 
(aerobic) 
MSMEG_3873 
CobM EC 2.1.1.133 Corrin ring 
(aerobic) 
MSMEG_3877 
CobF EC 2.1.1.152 Corrin ring 
(aerobic) 
MSMEG_5548 
CobK EC 1.3.1.54 Corrin ring 
(aerobic) 
MSMEG_3875  
CobL EC 2.1.1.132 Corrin ring 
(aerobic) 
MSMEG_3878 
CobH EC 5.4.99.61 Corrin ring 
(aerobic) 
MSMEG_3872 
CobB EC 6.3.5.9 Corrin ring 
(aerobic) 
MSMEG_2617 
CobNST EC 6.6.1.2 Corrin ring 
(aerobic) 
MSMEG_3864 (cobN); 
MSMEG_4277 (cobS); 
MSMEG_4275 (cobT) 
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Symbol EC# Synthesis 
step 
M. smegmatis gene number 
CbiK_CbiX EC 4.99.1.3 Corrin ring 
(anaerobic) 
MSMEG_0431/MSMEG_4529 
CbiL EC 2.1.1.151 Corrin ring 
(anaerobic) 
unidentified 
CbiH EC 2.1.1.272 Corrin ring 
(anaerobic) 
unidentified 
CbiF EC 2.1.1.271 Corrin ring 
(anaerobic) 
MSMEG_3877 (cobM) 
CbiG EC 3.7.1.12 Corrin ring 
(anaerobic) 
unidentified 
CbiD EC 2.1.1.195 Corrin ring 
(anaerobic) 
unidentified 
CbiJ EC 1.3.1.106 Corrin ring 
(anaerobic) 
MSMEG_3875 (cobK) 
CbiT EC 2.1.1.196 Corrin ring 
(anaerobic) 
unidentified 
CbiE EC 2.1.1.289 Corrin ring 
(anaerobic) 
unidentified 
CbiC EC 5.4.99.60 Corrin ring 
(anaerobic) 
MSMEG_3872 (cobH) 
CbiA EC 6.3.5.11 Corrin ring 
(anaerobic) 
MSMEG_2617 (cobB) 
CobR EC 1.16.8.1 Cbi-P  MSMEG_6035 
CobO_PduO EC 2.5.1.17 Cbi-P MSMEG_2616 (cobO); 
MSMEG_4934 (pduO); 
MSMEG_1544 (pduO) 
CobQ EC 6.3.5.10 Cbi-P MSMEG_2588 
CobC_CobD 
Protein  
EC 6.3.1.10 Cbi-P MSMEG_4305 (cobC); 
MSMEG_4310 (cobD) 
CobU_CobP EC 2.7.1.156 Cbi-P MSMEG_4274 (cobU) 
CobU_CobP EC 2.7.7.62 Cbi-P MSMEG_4274 (cobU) 
RibF EC 2.7.1.26 DMB  MSMEG_2653 
Fre EC 1.5.1.38 DMB  MSMEG_2800 
BluB EC 1.13.11.79 DMB  MSMEG_6053 
CobU_CobT EC 2.4.2.21 DMB 
attachment 
MSMEG_4275 (cobT) 
CobC EC 3.1.3.73 DMB 
attachment 
MSMEG_4305 (cobC) 
CobS_CobV EC 2.7.8.26 DMB 
attachment 
MSMEG_4277 (cobS) 
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4.2.2 Validation of de novo cobalamin biosynthesis in M. smegmatis by LC-
MS/MS 
Previous observations using an M. smegmatis metEcobK::hyg strain had suggested 
that M. smegmatis could produce and use cobalamin as a co-factor for MetH (Dr. 
Stephanie Dawes, unpublished). This genotype of this mutant was validated by PCR, 
confirming an in-frame deletion of the entire open reading frame (ORF) of metE and 
a disruption of cobK generated by the insertion of a hyg fragment (Figure 4.1A). To 
examine the growth phenotype of the metEcobK::hyg strain, 1 × 106 cells/ml were 
seeded in a 96-well plate and grown at 37C overnight in 7H9-OADC medium 
containing 10-fold dilutions of CNCbl or methionine. The highest concentration of 
CNCbl tested was 10g/ml and the highest methionine concentration was 1mM. 
Growth was inferred by the formation of visible colonies after 3 days’ incubation. 
There were no colonies in wells containing the metEcobK::hyg strain without 
supplement but in 7H9-OADC medium supplemented with either 1mM methionine or 
10g/ml CNCbl, similar colony sizes were observed between this mutant and a wild-
type control (Figure 4.1B). Below 10ng/ml CNCbl or 1M methionine (i.e., 1000-
fold dilutions of either supplement), the metEcobK::hyg strain did not form visible 
colonies in wells (Figure 4.1B). There were no differences between the growth curve 
of the metEcobK::hyg strain grown in 7H9-OADC medium supplemented with 
10g/ml CNCbl or in medium supplemented with 1mM methionine (Figure 4.1C). 
These data demonstrated that the metEcobK::hyg strain required methionine or 
CNCbl for growth in 7H9-OADC medium due to the absence of both MetE and MetH 
activity (due to the absence of de novo cobamide biosynthesis).  
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Figure 4.1: Genotypic and phenotypic characterization of the metEcobK::hyg strain. 
A. The genotype of metEcobK::hyg received from Dr. Stephanie Dawes (unpublished) was 
verified by PCR using primers 3875_F/R flanking the cobK allele and 6638_F/R flanking the 
metE allele. PCR confirmed the deletion of metE gene, resulting in a 471bp PCR product and 
the insertion of an 1124bp hyg fragment into the cobK allele, resulting in a 2593bp PCR 
fragment. The wild-type PCR products for metE and cobK were 2567bp and 1470bp, 
respectively. The dashed line shows the interface of images merged from two distict gels. B. 
Rescue of the metEcobK::hyg strain by exogenous CNCbl (CNCbl) or methionine. C. 
Growth curve of the metEcobK::hyg strain in 7H9-OADC medium in the presence or 
absence of 10g/ml exogenous CNCbl or 1mM methionine, showing failure of the strain to 
grow in unsupplemented medium. Absorbance measurements (OD620nm) were taken every 
15min on a microplate reader over a time course of 48h. The growth curve was plotted using 
“R.”  
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Previous work had also shown that when the medium contained exogenous CNCbl, 
the expression of MetE was repressed by a riboswitch (Warner et al., 2007). To 
investigate cobalamin production in M. smegmatis, a sensitive LC-MS/MS method 
was developed in the MMRU to directly quantify internal cobalamin concentrations 
(Dr. Gabriel Mashabela, unpublished). In this method, extracted cobalamin was 
derivatized to the cyanated form by boiling cell lysates in solution containing 
potassium cyanide. To examine cobalamin-dependent regulation of methionine 
biosynthesis, a strain which was cobalamin-deficient but expressing both MetE and 
MetH was needed. To generate this mutant, allelic exchange mutagenesis was used to 
replace the wild-type allele with deleted MSMEG_3875 allele, creating an unmarked 
in-frame deletion of 80% of the cobK ORF (Figure 4.2A). PCR and Southern blotting 
confirmed the successful isolation of cobK (Figure 4.2B-C), showing that this gene 
was nonessential for in vitro growth of M. smegmatis. The cobK strain exhibited no 
morphological differences compared to the parental wild-type and grew at the same 
rate as the wild-type strain (Figure 4.2D). 
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Figure 4.2: Generation and confirmation of M. smegmatis cobK strain. A. The deletion 
construct eliminated 636bp of cobK (diagonally patterned rectangle). Primers amplifying the 
region flanking (F) or internal (I) to the deleted portion of cobK were designed for PCR 
screening. B. The deletion was confirmed with PCR. Expected product sizes were observed 
for wild-type and cobK when flanking primers were used, but internal primers yielded a 
product in wild-type only. M – DNA molecular weight marker. C. Southern blotting 
confirmation of cobK. A PCR-generated probe for cobK was used to detect a fragment 
between two naturally occurring StyI restriction sites (down-facing arrows in A). The specific 
bands for wild-type (1892bp) and mutant (1255bp) were observed. D. Growth curves of wild-
type (solid black line) and cobK strain (grey dashed line) were generated by plotting 
OD600nm values of a shaking culture every 3h for 9h and after 24h. 
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To test whether the de novo cobamide biosynthetic pathway in M. smegmatis was 
compromised by deleting cobK, whole-cell lysates of the cobK strain and the parental 
wild-type strain were analysed by LC-MS/MS. Cobalamin was positively identified 
using an MRM method that detected two transitions corresponding to -ribazole 5-
phosphate (m/z, 678→359) and DMB (m/z, 678→147) (Figure 4.3A). If cobalamin 
were present, these two transitions would be observed as co-eluting peaks (Figure 
4.3B). 
 
Figure 4.3: Detection of cobalamin in M. smegmatis using LC-MS/MS. A. Cobalamin 
chemical structure. A corrin ring surrounds a centrally-chelated cobalt ion, coordinated by an 
alkyl upper ligand (R-group) and a lower base, DMB. Several chemical groups can occupy the 
R position, giving a unique identity to the cobalamin form: cyano- (cyanocobalamin), adeno- 
(adenosylcobalamin), methyl- (methylcobalamin) or hydroxyl- (aquacobalamin). B. Traces 
corresponding to a cyanocobalamin standard (CNCbl) showing the co-elution of -ribazole 5-
phosphate (blue trace) and DMB (red trace) at 2.79min. The LC-MS/MS method was 
optimized to detect -ribazole 5-phosphate (MW = 359g.mol-1; blue background in A) and 
DMB (MW = 147g.mol-1; red box in A).  
 
As expected, cell extracts of wild-type M. smegmatis culture produced high intensity 
cobalamin peaks (Figure 4.4). These findings provided direct proof of the 
functionality of the aerobic cobamide pathway in this organism. By contrast, 
cobalamin was not detected in the cobK strain (Figure 4.4). The deletion of cobK, 
therefore, abolished de novo cobalamin biosynthesis in M. smegmatis. That this mutant 
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grew normally without exogenously provided CNCbl indicated that MetE was 
functional in M. smegmatis and substituted for MetH in the absence of the co-factor. 
Because the LC-MS/MS method was optimized to specifically identify the cobamide 
bearing DMB as the lower ligand, the detection of cobalamin in M. smegmatis 
confirmed also DMB biosynthesis in this organism was also functional, via an as-yet-
unidentified pathway. 
 
Figure 4.4: LC-MS detection of de novo cobalamin biosynthesis in M. smegmatis. Cell 
extracts of wild type cobK analysed by LC-MS/MS to detect the two cobalamin transitions 
co-eluting peaks at 2.79min. The peaks corresponding to -ribazole 5-phosphate (blue trace) 
and DMB (red trace) were detected in extracts of the wild type strain but not in the cobK 
strain. Peak intensities are expressed as counts per second (cps). 
 
4.2.3 Transcriptional repression of metE by endogenous cobalamin in M. 
smegmatis  
Besides its role as a co-factor for MetH, cobalamin potentially regulates methionine 
biosynthesis in M. smegmatis as a ligand of a predicted riboswitch upstream of metE. 
In M. tuberculosis, cobalamin induces transcriptional repression of metE via this 
riboswitch (Warner et al., 2007). To test whether this was also true in M. smegmatis, 
metE gene expression levels in wild-type and cobK strains were compared using 
ddPCR. This quantitation revealed that the levels of metE in cobK were elevated by 
12.5× relative to the parental wild-type strain (Figure 4.5). This result indicated that 
the predicted riboswitch upstream of metE in M. smegmatis was functional and 
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sensitive to endogenous cobalamin. However, some metE transcripts were still 
detectable in the wild-type strain, implying that repression by internal co-factor was 
not absolute (Figure 4.5). The increased transcript count following the elimination of 
cobalamin in cobK was nonetheless consistent with predicted de-repression of the 
metE riboswitch. Cobalamin deficiency in cobK did not affect metH transcript levels 
(Figure 4.5). 
 
Figure 4.5: Transcriptional repression of metE by endogenous cobalamin in M. 
smegmatis. A. Absolute copy numbers of metE transcripts in M. smegmatis cultures were 
determined using ddPCR and normalized to the housekeeping gene, sigA. The cobalamin-
deficient cobK strain had over 10-fold increase in metE gene expression relative to wild-type. 
There was no difference in relative expression of metH between wild-type and cobK strains. 
The data are representative of two independent experiments. The error bars show the standard 
error of the mean for three technical replicates. 
 
4.2.4 Marginal control of metE gene expression by exogenous CNCbl in M. 
smegmatis 
The impact of exogenous CNCbl on the metE riboswitch was also evaluated by 
comparing gene expression levels in wild-type and cobK strains grown in 7H9 
medium supplemented with CNCbl. It was expected that, in the presence of exogenous 
CNCbl, the cobK strain would phenocopy the wild-type strain with respect to metE 
transcription. However, ddPCR showed that exogenous CNCbl only slightly repressed 
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metE in the mutant but did not cause detectable changes in metE expression in the 
wild-type strain (Figure 4.6).  
 
Figure 4.6: Relative metE gene expression in the presence of exogenous CNCbl. 
Quantification of metE transcription in wild type and cobK in the presence or absence of 
exogenous CNCbl using ddPCR. In unsupplemented cultures, the cobK mutant shows 10-
fold increase in metE gene expression relative to wild type. Providing B12 in the growth media 
produced a small but significant decrease in metE levels in cobK (p=0.0118; (*); ordinary 
two-way ANOVA) but not in the wild type, relative to unsupplemented cultures.  
 
As previously noted, the metEcobK::hyg strain could be rescued by methionine or 
CNCbl, which implied that uptake systems were intact in M. smegmatis. Therefore, it 
was surprising that exogenous CNCbl repressed metE only slightly in the cobK strain. 
One possibility was that the mutant might have harboured secondary mutations 
affecting the binding of cobalamin to the metE riboswitch. To test this assumption, the 
cobK strain and the parental wild-type strain were whole-genome sequenced to 
screen for such mutations. WGS data were also used as an additional screen for the 
deletion of cobK. To do this, a plot of read coverage along the genomic locus of cobK 
was made (Figure 4.7). 
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Figure 4.7: A plot of read coverage along the genomic coordinates of cobK in M. 
smegmatis. The wild-type strain is plotted in green and cobK in blue. The average coverage 
for each strain is indicated by a dashed line above the plot. The drop in read depth in cobK 
strain corresponded to the deleted portion of the gene. 
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Analysis of the WGS data revealed no SNMs in the 5’ upstream region or in the open 
reading frame of metE in either wild-type or cobK. In addition, no mutations were 
detected in any of the other genes involved in de novo cobalamin biosynthesis, 
confirming that the deletion of cobK was solely responsible for the abrogation of 
cobalamin production in this mutant. However, SNMs were found in six genes in the 
cobK strain but not in the parental wild-type strain (Table 4.2). Out of the six SNMs, 
three were non-synonymous (ns-SNM) in MSMEG_2148 (putative HNH 
endonuclease protein), MSMEG_3876 (putative phosphotransferase) and 
MSMEG_6127 (putative anti-anti-sigma factor). The other three were SNMs found 
upstream of the start codons of MSMEG_0691 (putative transcriptional regulatory 
protein), MSMEG_6270 (hypothetical protein) and MSMEG_6423 (a putative 
phosphodiesterase).  
Table 4.2: Unique SNMs detected in M. smegmatis cobK but not in the parental wild-
type strain 
Gene Annotation 
(Kapopoulou, 
Lew & Cole, 
2011) 
SNM Type of SNM Amino Acid 
Change 
MSMEG_0691 putative 
transcriptional 
regulatory 
protein 
1T>G upstream of 
start codon 
  
MSMEG_2148 HNH 
endonuclease 
domain protein 
1135T>C ns-SNM Trp379Arg 
MSMEG_3876 putative 
phosphotransfe
rase enzyme 
family protein 
887G>A ns-SNM Arg296His 
MSMEG_6127 anti-anti-sigma 
factor 
107T>G ns-SNM Leu36Arg 
MSMEG_6270 hypothetical 
protein 
1A>C upstream of 
start codon 
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Gene Annotation 
(Kapopoulou, 
Lew & Cole, 
2011) 
SNM Type of SNM Amino Acid 
Change 
1G>A 
MSMEG_6423 Glycerophosph
oryl diester 
phosphodiester
ase family 
protein 
1T>C 
1T>G 
upstream of 
start codon 
  
 
4.2.5 Uptake and assimilation of dicyanocobinamide in M. smegmatis 
Because WGS did not find any obvious mutations responsible for the weak repression 
of metE by exogenous CNCbl, it was then postulated that CNCbl uptake was so poor 
that only marginal control of metE expression was achieved. A second intriguing 
possibility was that the metE riboswitch discriminated between de novo synthesised 
cobalamin and exogenous CNCbl. To interrogate this notion, the cobalamin-deficient 
mutants were fed (CN)2Cbi; (procured from Sigma-Aldrich®) as a precursor for 
cobamide production. Previous studies had demonstrated that M. tuberculosis could 
assimilate this precursor into a physiologically functional cobamide (Gopinath, 
Venclovas, et al., 2013). Therefore, it was reasoned that M. smegmatis would similarly 
transport and assimilate (CN)2Cbi.  
It was first necessary to determine whether M. smegmatis could assimilate (CN)2Cbi. 
This was tested by finding out if (CN)2Cbi could rescue the metEcobK::hyg strain. 
To do this, the mutant was first grown in 7H9 medium to exponential phase with 1mM 
methionine to support its growth, and then serially diluted and spotted on agar 
containing 10M (CN)2Cbi. This assay confirmed that (CN)2Cbi supported the growth 
of metEcobK::hyg (Figure 4.8). However, at this concentration of (CN)2Cbi, 
metEcobK::hyg took longer to form colonies than when a similar concentration of 
CNCbl was used (Figure 4.8). In the CNCbl-containing plates, only three days of 
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incubation were required for distinctly visible colonies to emerge. By contrast, it took 
13 days to form colonies of comparable sizes in the (CN)2Cbi plates (Figure 4.8). This 
was not surprising, as it has been reported that the assimilation of (CN)2Cbi in 
mycobacteria is very poor (Gopinath, Venclovas, et al., 2013). Nevertheless, these 
observations clearly demonstrated that M. smegmatis could utilize (CN)2Cbi.  
 
Figure 4.8: Uptake and assimilation of dicyanocobinamide by M. smegmatis. Spotting 
assays of exponentially-growing cultures of wild-type and metEcobK::hyg strains on 7H10-
OADC agar containing either 10g/ml CNCbl or 10M (CN)2Cbi, or without 
supplementation. Plates were imaged at 3 days and the (CN)2Cbi plate was reimaged after 13 
days.  
 
Interestingly, there was no difference in the growth rate of metEcobK::hyg in liquid 
culture when either (CN)2Cbi or CNCbl was used; i.e., in both conditions, similar 
OD600nm values were obtained at any given time point. However, the uptake of 
(CN)2Cbi in liquid culture was accompanied by a remarkable change in colour of the 
spent media (Figure 4.9). In the metEcobK::hyg strain, the colour of the media 
changed from the initial purple colour of (CN)2Cbi to a final pale-yellow colour, in 
contrast to that of wild-type and cobK spent media, which changed to a rusty colour. 
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These observations hinted that, although the uptake of (CN)2Cbi was poor in M. 
smegmatis, metabolic necessity could trigger increased salvage. In this case, the 
absolute requirement for cobalamin in metEcobK::hyg might have presented a 
stronger impetus for (CN)2Cbi assimilation, unlike in the wild-type and cobK strains, 
which could grow without supplementation.  
 
Figure 4.9: Dicyanocobinamide uptake in M. smegmatis in liquid cultures. M. smegmatis 
wild-type or mutant strains were grown to stationary phase (OD600nm > 2) with 30M (CN)2Cbi 
overnight in a shaking incubator. The spent media was harvested by centrifugation and filtered 
through a 0.22m syringe filter. (CN)2Cbi uptake was accompanied by distinctive spent media 
colour changes. The purple colour of (CN)2Cbi faded more strikingly in the metEcobK::hyg 
strain than in the other strains. 
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4.2.6 LC-MS/MS confirmation of de novo cobalamin biosynthesis via 
dicyanocobinamide assimilation  
To confirm that M. smegmatis used exogenous (CN)2Cbi as a precursor for de novo 
cobalamin biosynthesis, wild-type, cobK and metEcobK::hyg strains were grown 
in liquid cultures containing (CN)2Cbi and cell extracts were analysed by LC-MS/MS 
for de novo synthesised cobalamin, which was derivatized to the cyanated form by 
boiling cell lysates in solution containing potassium cyanide. To circumvent poor 
uptake, (CN)2Cbi was used at a high concentration (30M). Since (CN)2Cbi was 93% 
pure and contained trace amounts (≤ 0.1%) of CNCbl as per the manufacturer’s 
specifications, a 1M control (CN)2Cbi sample was analysed for background 
cobalamin peaks, expecting that at this concenctration, possible CNCbl contamination 
(≤ 1nM) was high enough to detect via LC-MS/MS. LC-MS/MS data showed that the 
cobalamin signal in the (CN)2Cbi control was below the limit of detection (Figure 
4.10), confirming that any cobalamin found in (CN)2Cbi-supplemented cultures would 
be a true reflection of (CN)2Cbi conversion. Consistent with phenotypic data, 
cobalamin peaks were detected in cell extracts of metEcobK::hyg supplemented 
with (CN)2Cbi, although the intensity of the cobalamin peaks was approximately 3-
fold lower that of unsupplemented wild-type strain (Figure 4.10). In contrast, 
cobalamin was not detected in the cobK strain despite supplementation with excess 
(CN)2Cbi (Figure 4.10), which reinforced the presumption that measurable (CN)2Cbi 
uptake occurred only in cells in which the co-factor was essential for growth. In sum, 
the LC-MS/MS method validated the intactness of the (CN)2Cbi salvage pathway; i.e., 
de novo cobalamin biosynthesis in M. smegmatis can proceed via the (CN)2Cbi salvage 
pathway.  
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Figure 4.10: LC-MS confirmation of dicyanocobinamide-assimilation in M. smegmatis. A. 
A sample of commercial (CN)2Cbi showing that potentially-contaminating CNCbl is 
undetectable. B. De novo cobalamin production in wild type bacilli cultured in 
unsupplemented 7H9-OADC medium. C-F. Detection of cobalamin in metEcobK::hyg (C-
D) or cobK (E-F) strains grown with or without (CN)2Cbi. Peaks corresponding to -ribazole 
5-phosphate (blue trace) and DMB (red trace) were detected in the (CN)2Cbi-supplemented 
metEcobK::hyg strain only (arrow). The “no supplement” metEcobK::hyg strain was 
grown in medium containing 1mM methionine. 
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4.2.7 Control of metE repression by de novo synthesised cobalamin derived from 
assimilated dicyanocobinamide 
Because LC-MS/MS showed that the amount of cobalamin derived from (CN)2Cbi 
assimilation was too low to be detected in wild-type and the cobK strains, it was 
interesting to explore whether these ultralow concentrations were still sufficient to 
measurably repress metE. To investigate this possibility, cultures of wild-type and 
cobK strains were grown in (CN)2Cbi-containing media, followed by quantitation of 
metE transcripts using ddPCR. Again, a high concentration of (CN)2Cbi was used to 
offset poor uptake. Quantitation analysis showed that (CN)2Cbi supplementation had 
no repressive effect on metE (Figure 4.11), which was consistent with poor uptake. 
Additionally, these findings suggested that on its own, (CN)2Cbi might not have been 
a compatible ligand for the metE riboswitch. However, since the LC-MS/MS method 
specifically detected DMB as a marker of de novo synthesised cobalamin, it was not 
possible to measure intracellular accumulation of (CN)2Cbi itself.  
 
Figure 4.11: Relative expression of metE in wild-type and cobK cultures supplemented 
with dicyanocobinamide. Absolute quantification of metE transcripts in the presence or 
absence of (CN)2Cbi using ddPCR. (CN)2Cbi supplementation did not change metE transcript 
level in either wild type or cobK, relative to unsupplemented cultures. The graphed data are 
representative of two independent experiments. The error bars show the standard error of the 
mean. 
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4.2.8 Putative cobamide transporters in M. smegmatis 
The genomics, gene expression and LC-MS/MS data supported the functionality of 
CNCbl and (CN)2Cbi uptake and assimilation systems in M. smegmatis, even though 
the proteins and mechanisms involved are uncharacterized. In Gram negative bacteria, 
extracellular cobamides are trafficked into cells by the BtuB-TonB-ExbBD-BtuF-
BtuCD system (Noinaj et al., 2010). Unlike M. tuberculosis, M. smegmatis is one of 
the few mycobacteria that encode homologues of btuF, btuC, and btuD. In M. 
smegmatis, these genes occur as co-operonic partners: MSMEG_6064 (btuF), 
MSMEG_6063 (btuC), and MSMEG_6062 (btuD) (Figure 4.12A; Table 4.3) 
(Novichkov et al., 2013). The M. smegmatis genome also encodes paralogs of these 
three genes in a separate operon which comprises two copies of btuF2 (MSMEG_4561 
and MSMEG_4560), btuC2 (MSMEG_4559) and btuD2 (MSMEG_4557). Cobalamin 
riboswitches are predicted upstream of MSMEG_6064 and MSMEG_4561, which are 
the first genes in their respective operons (Figure 4.12A; Table 4.3). In addition to 
these proteins, two paralogous genes (MSMEG_3655/MSMEG_4380) encoding 
homologues of the M. tuberculosis BacA are also found in the M. smegmatis genome 
(Figure 4.12A; Table 4.3). These proteins have been predicted to associate with the 
inner membrane of the mycobacterial cell envelope (Hermann et al., 2018). 
Table 4.3: Putative cobamide transporters in M. smegmatis 
Symbol Annotation (Kapopoulou, Lew & Cole, 
2011) 
M. smegmatis 
gene number 
bacA ABC transporter, permease/ATP-binding 
protein 
MSMEG_3655; 
MSMEG_4380 
btuF* Vitamin B12 ABC transporter, B12-binding 
component 
MSMEG_6064 
btuC Vitamin B12 ABC transporter, permease 
component 
MSMEG_6063 
btuD Vitamin B12 ABC transporter, ATPase 
component 
MSMEG_6062 
btuF2 
(MSMEG_4561)* 
Vitamin B12 ABC transporter, B12-binding 
component 
MSMEG_4561; 
MSMEG_4560 
btuC2 Vitamin B12 ABC transporter, permease 
component 
MSMEG_4559 
btuD2 Vitamin B12 ABC transporter, ATPase 
component 
MSMEG_4557 
* Cobalamin riboswitches are predicted upstream of these genes (Novichkov et al., 2013). 
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4.2.9 Riboswitch control of putative cobamide transport in M. smegmatis 
Because putative cobalamin riboswitches occurred upstream of the btuFCD and 
btuF2C2D2 operons, the expression levels of these proteins in the presence or absence 
of CNCbl were assessed using targeted MS. To this end, membrane fractions of wild-
type and metEcobK::hyg strains grown in methionine-supplemented media were 
prepared and digested with trypsin to generate unique peptides. Tryptic peptides 
corresponding to BtuF and BtuF2 (MSMEG_4561) were then detected and quantitated 
by MS and analysed with the Skyline software. As a control for a non-riboswitch 
associated transporter, the expression profile of one of the two BacA paralogs 
(MSMEG_3655) was also assessed. MSMEG_4380 was not analysed since the 
reference spectral library did not contain any peptides for this protein. Analysis 
showed that all three proteins had higher peak intensities in the metEcobK::hyg 
strain than in the wild-type (Figure 4.12B). The peak intensities of BacA, BtuF and 
BtuF2 (MSMEG_4561) were 1.4×, 3.5×, and 9.4× higher in metEcobK::hyg than 
in wild-type, respectively (Figure 4.12B). The significantly lower levels of BtuF and 
BtuF2 (MSMEG_4561) in the wild-type strain – a de novo cobamide producer – were 
suggestive of riboswitch-based downregulation of these proteins. That is, the inferred 
overexpression of these putative transporters in metEcobK::hyg – which lacks de 
novo cobamide – indicated de-repression and reflected the demand for cobalamin in 
this mutant. 
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Figure 4.12: Protein expression profiles of BacA, BtuF and BtuF2 (MSMEG_4561) in wild-
type or metEcobK::hyg. A. A schematic representation of bacA genes and the btuFCD and 
btuF2C2D2 operons in M. smegmatis. Cobalamin riboswitches (red spheres) are predicted 
upstream of btuF and btuF2 (MSMEG_4561). Gene numbers in M. smegmatis are shown 
below each gene name. B. Targeted MS analysis of BacA, BtuF and BtuF2 (MSMEG_4561) 
protein expression. Log2 peak intensities of BacA, BtuF and BtuF2 (MSMEG_4561) in cell 
wall fractions of wild type and metE cobK::hyg strains cultured in media containing 10g/ml 
CNCbl or without CNCbl (No CNCbl). Similar levels of BacA were observed in the presence 
or absence of CNCbl in both wild type and metE cobK::hyg strains. In the absence of CNCbl, 
BtuF and BtuF2 (MSMEG_4561) expression was higher in the metE cobK::hyg strain than 
in the wild type (p<0.0001; (****); ordinary two-way ANOVA). CNCbl strongly repressed 
BtuF and BtuF2 (MSMEG_4561) in the metE cobK::hyg strain (p<0.0001; (****); ordinary 
two-way ANOVA) but did not affect the levels of both proteins in the wild type strain. The 
data shown represent two independent experiments. The error bars show the standard error of 
the mean. ns – not significant.  
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When CNCbl was used as a supplement instead of methionine, the peak intensities of 
the three proteins were unchanged in the wild-type strain (Figure 4.12B). The 
observation that BtuF and BtuF2 (MSMEG_4561) peak intensities were not affected 
implied that exogenous CNCbl had not resulted in more repression of these two 
riboswitch-associated proteins; i.e., in addition to repression by endogenously 
produced cobalamin. Another explanation for this result was that further repression 
had occurred, but the change was probably too small to be detected by this analysis. 
As expected, protein levels of BacA, which does not have a predicted riboswitch, were 
unaffected by CNCbl (Figure 4.12B).  
In contrast, BtuF and BtuF2 (MSMEG_4561) levels were reduced in 
metEcobK::hyg to levels similar to those observed in wild-type (Figure 4.12B). The 
ability of exogenous CNCbl to repress the BtuF/ BtuF2 (MSMEG_4561) proteins 
indicated the presence of functional cobalamin riboswitches controlling their 
respective operons. However, it seemed that cobamide uptake was not affected despite 
the observed riboswitch-based repression of the BtuFCD/BtuF2C2D2 operons because 
metEcobK::hyg was still able to grow on exogenous CNCbl, possibly because the 
level of uptake via BtuFCD/BtuF2C2D2 was still sufficient to support growth even 
under repressed conditions. In M. smegmatis, there are two homologues of BacA 
sharing strong amino acid sequence identities between each other as evaluated by 
standard BLASTP alignment (Altschul et al., 1997). Both putative M. smegmatis BacA 
have been reported to associate with the inner membrane of the cell envelope 
(Hermann et al., 2018), supporting their potential roles as cobamide transporters. 
Therefore, the ability of metEcobK::hyg to grow in exogenous CNCbl, despite the 
repression of BtuF and BtuF2 (MSMEG_4561), might have also been because CNCbl 
uptake was unaffected due to the presence of the two copies of M. smegmatis BacA. 
4.3 Discussion 
Genomic analyses revealed that M. smegmatis has the genetic potential for de novo 
cobamide biosynthesis, encoding nearly 30 enzyme-catalysed steps of the the de novo 
cobamide biosynthetic pathway. Prior to this study, de novo production of cobalamin 
in M. smegmatis had been inferred from indirect evidence only, notwithstanding the 
widespread use of this organism as a mycobacterial model. Several decades ago, de 
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novo cobamide production in M. smegmatis was suggested when whole cell lysates 
and culture filtrates of this organism supported the growth of Lactobacillus 
leichmannii, a cobamide auxotroph (Karasseva, Weiszfeiler & Lengyel, 1977). 
Another piece of indirect evidence pointing to the presence of endogenous cobamides 
in M. smegmatis came from an experiment  showing that mutants lacking genes 
involved in the methylcitrate pathway, which is essential for catabolizing propionate, 
used the cobalamin-dependent methylmalonyl pathway to deal with the toxicity of the 
stereoisomers of 2-methylcitrate, the by-product of propionate produced by 2-
methylcitrate synthase (PrpC; EC 2.3.3.1) (Upton & McKinney, 2007). This chapter 
also presented direct evidence for de novo biosynthesis of cobalamin and cobalamin-
dependent regulation of methionine biosynthesis in M. smegmatis. The experimental 
approach involved a combination of genomics, genetics, analytical chemistry, and 
targeted profiling of gene and protein expression. The deletion of CobK, a precorrin-
6x reductase, eliminated de novo cobamide production, validating the functionality of 
this gene in M. smegmatis. Further experiments are necessary to to verify the functions 
of other putative proteins in the de novo cobamide biosynthesis and salvage pathways 
in this organism. 
The functionality of (CN)2Cbi salvage in M. smegmatis was confirmed by the data 
showing that cobalamin could also be produced using (CN)2Cbi as a precursor. 
Although the metabolite analysis described in this chapter was insufficient to fully 
characterize the chemical structure of the de novo synthesised cobamide in M. 
smegmatis, the LC-MS/MS method provided clues about the structure of the cobamide 
molecule produced by this organism, identifying cobalamin as the likely cobamide 
form in this organism and DMB as the likely lower base. Whether M. smegmatis 
produces other cobamide forms or whether DMB is the only lower base or ligand, was 
beyond the scope of the work described in this thesis and remains the subject of future 
investigation. The LC-MS/MS data presented herein showed that deleting 80% of the 
coding sequence of cobK (Figure 4.2), encoding a precorrin-6a reductase involved in 
corrin ring synthesis, completely abolished de novo cobalamin biosynthesis. Similar 
LC-MS/MS analysis of metEcobK::hyg, in which the cobK gene was interrupted by 
a hyg fragment, also confirmed that the inactivation of cobK was sufficient to eliminate 
de novo cobalamin biosynthesis. However, when (CN)2Cbi was provided 
exogenously, the corrin ring step could be bypassed, restoring cobalamin biosynthesis 
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in this bacterium. The mechanism by which corrinoids are assimilated in mycobacteria 
is still unknown, and mycobacterial homologues of BtuM, a CNCbl decyanase 
described in other organisms (Rempel et al., 2018) are as-yet unidentified.  
The utilization of exogenous cobamides by mycobacteria is widely reported in the 
literature (Gopinath, Venclovas, et al., 2013; Boot et al., 2016; Guzzo et al., 2016; 
Lawrence et al., 2018). Targeted proteomics confirmed that M. smegmatis expresses 
homologues of classic BtuFCD-type cobamide transporters (Noinaj et al., 2010) as 
well as the atypical transport protein BacA (Gopinath, Venclovas, et al., 2013). The 
presence of these proteins in M. smegmatis raises the possibility of the existence of an 
active transport system for cobamides akin to the Ton-dependent system found in 
Gram negative bacteria. However, the M. smegmatis BtuFCD proteins have been 
found to associate with the inner membrane in this organism (Hermann et al., 2018). 
The proteins involved in ferrying cobamides through the mycobacterial outer 
membrane and the periplasmic space still await discovery.  
It was clear that corrinoid uptake in M. smegmatis was poor except under strict 
methionine auxotrophy. Cobalamin riboswitches are predicted upstream of BtuF and 
BtuF2 (MSMEG_4561), each of which occur in the 5’ end of three-gene operons with 
BtuCD and BtuC2D2, respectively. Proteomics data established that these 
riboswitches are functional, suppressing their cognate proteins in the presence of 
cobalamin. This riboswitch-based control might explain, albeit partially, the poor 
uptake of CNCbl although it could not explain the apparently poor transport of 
(CN)2Cbi, which would not be a natural ligand for these riboswitches. It is unclear why 
this organism also expressed BacA alongside BtuFCD/BtuF2C2D2 transporters, 
although the fact BacA has been linked to drug resistance (Domenech et al., 2009) 
supports the view that cobamide transport might be a secondary role for this protein.  
Due to the presence of multiple candidate cobamide transporters in M. smegmatis, 
complex genetic manipulations that were beyond the scope of this thesis would be 
required to selectively or collectively inactivate them for more in-depth 
characterization. However, the preliminary data presented herein signify important 
first steps to understanding mycobacterial acquisition of cobamides. Follow-up work 
is planned to further explore putative cobamide transporters in M. smegmatis using 
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inducible knockdown platforms that are amenable to multiplexing such as the recently 
described mycobacterial CRISPRi system (Rock et al., 2017). 
In this chapter, the notion that the risk of methionine starvation was a major driver of 
in vitro uptake and assimilation of CNCbl and (CN)2Cbi was proposed. The data 
supporting this hypothesis stemmed from observations that the metEcobK::hyg 
strain, which required CNCbl for growth, more efficiently converted (CN)2Cbi to 
cobalamin than the cobK strain. Because MetE was active in the cobK strain, the 
requirement for CNCbl was obviated. However, when metE was also deleted in the 
background of a disrupted cobK, generating metEcobK::hyg, methionine 
auxotrophy occurred because the absence of cobalamin deactivated MetH. 
Consequently, a need for externally-sourced co-factor was created, which 
subsequently triggered corrinoid salvage.  
The cobalamin riboswitch upstream of metE was shown to be functional, and 
transcriptionally controlled this gene. It was clear that although the suppression of 
metE by endogenous cobalamin was substantial, it was incomplete, and some gene 
expression could still be detected. Furthermore, exogenous CNCbl only marginally 
repressed metE presumably due to poor corrinoid uptake in M. smegmatis. This 
phenotype was in sharp contrast to that described in M. tuberculosis, in which CNCbl 
has been shown to be readily transported in vitro (Warner et al., 2007). This difference 
between M. smegmatis and M. tuberculosis could be related to their unique 
environmental adaptations. Presumed to be cobamide-deficient, M. tuberculosis may 
have evolved to fully rely on exogenous cobamides, possibly via a constitutive uptake 
machinery. That M. tuberculosis appears to have dispensed with the riboswitch-
controlled BtuFCD protein complex supports this theory. In this regard, it will be 
instructive to fully elucidate the proteins and mechanisms involved in regulating 
cobamide utilization during infection.  
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5 Conditional essentiality of the gene encoding the cobalamin-
dependent methionine synthase, MetH, in M. smegmatis 
5.1 Overview 
In the previous chapter, it was demonstrated that the absence of cobalamin resulted in 
higher metE gene expression due to the de-repression of the metE riboswitch whereas 
in the wild-type M. smegmatis, constitutive cobalamin biosynthesis kept metE levels 
low. Accordingly, it was hypothesized that the repression of metE caused M. 
smegmatis to rely solely on MetH for methionine biosynthesis. In this chapter, the 
conditional essentiality of metH is defined based on loss of cell viability following the 
inactivation of the metH gene. In light of recent findings linking MetH and cobalamin 
to the intrinsic resistance of M. tuberculosis to sulphonamides (Guzzo et al., 2016), 
the implications of metH essentiality for antimycobacterial drug discovery research are 
highlighted and discussed. 
5.2 Results 
5.2.1 Allelic exchange mutagenesis fails to produce a metH knockout in 
cobalamin–replete M. smegmatis 
Methionine is essential for bacterial viability owing to its multiple metabolic roles, 
including the initiation of translation and the synthesis of S-adenosylmethionine 
(SAM), a cellular donor of methyl groups (Ferla & Patrick, 2014; Ferguson, 2016). In 
M. smegmatis, the last step in the biosynthesis of methionine is catalysed by two 
methionine synthases, MetE and MetH (Figure 5.1). In the preceding chapter, it was 
shown that the elimination of cobamide biosynthesis resulted in the upregulation of 
MetE, suggesting that metE must be under constitutive repression by de novo 
synthesised cobalamin in wild-type M. smegmatis. However, because Co(I)cobalamin 
is a co-factor for MetH (Gonzalez et al., 1992), the observed deficiency in MetE 
activity in the wild-type strain would not impede methionine biosynthesis. This 
observation led to the hypothesis that if M. smegmatis metH were deleted, it would 
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effectively deplete de novo methionine biosynthesis because of the cobalamin-
mediated suppression of metE expression.  
 
Figure 5.1: The final step in the de novo methionine pathway in M. smegmatis. The transfer 
of a methyl group from 5-methyl-THF (5-MTHF) to homocysteine resulting in methionine 
and tetrahydrofolate (THF) as a by-product is catalysed by either MetE, the cobalamin-
independent methionine synthase, or MetH, with Co(I)cobalamin as a co-factor. MetE is under 
constitutive repression by a cobalamin riboswitch. 
 
To test this premise, an attempt was made to generate an unmarked metH knockout 
(KO) mutant of M. smegmatis in either a cobalamin-replete (wild-type) or –deficient 
(cobK) background using the standard two-step allelic exchange mutagenesis (Parish 
& Stoker, 2000; Gopinath, Warner & Mizrahi, 2015). First, a suicide vector carrying 
the metH deletion construct (Figure 5.2) was inserted into wild-type M. smegmatis by 
electroporation. It was feared that the strong repression of metE by de novo synthesised 
cobalamin as demonstrated in the previous chapter, would counter-select against metH 
 88 
 
KO mutants because metH deletion would essentially eliminate all M. smegmatis 
methionine synthases, depleting the bacilli of methionine. Therefore, to increase the 
likelihood of recovering metH KOs, selection plates were supplemented with 
exogenous methionine.  
Out of 154 putative double crossover (DCO) colonies that were screened by PCR, none 
bore the metH allele. It was possible that this was a result of the inherently low 
recombination efficiency of the allelic exchange method (Gopinath, Warner & 
Mizrahi, 2015). Therefore, it was thought that by using a hyg-marked metH::hyg 
construct (Figure 5.2), recombination efficiency would be improved by essentially 
“forcing” the recovery of colonies bearing the metH::hyg allele. Again, selection 
plates were supplemented with methionine. With the construct carrying the deletion-
insertion allele, 60 sucrose resistant DCOs were screened, all having the wild-type 
allele and were presumed to have acquired resistance to hygromycin spontaneously or 
via rearrangement of the allelic exchange vector. The failure to delete metH despite 
methionine supplementation hinted that this gene was essential for growth in the wild-
type M. smegmatis background due to the repression of MetE in the presence of de 
novo synthesised cobalamin in this background. In the previous chapter, it was 
observed that the minimal concentration of methionine that supported the growth of 
the metEcobK::hyg strain – a cobalamin/methionine auxotroph – was 1M (Figure 
4.1B), 1000-fold less than the concentration provided exogenously in this experiment. 
However, as the growth rate of the the metEcobK::hyg strain was the same as that 
of the wild type strain supplemented with 1mM methionine (Figure 4.1C), this 
concentration was not harmful to the bacilli. It was assumed, therefore, that although 
exogenous methionine was taken up by the bacilli, this uptake could not keep up with 
the demand for methionine and hence metH or metH::hyg colonies could not be 
recovered in a cobalamin-replete strain. To confirm this possibility, an attempt was 
made to delete this gene in the cobK strain, a cobalamin-deficient background.  
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Figure 5.2: The deletion strategy for generating the metH knockout. The deleted region 
(chequered pattern) eliminated the entire cobalamin binding domain (CBL) and partially 
disrupted the SAM binding domain (SAM). A hyg fragment was inserted into a BglII site in 
the original metH plasmid to generate a marked construct. MTH – methyltetrahydrofolate 
binding domain; HCY – homocysteine binding domain 
 
Following the failure to isolate either metH or metH::hyg strains in the wild-type 
background, the deletion construct was electroporated into the cobK strain and 
resulting transformants were screened for the metH allele. In this case, exogenous 
methionine was not provided in selection plates because it was anticipated that the lack 
of cobalamin in cobK would alleviate metE repression and provide an alternative 
route (via MetE) to de novo methionine biosynthesis. In the cobK background, 
metH strains were readily isolated: PCR screening verified the cobKmetH 
genotype in 9 of 34 colonies tested (Figure 5.3). In all cases, the metH genotype was 
validated by Sanger sequencing. 
 90 
 
 
Figure 5.3: PCR confirmation of metH deletion in the cobK background. Flanking (Fp) 
and internal (Ip) primers were designed to amplify outside or inside the deleted genes. Six out 
of 9 positive cobKmetH clones (H-L) are shown. Flanking primers yielded PCR products 
of expected sizes (metH – 2382bp; cobK – 1470bp). When using internal primers, PCR 
products of expected sizes were observed in wild-type (metH – 1256bp; cobK – 404bp) but 
were missing in the plasmids or clones. The dashed line shows the break between images 
merged from two distict gels. 
 
5.2.2 Lack of de novo cobalamin biosynthesis in the cobKmetH strain 
De novo production of cobalamin and the degree to which (CN)2Cbi was assimilated 
by the cobKmetH strain was assayed by LC-MS/MS analysis as described (chapter 
2, Materials and Methods). As expected, cobalamin could not be detected in extracts 
of the cobKmetH strain (Figure 5.4A). As was the case with the parental cobK 
strain, de novo synthesised cobalamin was also not detectable in extracts of the 
cobKmetH strain when the organism was cultured in the presence of (CN)2Cbi 
(Figure 5.4B). As described in chapter 3, exogenous CNCbl was shown to result in 
modest repression of metE transcription. It was therefore hypothesised that, in the 
context of metH deletion, this partial repression would reduce internal methionine 
levels and possibly retard M. smegmatis growth. To investigate whether this was the 
case, the cobKmetH strain was cultured in media containing CNCbl. However, 
exogenous CNCbl did not affect growth of the cobKmetH strain in batch culture 
when compared to an unsupplemented control. Similarly, there were no differences in 
growth on solid media between CNCbl-supplemented and controls cells (Figure 
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5.4C). Furthermore, supplementation with (CN)2Cbi had no effect on growth (Figure 
5.4C), consistent with the observations reported in the previous chapter that the uptake 
of CNCbl and (CN)2Cbi in M. smegmatis was poor.  
 
Figure 5.4: Cyanocobalamin and dicyanocobinamide uptake by cobKmetH. A-B. LC -
MS/MS traces of cobKmetH cell extracts showing the lack of detectable cobalamin 
production despite Cbi supplementation. C. CNCbl and (CN)2Cbi uptake in the cobKmetH 
strain determined by a spotting assay on 7H10 agar containing CNCbl or (CN)2Cbi. Prior to 
spotting, cells were grown in 7H9-OADC medium to exponential phase (OD600 ≈ 0.6) followed 
by 10-fold serial dilutions. Plates were imaged after 3 days’ incubation at 37C.  
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5.2.3 Riboswitch-mediated regulation of metE in the cobKmetH strain 
The levels of metE transcript in the cobKmetH strain in the presence of de novo 
synthesised cobalamin or exogenous CNCbl were also quantified by ddPCR and 
compared to gene expression levels in the parental cobK strain. Similar to the cobK 
strain, the cobKmetH strain had elevated metE gene expression compared to wild-
type strain (Figure 5.5A). As in the cobK parental strain, the levels of metE in 
cobKmetH were also slightly, but not significantly, decreased by exogenous CNCbl 
and unaffected by exogenous (CN)2Cbi (Figure 5.5B). 
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Figure 5.5: Analysis of metE transcription in cobKmetH relative to wild type in the 
presence of or absence of exogenous CNCbl. A. Transcript copy numbers of metE in CNCbl-
supplemented wild-type, cobK and cobKmetH strains were determined by ddPCR 
Exogenous CNCbl caused a 1.3× reduction in metE transcript levels in cobKmetH 
(p<0.0001; (****); two-way ordinary ANOVA). B. metE transcription in cobKmetH 
relative to wild type in the presence or absence of exogenous (CN)2Cbi. The data shown are 
representative of two independent experiments. Error bars represent the standard error of the 
mean. 
 
To find out whether de novo synthesised cobalamin had any effect on metH expression, 
levels of metH transcript were compared between the wild-type and cobK strains. To 
examine the metH expression profile in the context of metE deficiency, metH transcript 
levels were analysed in a metE strain, which had an in-frame deletion of the entire 
metE ORF (Dr. Stephanie Dawes, unpublished) (Figure 5.6A). Across these three 
strains, similar levels of metH transcripts were observed (Figure 5.6B), implying that 
metH gene expression was independent of cobalamin availability and metE levels.  
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Figure 5.6: Analysis of metH expression profile in M. smegmatis. A. PCR genotyping of the 
wild type and metE strains using the 6638_F/R primer pair targeting the flanking regions of 
the metE gene confirmed the deletion of the metE ORF in the metE strain, resulting in a 
471bp PCR product. The wild-type PCR product was 2567bp. B. Relative metH gene 
expression in wild-type, cobK and metE strains. Absolute copy numbers of metH transcript 
were determined by ddPCR and normalized to the copy number of sigA transcript. There was 
no difference in metH expression between the mutants and the wild type strain. PCR image 
courtesy of Rendani Mbau. ns – not significant (ordinary one-way ANOVA). 
 
It was suspected that the small (but statistically significant) reduction in metE 
transcript due to exogenous CNCbl (Figure 5.5A), was related to poor CNCbl uptake. 
This finding also explained why the cobKmetH strain, which encodes the cobalamin 
sensitive metE gene, grew in culture containing CNCbl. To exclude the possibility that 
this unexpected lack of sensitivity to CNCbl was due to suppressor mutations in the 
riboswitch, WGS analysis was performed on this mutant. WGS revealed no mutations 
in the metE riboswitch in the cobKmetH strain, implying that the lack of sensitivity 
to the exogenous cofactor in this strain was not due to any inactivating mutations in 
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the metE riboswitch. However, one synonymous SNM (s-SNM) and three ns-SNMs 
that were missing in the parental cobK strain were identified in cobKmetH (Table 
5.1). These mutations were found in three genes (MSMEG_0619, MSMEG_4183 and 
MSMEG_5492) of unknown functions. Based on the genomic context of these genes, 
their functions were unlikely to be related to cobamide or methionine metabolism. The 
M. tuberculosis homologues encoding proteins with assigned functions were found for 
MSMEG_0619 (PPE family protein PPE4) and MSMEG_5492 (acetyl-/PrP-CoA 
carboxylase (beta subunit) AccD2) (Table 5.1). MSMEG_4183 did not have any 
homologues in M. tuberculosis but the Mycobrowser portal (Kapopoulou, Lew & 
Cole, 2011) predicted it to encode a putative phosphoglycolate phosphatase 
respectively (Table 5.1). Because the cloned metH fragment (Figure 5.2) is 
immediately adjacent to MSMEG_4183, it was assumed that the ns-SNM detected in 
this gene was likely due to mismatches that might have happened during the repair of 
double stranded DNA breaks which sometimes occur during homologous 
recombination. 
Table 5.1: Unique SNMs detected in cobKmetH relative to the parental cobK strain 
Gene ID Product SNM Type of 
SNM 
Amino Acid 
Change 
MSMEG_0619 PE/PPE family 
protein 
271G>T ns-SNM Val91Phe 
MSMEG_4183 phosphoglycolate 
phosphatase, 
chromosomal 
34C>A ns-SNM Leu12Met 
MSMEG_5492 acetyl-CoA 
carboxylase 
carboxyltransferase 
(AccD2) 
480G>A s-SNM Gln160Gln 
 
5.2.4 Mass spectrometric profiling of MetE protein expression 
To test the effect of endogenous and exogenous CNCbl on MetE protein expression, 
MS was used to detect two unique MetE peptides in the wild-type and cobK strains 
grown with or without CNCbl. Consistent with incomplete metE repression in the 
presence of cobalamin (as reported in the previous chapter), MetE peptides were 
detected in the wild-type strain (Figure 5.7). As expected, analysis of absolute peak 
 96 
 
intensities showed that MetE protein levels were 3.5× higher in cobK than in wild-
type because of the riboswitch-based repression by endogenous cobalamin. (Figure 
5.7). When CNCbl was added to growth medium, MetE peptides could no longer be 
detected in the wild-type strain, possibly due to an additive repressive effect by 
exogenous CNCbl. However, in the cobK strain, MetE peak intensity was halved in 
the presence of exogenous CNCbl (Figure 5.7). Based on these findings and the gene 
expression analysis described above, it is plausible that, in M. smegmatis, the metE 
riboswitch is not in a natural stoichiometric equilibrium with de novo synthesised 
cobalamin ligand and that increasing the concentration of internal cobalamin (i.e., 
through supplementation with exogenous CNCbl) led to stronger repression. 
 
Figure 5.7: MetE protein expression analysis using mass spectrometry. Targeted MS 
analysis of MetE protein expression. Log2 peak intensities of MetE tryptic peptides in wild 
type and cobK grown in the presence or absence of exogenous CNCbl (CNCbl). MetE 
peptide levels were more decreased in CNCbl-supplemented wild type (p=0.0071; (**) 
ordinary two-way ANOVA) than in CNCbl-supplemented cobK (p=0.0001; (***); ordinary 
two-way ANOVA). 
 
5.2.5 Loss of cell viability following transcriptional knockdown of metH in M. 
smegmatis 
Since it was not possible to generate allelic exchange deletions in metH in a wild-type 
M. smegmatis background, a conditional knockdown of this gene was made using the 
CRISPRi strategy (Rock et al., 2017). For this approach, PLJR962, a Km-selectable, 
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chromosomally integrating CRISPRi plasmid optimized for M. smegmatis (Rock et 
al., 2017) was used. This vector contains an anhydrotetracycline (ATc)-inducible 
deactivated CRISPR-associated protein-9 nuclease from Streptococcus thermophilus 
(dCas9Sth1) as well as an ATc-inducible, target-specific sgRNA handle (Figure 5.8). 
Upon induction by ATc, dCas9Sth1 is directed to the target gene by the sgRNA, where 
the dCas9Sth1-sgRNA complex binds a protospacer adjacent motif (PAM) on the DNA. 
This binding physically blocks the RNA polymerase preventing transcription initiation 
or elongation (Figure 5.8). Transcriptional interference in a gene required for growth 
would lead to loss of cell viability, which was inferred from the loss of colony 
formation ability.  
 
Figure 5.8: Schematic of the mycobacterial CRISPRi system (Rock et al., 2017). The 
PLJR962 CRISPRi vector is a kanamycin selectable and contains tetracycline-inducible 
promoters for the catalytically-dead Cas9 protein from S. thermophilus (dCas9Sth1) (blue) and 
a scaffold of short guide RNAs (sgRNA) (purple) specific to target DNA. Anhydrotetracycline 
(ATc) (green) induces the expression of dCas9Sth1 and the sgRNA scaffold, which form a 
complex and bind target DNA blocking the RNA polymerase (orange) and causing 
transcriptional interference (indicated by the red ├ symbol). Figure adapted with permission 
from (de Wet et al., 2018) 
Rock et al. reported that some leakiness in the CRISPRi system could be expected 
(Rock et al., 2017). However, the authors also recommended that, to improve target 
specificity and minimize leaky gene expression, high concentrations of ATc 
(100ng/ml) and sgRNAs with appropriate PAM sequences should be used. Therefore, 
to assess which sgRNAs targeting M. smegmatis metH would optimally induce gene 
silencing, a panel of 13 pairs of sgRNA oligos was tested (Table 5.2). Each sgRNA 
had an assigned PAM score between 1 and 25 in descending order of predicted strength 
(Rock et al., 2017). Among the 13 sgRNAs, the highest PAM score was 11 and the 
lowest was 1 (Table 5.2). The sgRNAs were designed to target random positions from 
the transcription start site (TSS) of metH (Table 5.2).  
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Table 5.2: sgRNAs targeting the metH ORF in M. smegmatis 
metH construct sgRNA ID Distance from TSS PAM Score 
PLJR962_metH1 sgRNA1 3603 3 
PLJR962_metH2 sgRNA2 3060 4 
PLJR962_metH3 sgRNA3 3057 1 
PLJR962_metH4 sgRNA4 2934 11 
PLJR962_metH5 sgRNA5 2904 5 
PLJR962_metH6 sgRNA6 2242 4 
PLJR962_metH7 sgRNA7 2184 11 
PLJR962_metH8 sgRNA8 2002 4 
PLJR962_metH9 sgRNA9 1791 11 
PLJR962_metH10 sgRNA10 1785 11 
PLJR962_metH11 sgRNA11 1743 11 
PLJR962_metH12 sgRNA12 1737 5 
PLJR962_metH15 sgRNA15 729 5 
 
The success of the transformation and gene silencing were simultaneously determined 
by including ATc in the selection plates. An sgRNA for mmpL3, a known essential 
gene involved in mycolic acid biosynthesis, was used as a positive control. As 
expected, induction of mmpL3 KD by ATc was lethal (Figure 5.9). Interestingly, 
varying degrees of inhibition of colony formation were observed among the 13 metH 
KD constructs (Figure 5.9). Six constructs fully inhibited colony growth, two partially 
suppressed colony formation, and five showed no differences in colony numbers 
between induced and uninduced plates (Figure 5.9). These variations could have been 
due to leakiness in the CRISPRi system.  
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Figure 5.9: Optimization of CRISPRi knockdown of metH in M. smegmatis. The mmpL3 
or metH conditional knockdown constructs were electroporated in the wild type M. smegmatis 
background and selected on Km-containing 7H10-OADC agar with (ATc) or without (No 
ATc) 100ng/ml ATc. ATc-induced CRISPRi gene silencing of mmpL3 completely inhibited 
colony formation but the thirteen conditional knockdown constructs of metH suppressed 
colony formation to varying degrees. The sgRNAs that produced complete inhibition of colony 
formation are highlighted in red, those with partial inhibition in blue, and those with no 
inhibition in black. The PAM score for each sgRNA is indicated in brackets. 
 
From these results, it was clear that stronger gene silencing was associated with PAM 
score values closer to 1, i.e., the six constructs that completely inhibited growth 
(sgRNA1, 2, 3, 5, 6, 15) had PAM scores ranging from 1 to 5 (Table 5.2). Out of the 
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five constructs that failed to suppress growth, three had a PAM score of 11 (sgRNA4, 
7, 9), and two had a score of 4 (sgRNA8) and 5 (sgRNA12) (Table 5.2). The observed 
differences in knockdown efficiencies were unlikely to be related to the genomic 
coordinates of the sgRNA. There was no relationship between the degree of growth 
suppression and the distance of the sgRNA from transcription start site of metH. Using 
CRISPRi-seq, however, it was observed that higher knockdown efficiency was 
associated with sgRNAs targeting the first 5% sequences of a gene (i.e., closer to the 
5’ end) (de Wet et al., 2018).  
Notwithstanding the variations in the degree of growth inhibition, these data validated 
the essentiality of metH for the growth of M. smegmatis, in line with predictions made 
independently by CRISPRi-seq, a high throughput knockdown screen developed in the 
MMRU to target M. smegmatis genes which have known M. tuberculosis homologs 
and by Tn-seq analysis (Figure 5.10) (de Wet et al., 2018).  
 
 
Figure 5.10: Tn-seq analysis of the essentiality of M. smegmatis metH. Sequenced data were 
analysed using the Hidden Markov Model (HMM) which is embedded in the TRANSIT 
software for Himar1 Tn-seq analysis (DeJesus et al., 2015). Read counts for metH gene in 
wild-type M. smegmatis were obtained from deep sequencing of Tn insertion libraries. Only 2 
insertions (shown in red, indicated by arrowheads) out of the 37 TA sites in this gene (black 
vertical lines) were found in the metH ORF. The data shown represent three biological 
replicates. Analysis courtesy of Irene Gobe. 
 
5.2.6 Transcriptional interference of the M. smegmatis metH causes methionine 
deficiency 
Since metE was under cobalamin-dependent repression in M. smegmatis, the 
knockdown of metH was expected to effectively inactivate both methionine synthases, 
resulting in lethal methionine depletion. Given that attempts to generate a metH strain 
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had been unsuccessful in spite of methionine supplementation, the question of whether 
exogenous methionine would restore colony formation in the metH KD was tested. To 
do this, knockdowns were selected on methionine-containing plates using sgRNA2 
and sgRNA3, which reproducibly suppressed colony growth upon CRISPRi induction 
with ATc. Results showed that, when methionine was included in selection plates, 
gene silencing with CRISPRi failed to suppress growth in contrast to when there was 
no methionine (Figure 5.11).  
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Figure 5.11: Rescue of the metH knockdown in the wild-type background by methionine. 
M. smegmatis wild-type cells were transformed with metH knockdown constructs and selected 
on plates containing 1mM methionine with ATc (+ATc) or without ATc (No ATc). CRISPRi 
knockdown of metH was growth-inhibitory in M. smegmatis but growth could be restored by 
exogenous methionine.  
 
To determine whether the restoration of viability in metH knockdowns was possible at 
1M – the lowest concentration of exogenous methionine that supported the growth 
of the metEcobK::hyg strain (a methionine auxtroph) (Figure 5.12A) – a metH 
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knockdown strain was generated by inserting the metH CRISPRi vector in the metE 
backround. It was expected that in the metE background, ATc-mediated silencing of 
metH would eliminate the only remaining methionine synthase, resulting in the 
complete shutdown of methionine biosynthesis. Transformants carrying the metH KD 
construct were plated on agar containing Km, without ATc, and a single colony was 
then cultured to exponential phase and serially diluted and spotted on media containing 
ATc and 1M or no methionine. For comparison, another spotting assay was set up 
with 10M methionine. Knocking down metH in the metE background resulted in 
growth inhibition in the absence of methionine (Figure 5.12B), establishing 
methionine deficiency as the reason for the loss of viability in M. smegmatis metH 
knockdown strains. Both 1M and 10M methionine concentrations restored colony 
growth but, at the lower concentration, colony sizes were markedly smaller (Figure 
5.12B).  
Considering the inability of exogenous methionine to rescue metH KOs, this was also 
a curious finding. In principle, by knocking down metH, the activity of the protein 
would be gradually reduced. As a result, metH KDs in the wild-type background would 
have had the chance to accumulate methionine to overcome the inactivation of MetH 
and MetE (due to the repression by de novo synthesised cobalamin). In contrast, a 
metH deletion would have eliminated the ORF of the gene, completely abrogating 
MetH activity. Because of this, the metH KOs would survive in the wild-type 
background, since the demand for methionine could not be met and hence metH 
colonies could not form on selection plates. To verify that there was no residual MetH 
activity in the metH knockdown, one of the spotting assay plates had CNCbl. It was 
expected that if the CRISPRi system had partially reduced MetH activity, then CNCbl 
would restore growth of the KD strain in the metE background. Exogenous CNCbl 
was unable to rescue the metH knockdown in the metE background (Figure 5.12B), 
showing that there was no residual MetH activity. However, the possibility that this 
result was due to inefficient CNCbl uptake could not be ruled out in this assay. 
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Figure 5.12: The rescue of metH knockdown in the metE background by methionine. A. 
Cell viability assay of the metEcobK::hyg strain, a methionine auxotroph, in the presence 
or absence of 10-fold dilutions exogenous methionine, as determined using the MABA. The 
transition from blue to pink indicates cell growth. B. Spotting assay of a 10-fold serially diluted 
exponential-phase culture of the metE strain carrying the metH knockdown construct. The 
agar plates contained either methionine or CNCbl and either ATc to induce metH silencing or 
without ATc as a control. The colony clearance in the metH KD in the metE strain was 
rescued by 1M and 10M methionine.  
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5.2.7 Essentiality of M. smegmatis metH is conditional on cobalamin-mediated 
metE repression 
The CRISPRi system was also used to test the hypothesis that the absence of MetE 
activity and the availability cobalamin were both prerequisites for metH to become 
essential. To achieve this aim, the effect of metH silencing was compared between the 
cobalamin replete (wild-type) and the cobalamin deplete (cobK) backgrounds. Since 
metE was de-repressed in the cobK strain, allowing the expression of MetE as an 
alternative methionine synthase, the induction of metH knockdown did not suppress 
growth (Figure 5.13), as predicted. However, when CNCbl was included in selection 
plates, colonies still formed even after inducing the metH knockdown (Figure 5.13), 
a phenotype which was reminiscent of the survival of the metHcobK strain in 7H10-
OADC agar containing CNCbl (Figure 5.4C), and supported the observations made 
previously that CNCbl uptake in the cobK strain was poor. 
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Figure 5.13: The essentiality of metH in M. smegmatis is dependent on intact de novo 
cobalamin biosynthesis. The metH CRISPRi construct was transformed into cobK strains 
and selected on kanamycin with ATc (+ATc) or without ATc (No ATc) and with or without 
CNCbl. Induction of metH knockdown in ATc-containing plates did not inhibit colony 
formation in cobK. Addition of CNCbl to ATc plates did not affect colony formation.  
 
The ability of cobK metH KDs to survive exogenous CNCbl also implied that the 
amount of externally-sourced cobalamin in this mutant was too low to repress metE 
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enough to cause methionine depletion. To test the theory, a spotting assay of the metH 
knockdown in the wild-type background was done, in which ATc-containing plates 
were supplemented with methionine or CNCbl. In the ATc only plates, barely 
discernible colonies were detected at 100-, 1000- and 10000-fold dilutions (Figure 
4.13). However, these faint colonies disappeared completely in plates containing 
CNCbl (Figure 5.14). The disappearance of these faint colonies in the wild-type strain 
after exposure to exogenous CNCbl endorsed the previously stated idea of incomplete 
repression of metE by de novo synthesised cobalamin. This apparently additive effect 
of exogenous CNCbl on colony suppression also confirmed that CRISPRi-mediated 
silencing of the metH gene was robust; i.e., the faint colonies were not a result of 
residual MetH activity. Overall, these findings established that the two conditions that 
made metH essential in M. smegmatis were the availability of enough internal 
cobalamin and a strong repression of metE. 
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Figure 5.14: Spotting assays of metH knockdowns in the wild-type strain. An exponential 
culture of M. smegmatis wild-type strain carrying the metH knockdown construct was serially 
diluted and spotted on agar containing methionine or CNCbl with ATc (ATc) or without ATc 
(No ATc). In the wild-type strain, ATc-induced metH knockdown was growth-inhibitory but 
faint colonies (circled) were visible in the ATc only plates which disappeared in plates 
containing ATc and CNCbl. Methionine complemented the knockdown phenotype.  
 
5.2.8 Single cell analysis with time-lapse microscopy reveals a growth arrest 
phenotype in the metH knockdowns 
The metH KD phenotype was analysed at the single-cell level with microfluidics and 
live-cell imaging using time-lapse phase contrast microscopy. To induce gene 
silencing, cells were exposed to ATc for 6h (two doublings) prior to running the 
microfluidics protocol for a total of 43h. For comparison, a control experiment using 
the uninduced strain (i.e. a wild-type background carrying the metH KD construct 
without exposure to ATc) was set up in parallel. Compared to the uninduced control, 
the metH KD proliferated more slowly and cell division stagnated after 24h (Figure 
5.15; Supplementary Movies 1-5, supplementary information online). By 24h, 
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colonies of the uninduced control had expanded into a lawn of cells occupying the 
entire field of view (Figure 5.15; Supplementary Movies 1-5, supplementary 
information online). In contrast, metH KD colony sizes were smaller. The limited 
expansion of metH KD colonies was consistent with methionine depletion and 
correlated with the previous observations showing that the metH KD in uninduced 
control was unable to form colonies on agar. These observations provided compelling 
evidence of the essentiality of metH for growth in M. smegmatis. 
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Figure 5.15: Live-cell imaging of the metH knockdown using time-lapse phase-contrast 
microscopy. Real-time visualization of methionine starvation in the metH conditional 
knockdowns using phase-contrast time-lapse microscopy. Compared to the uninduced control 
(No ATc) the metH conditional knockdown (ATc) had severe growth stunting. The images 
shown are still-frames captured at 0, 12, and 24h time points. Images were taken from 
Supplementary Movie 2. Scale bars represent 5m. 
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5.2.9 Whole-genome sequencing analysis of M. tuberculosis clinical isolates 
reveals naturally occurring metH deletions 
The metH deletion construct described in this chapter was made to mimic a natural 
large sequence deletion in the ppe37-metH genomic locus which eliminates the 
cobalamin binding domain and partially disrupts the SAM binding domain in M. 
tuberculosis CDC1551 (Warner et al., 2007). To determine if this deletion was unique 
to CDC1551, which is a lineage 4 (L4) strain, an analysis of WGS data for 169 M. 
tuberculosis clinical isolates from a high burden disease setting in Cape Town, South 
Africa (Koch et al., 2017), was conducted. This analysis identified 12 clinical isolates 
belonging to a subclade of L4 strains with the same large sequence deletion in MetH 
as the CDC1551 strain (Figure 5.16). Genomic DNA samples isolated from these 12 
M. tuberculosis clinical strains was screened by PCR to validate the predicted 
deletions. In 10 of the 12 M. tuberculosis clinical strains, PCR confirmed the metH 
deletions (Figure 5.16). The deletions in the two other strains could not be ascertained 
by PCR because their genomic DNA had degraded while in storage. 
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Figure 5.16: Whole genome analysis and PCR verification of naturally-occurring metH 
deletions in M. tuberculosis clinical isolates. Whole-genome sequence data were analysed 
for large deletions in genomes of 169 circulating clinical strains from Cape Town, South 
Africa. A large deletion in the ppe37-metH genomic locus was identified in 12 isolates 
(indicated by blue bar). The deletions were verified in 10 of the 12 isolates by PCR using the 
high fidelity Phusion polymerase and primers TB_metH_F/R, which target flanking the 
PPE37-metH region of M. tuberculosis H37Rv. In H37Rv, this region was intact, resulting in 
a 5.6kbp PCR product, whereas in the clinical isolates, the deletion produced a 3.3kbp PCR 
product. The dashed lines show break between images merged from distinct gels. WGS 
analysis courtesy of Dr. Jon Ambler. 
 
These findings suggested that potentially inactivating metH mutations were 
widespread globally. Other genomic screens of clinical isolates from around the world 
have identified 25 ns-SNMs spread throughout the MetH protein (Comas et al., 2013). 
In the analysis conducted here, 10 s-SNMs and 13 ns-SNMs in metH were also found 
distributed among 39 of the 169 M. tuberculosis clinical isolates. (Table 5.3).  
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Table 5.3: SNMs identified at metH locus in M. tuberculosis clinical strains 
Rv number  SNM Amino Acid 
Change 
Type of SNM Number of strains 
with SNM at site 
Rv2124c G1A Val1Met ns-SNM 3 
Rv2124c C40T Leu14Phe ns-SNM 2 
Rv2124c C69T Val23Val s-SNM 2 
Rv2124c A96G Leu32Leu s-SNM 1 
Rv2124c T275G Iso92Ser ns-SNM 1 
Rv2124c T294C Asp98Asp s-SNM 1 
Rv2124c G373A Gly125Arg ns-SNM 1 
Rv2124c T405C Thr125Thr s-SNM 6 
Rv2124c C416T Thr139Iso ns-SNM 3 
Rv2124c G660T Glu220Asp ns-SNM 2 
Rv2124c C723T His241His s-SNM 2 
Rv2124c G887A Gly296Asp ns-SNM 2 
Rv2124c A1002G Ala334Ala s-SNM 1 
Rv2124c A1447C Lys483Gln ns-SNM 1 
Rv2124c G1616A Arg539His ns-SNM 1 
Rv2124c A2254G Iso752Val ns-SNM 1 
Rv2124c C2952T Asp984Asp s-SNM 1 
Rv2124c T3292G Tyr1098Asp ns-SNM 1 
Rv2124c G3397A Gly1133Ser ns-SNM 2 
Rv2124c C3423T Gly1141Gly s-SNM 2 
Rv2124c C3445G Arg1149Gly s-SNM 1 
Rv2124c G3537C Ala1179Ala s-SNM 1 
Rv2124c C3540T Phe1180Phe ns-SNM 1 
 
5.2.10 The role of MetH in anti-folate resistance in M. smegmatis 
The methionine and folate biosynthesis pathways are tightly coupled. 5-MTHF, the 
donor of the methyl group used in the methylation of homocysteine by MetH or MetE 
is a product of the folate biosynthesis pathway. Blanco et al. showed that the disruption 
of the 5,10-methylenetetrahydrofolate reductase, MetF, which catalyses the 
biosynthesis of 5-MTHF, led to methionine auxotrophy in Streptomyces lividans 
(Blanco, Coque & Martin, 1998). In humans, an imbalance in folate biosynthesis is 
associated with cobalamin deficiency (Palmer et al., 2017). The biochemical 
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anomalies involved in humans are well characterized, and they involve the inability of 
MetH – the sole methionine synthase in humans – to transfer methyl groups from 5-
MTHF in the absence of cobalamin (Krebs, Hems & Tyler, 1976). This causes a 
phenomenon termed the “methyl folate trap,” which is the harmful accumulation of 5-
MTHF, depleting thymine. Because cobalamin deficiency in humans also impairs the 
biosynthesis of SAM, a repressor of MetF, the reduced SAM levels ultimately also 
increase the cellular pool of 5-MTHF (Krebs, Hems & Tyler, 1976).  
Recently, methionine biosynthesis in M. smegmatis was implicated in intrinsic 
mycobacterial resistance to sulphur-containing antibiotics known as sulphonamides or 
SULFAs (Guzzo et al., 2016). SULFAs were the first drugs used for TB treatment, but 
their use gradually declined due to toxicity and were replaced with the safer INH-RIF 
combination therapy (Libecco & Powell, 2004; Forgacs et al., 2009). Currently, 
SULFAs are clinically indicated for urinary tract infections, bacterial meningitis, 
Salmonella infections, and chronic bronchitis (Libecco & Powell, 2004).  
SULFAs target de novo folate biosynthesis by competing with para-aminobenzoic acid 
(PABA), a substrate of dihydropteroate synthase (DHPS) (Figure 5.17) (Libecco & 
Powell, 2004). The enzymatic reaction catalysed by DHPS generates THF, which is a 
precursor for the one-carbon pool by folate where it is terminally converted to 5-
MTHF. The transfer of the methyl group from 5-MTHF to homocysteine by MetH 
recycles 5-MTHF back to THF (Figure 5.17). Interestingly, Guzzo et al. showed that 
either the inactivation of metH, but not of metE, or a deletion of the gene encoding the 
cobalamin biosynthesis fusion protein CobIJ, led to the accumulation of 5-MTHF in 
M. smegmatis (Guzzo et al., 2016). Furthermore, these mutants (with the exception of 
the metE strain) showed increased susceptibilities to SULFAs relative to the wild-
type strain (Guzzo et al., 2016). These tantalizing results prompted an examination of 
the role of MetH in anti-folate resistance. 
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Figure 5.17: The link between methionine biosynthesis and the one carbon pool by folate 
in M. smegmatis. Tetrahydrofolate (THF) is a derivative of the folate biosynthesis pathway 
and is a precursor of 5-methyl THF, the methyl donor in the conversion of L-homocysteine 
(HCY) to L-methionine (MET) by MetH using Co(I)cobalamin as a co-factor. SULFAs (SMZ 
– sulfamethoxazole; STZ – sulfathiazole; SDZ – sulfadiazine) target folate biosynthesis by 
competing with para-aminobenzoic acid (PABA) for binding to FolP (dihydropteroate 
synthase). Trimethoprim (TMP) targets FolA (dihydrofolate reductase). 
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5.2.11 Cobalamin deficiency in M. smegmatis enhances susceptibility to 
sulphonamides 
As described in the previous sections, attempts to delete metH in M. smegmatis were 
unsuccessful due to the demonstrated essentiality of this gene in this organism. 
However, with the cobalamin deficient – and consequently MetH deficient – mutants 
(cobK and cobKmetH) and the MetE null mutant (metE) in hand, the predicted 
role of cobalamin deficiency in boosting SULFA sensitivity in M. smegmatis could be 
examined. For this objective, sulfamethoxazole (SMZ), sulfathiazole (STZ) and 
sulfadiazine (SDZ) were used as representative SULFAs.  
First, the minimum inhibitory concentration, defined as the concentration of each 
SULFA required to inhibit 90% (MIC90) of the growth of wild-type M. smegmatis 
culture from a starting inoculum of 2.5–5.0  103 cfu/ml was determined using the 
microplate alamar blue (resazurin) assay (MABA). The observed MIC90 value for all 
three SULFAs was 1.56g/ml (Table 5.4), which corresponded to reported values 
(Guzzo et al., 2016).  
Table 5.4: MIC90 of SULFAs used in this study 
SULFA Drug WT cobK metE cobKmetH 
SMZ 1.56g/ml 0.2g/ml 1.56g/ml 0.2g/ml 
STZ 1.56g/ml 0.2g/ml 1.56g/ml 0.2g/ml 
SDZ 1.56g/ml 0.2g/ml 1.56g/ml 0.2g/ml 
 
The susceptibilities of strains lacking de novo synthesised cobalamin (cobK and 
cobKmetH) or strains capable of de novo cobalamin biosynthesis (wild-type and 
metE) to SULFAs were then compared. For all three SULFAs, the MIC90 value in 
strains lacking de novo synthesised cobalamin was 8-fold lower than in those with 
functional de novo cobalamin biosynthesis (Table 5.4). There were no differences in 
MIC90 between the wild-type and metE strains (Table 5.4). These results directly 
implicated cobalamin deficiency and, consequently, MetH inactivation, in enhancing 
sensitivity to SULFAs. Therefore, it was thought that exogenous CNCbl might reverse 
this sensitivity. To explore this possibility, the MABA was repeated, including 
 117 
 
10g/ml CNCbl in the wells. Again, MIC90 values of SMZ, STZ and SDZ were 
compared between strains lacking de novo synthesised cobalamin-deficient and those 
capable of de novo cobalamin biosynthesis. 
Exogenous CNCbl did not change the MIC90 values of all three SULFAs in wild-type, 
cobK, and metE strains (Table 5.5), which was not surprising in the context of poor 
CNCbl uptake as already discussed. Unexpectedly, however, the cobKmetH strain 
was hypersensitive to SULFAs in the presence of exogenous CNCbl. The SULFA 
MIC90 values of this mutant in the presence of CNCbl was 0.02g/ml (Table 5.5)  
Table 5.5: MIC90 of SULFAs in the presence of exogenous CNCbl 
SULFA + CNCbl WT cobK metE cobKmetH 
SMZ + CNCbl 1.56g/ml 0.2g/ml 1.56g/ml 0.02g/ml 
STZ + CNCbl 1.56g/ml 0.2g/ml 1.56g/ml 0.02g/ml 
SDZ + CNCbl 1.56g/ml 0.2g/ml 1.56g/ml 0.02g/ml 
 
Although the sensitivity of the cobKmetH strain had been predicted to occur due to 
the cobalamin-mediated suppression of MetE, this phenotype had not been observed 
in shaking cultures and in agar as discussed in previous sections. Serendipitously, 
however, it appeared that this sensitivity phenotype was unmasked by the lower 
inoculum concentration in the MABA (2.5–5 103 cfu/ml) compared to the higher 
concentration of the inoculum typically used to start batch cultures (1 ×106 cfu/ml). 
Compounded with poor CNCbl uptake, this inoculum effect explained how an 
outgrowth of cells that inefficiently transported CNCbl would have eclipsed the 
CNCbl sensitivity phenotype in batch cultures of the the cobKmetH strain. By 
contrast, the lower inoculum in the MABA effectively decreased the probability of an 
outgrowth. Therefore, when SULFAs were used in the assay in combination with 
CNCbl, the growth of cobKmetH became severely inhibited (Figure 5.18; Figure 
5.19; Figure 5.20). The severe retardation of the growth of cobKmetH by CNCbl 
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in the MABA proved that M. smegmatis could take up small amounts of exogenous 
co-factor. 
 
 
Figure 5.18: Inhibition of M. smegmatis growth by sulfamethoxazole. The percentage 
inhibition at different concentrations of SMZ in the presence (solid lines) or absence (dashed 
lines) of CNCbl was determined using the MABA. Even without SMZ, CNCbl inhibited 70% 
of cell growth of cobKmetH (red arrowhead). 
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Figure 5.19: Inhibition of M. smegmatis growth by sulfathiazole. The percentage inhibition 
at different concentrations of STZ in the presence (solid lines) or absence (dashed lines) of 
CNCbl was determined using the MABA. Even without STZ, CNCbl inhibited 70% of cell 
growth of cobKmetH (red arrowhead). 
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Figure 5.20: Inhibition of M. smegmatis growth by sulfadiazine. The percentage inhibition 
at different concentrations of SDZ in the presence (solid lines) or absence (dashed lines) of 
CNCbl was determined using the MABA. Even without SDZ, CNCbl inhibited 80% of cell 
growth of cobKmetH (red arrowhead). 
 
Due to the observed limited CNCbl uptake, it was thought that preincubation of M. 
smegmatis with the co-factor before setting up the MABA would allow cobalamin to 
accumulate inside cells, thereby enhancing the resistance of these cells to SULFAs. To 
test this idea, an experiment was set up whereby cells were seeded on the microplate 
and preincubated with CNCbl for one (3h) and two doubling times (6h) prior to 
introducing SULFAs. Alternatively, the assay was set up with cells that had not been 
preincubated with CNCbl (0h); i.e., the SULFAs and CNCbl were added 
simultaneously at the beginning of the assay. The proportion of viable cells at the 
endpoint of each assay (0h, 3h, and 6h) – as indicated by fluorescence intensity 
following resazurin reduction – was plotted against the concentration of SULFA drug. 
Overall, longer preincubation times with CNCbl were associated with improved ability 
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to tolerate SULFAs. However, the cobKmetH strain was severely inhibited by 
SULFAs (Figure 5.21; Figure 5.22; Figure 5.23).  
 
 
Figure 5.21: Extended preincubation with CNCbl enhances resistance to 
sulfamethoxazole. Cells were preincubated with CNCbl for 0h (blue), 3h (orange) and 6h 
(green) prior to SMZ exposure. The percentage of cell survival was calculated using the 
MABA. Longer duration of pre-exposure to CNCbl was associated with resistance to SMZ. 
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Figure 5.22: Extended preincubation with CNCbl enhances resistance to sulfathiazole. 
Cells were preincubated with CNCbl for 0h (blue), 3h (orange) and 6h (green) prior to STZ 
exposure. The percentage of cell survival was calculated using the MABA. Longer duration 
of pre-exposure to CNCbl was associated with resistance to STZ 
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Figure 5.23: Extended preincubation with CNCbl enhances resistance to sulfadiazine. 
Cells were preincubated with CNCbl for 0h (blue), 3h (orange) and 6h (green) prior to SDZ 
exposure. The percentage of cell survival was calculated using the MABA. Longer duration 
of pre-exposure to CNCbl was associated with resistance to SDZ. 
 
At 0h preincubation, the concentration of STZ and SMZ that was needed to inhibit 
50% of growth (MIC50) of wild-type and metE in the presence of CNCbl was roughly 
0.15g/ml while that of SDZ was 0.3g/ml. By contrast, 0.05g/ml of STZ and SMZ 
and 0.15g/ml of SDZ were required to inhibit 50% growth of CNCbl-supplemented 
cobK (Table 5.6). Pre-exposing the cultures to CNCbl for 3h doubled the MIC50 of 
all the three SULFAs for wild-type and metE only, but the MIC50 for cobK remained 
constant. At 6h preincubation, the proportion of wild-type and metE cells surviving 
was above 50% across the range of concentrations tested (0–10g/ml) (Table 5.6; 
Figure 5.21; Figure 5.22; Figure 5.23). However, at 6h pre-exposure, the survival 
rate of cobK strain was 30–40%, and in this case, the MIC50 values for STZ, SMZ 
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and SDZ in this mutant were 0.1g/ml, 0.19g/ml, and 0.29g/ml respectively (Table 
5.6). The MIC50 of cobKmetH could not be determined, as the growth of 
cobKmetH was inhibited by 50% by CNCbl alone (Figure 5.21; Figure 5.22; 
Figure 5.23). 
Table 5.6: MIC50 of SULFAs used in the preincubation experiment 
0h WT cobK metE cobKmetH 
SMZ + CNCbl 0.15g/ml 0.05g/ml 0.14g/ml undetermined 
STZ + CNCbl 0.13g/ml 0.06g/ml 0.13g/ml undetermined 
SDZ + CNCbl 0.3g/ml 0.15g/ml 0.31g/ml undetermined  
3h WT cobK metE cobKmetH 
SMZ + CNCbl 0.22g/ml 0.05g/ml 0.19g/ml undetermined 
STZ + CNCbl 0.27g/ml 0.08g/ml 0.26g/ml undetermined 
SDZ + CNCbl 0.63g/ml 0.22g/ml 0.56g/ml undetermined  
6h WT cobK metE cobKmetH 
SMZ + CNCbl >10g/ml g/ml >10g/ml undetermined 
STZ + CNCbl >10g/ml g/ml >10g/ml undetermined 
SDZ + CNCbl >10g/ml 0.29g/ml >10g/ml undetermined 
 
5.2.12 MetH activity is a primary determinant of resistance to SULFA in M. 
smegmatis 
The observation that the presence of CNCbl correlated with increased ability to survive 
SULFAs supported the notion that SULFA resistance was mediated primarily by MetH 
(Guzzo et al., 2016). In the wild-type and metE strains, which had better survival 
profiles than cobK, MetH was the primary methionine synthase. However, in cobK, 
MetH was inactive due to the absence of de novo synthesised cobalamin. Also, because 
of poor CNCbl uptake, the exogenous co-factor marginally improved survivability of 
cobK in the presence of SULFAs. Thus, these data also supported the notion that 
resistance to SULFAs required MetH activity.  
To further explore this idea, a SULFA sensitivity assay was developed using the metH 
CRISPRi knockdown strain. To allow cells carrying the metH CRISPRi construct to 
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survive metH silencing, 1mM methionine was added to ATc-containing wells. Starting 
with an inoculum of 1 x 103 cfu/ml, the assay was set up in a 96-well plate, using 
0.4g/ml SMZ (equivalent to 0.25 MIC) and bacterial growth was monitored by 
taking periodic OD620nm measurements over the course of 15 doubling times (45h). As 
expected, metH knockdown led to growth inhibition but was rescued by supplementing 
with methionine (Figure 5.24A). When SMZ was used at 0.25 MIC, there was 
reduced growth in uninduced cells (i.e., wild-type cells) and a clear separation in 
growth curves between metH knockdowns and wild-type cells could be observed 
(Figure 5.24B). The survival of metH knockdowns in the presence of SMZ was 
improved when methionine was included, and the separation of growth curves became 
clearer when the experiment duration was by another 5 doubling times to 60h (Figure 
5.24B). From these findings, it was concluded that MetH activity was needed to resist 
SMZ and that exogenous methionine somewhat antagonized SMZ in the absence of 
MetH.  
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Figure 5.24: MetH is a driver of sulfamethoxazole resistance in M. smegmatis. A. The 
growth of the metH knockdown or wild-type cells grown with or without methionine was 
monitored by taking periodic OD620nm measurements. The metH knockdown failed to grow 
over the course of 15 doubling times but was rescued by exogenous methionine. B. 
Susceptibility of metH knockdowns to SMZ in the presence of exogenous methionine. Wild-
type cells had better survival compared to the metH knockdown. Exogenous methionine 
slightly improved survivability of the knockdown. 
 
5.3 Discussion 
In M. tuberculosis, the gene encoding the cobalamin-independent methionine 
synthase, MetE, is annotated as essential but the gene encoding the cobalamin-
dependent methionine synthase, MetH, is non-essential (Kapopoulou, Lew & Cole, 
2011). The essentiality of metE assumes that M. tuberculosis is incapable of de novo 
cobalamin biosynthesis, a deficiency which has a two-fold impact on methionine 
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biosynthesis. First, the absence of cobalamin inactivates MetH by depriving it of its 
co-factor. Secondly, lack of cobalamin releases MetE from a riboswitch-mediated 
repression (Warner et al., 2007). Therefore, MetE is indispensable in M. tuberculosis. 
On the other hand, the cobalamin-producing M. smegmatis can use either methionine 
synthase. In theory, MetE is expected to take over from MetH if de novo cobalamin 
production were compromised and alternatively, MetH would compensate if MetE 
activity were eliminated. However, due to the presence of a cobalamin riboswitch 
controlling MetE in M. smegmatis, the loss of MetH in a background of de novo 
cobalamin production would be growth inhibitory. In the present work, the essentiality 
of this gene was confirmed using the mycobacterial CRISPRi system (Rock et al., 
2017). The abrogation of de novo cobalamin biosynthesis sufficiently offset the growth 
inhibition phenotype that was observed following the loss of metH. 
Consequently, a simple model for the essentiality of metH in M. smegmatis is 
proposed. In this mechanism, a functional metE riboswitch and enough concentrations 
of internal cobalamin are required (Figure 5. 25A). Because endogenous cobalamin is 
available in M. smegmatis, the co-factor facilitates methionine biosynthesis via MetH, 
while simultaneously repressing metE via the riboswitch. However, when de novo 
cobalamin biosynthesis is disrupted, MetE is available whereas MetH becomes 
inactive (Figure 5.25B). In this manner, M. smegmatis is protected from methionine 
starvation. However, when MetH is deleted while de novo cobalamin biosynthesis is 
still intact, cells effectively lose both methionine synthases, resulting in methionine 
depletion and eventual growth inhibition (Figure 5.25C). This also creates the methyl 
folate trap, which has been reported to underlie increased susceptibility of. smegmatis 
and M. tuberculosis to SULFAs (Guzzo et al., 2016).  
A formal validation of the functionality of the M. smegmatis metE riboswitch 
functionality has not been presented because attempts to introduce mutations in the 
aptamer region of this riboswitch were not successful despite repeated efforts to do so. 
However, in spite of this missing piece of data, the evidence presented in this thesis is 
compelling to support the assertion that the availability of cobalamin and the presence 
of a functional metE riboswitch underlies the essentiality of metH. 
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Figure 5.25: A proposed mechanism for the essentiality of metH in M. smegmatis. A-B. De 
novo methionine biosynthesis in M. smegmatis can occur via MetH using Co(I)cobalamin 
(Co(I)B12) as a co-factor, or via MetE. Cobalamin represses metE via a riboswitch whereas in 
the absence of cobalamin, only MetE is viable. MetH and MetE transfer a methyl group from 
5-methyl tetrahydrofolate (5-MTHF) to homocysteine, producing tetrahydrofolate (THF) as 
an intermediate. C. If MetH were deleted in the presence of cobalamin, the cell would lose 
both methionine synthases, succumbing to methionine starvation. Loss of MetH may also lead 
to the accumulation of 5-MTHF, creating the methyl folate trap. 
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Surprisingly, Guzzo et al. (2016) reported the use of a standard recombineering 
method to successfully delete the M. smegmatis metH. The evidence presented herein, 
which has experimentally validated metH as an essential gene in M. smegmatis and is 
supported by independent Tn-seq and CRISPRi-seq analysis (de Wet et al., 2018), 
therefore contradicts the findings of these authors. In the present study, metH could 
not be deleted by allelic exchange mutagenesis which takes advantage of endogenous 
recombination pathways in mycobacteria to replace a wild-type with a mutant allele. 
Since MetE is under cobalamin-mediated repression in M. smegmatis, the deletion of 
metH would render the organism unable to produce methionine, making the metH 
knockout mutants non-viable. One possible explanation for the discrepancy between 
the results presented here and those in Guzzo et al. (2016) is the likely presence of 
spontaneous suppressor mutations affecting the function of the metE riboswitch in the 
M. smegmatis laboratory strain used by those authors. It is well known that random 
mutations accumulate due to serial passaging of bacterial culture (Kucukyildirim et 
al., 2016; Schroeder et al., 2018), a caveat that the paper did not address. To exclude 
the possibility of inadvertent second-site mutations as potential confounding factors 
when drawing conclusions from genetic studies, all the mutant strains generated in this 
study were subjected to WGS analysis.  
There are efforts to engineer cobalamin derivatives as delivery vehicles for drugs and 
biomarkers (Romine et al., 2017; Gryko et al., 2018; Lawrence et al., 2018). Studies 
have presented clear evidence of cobamide uptake in M. tuberculosis via a non-
canonical transporter (Warner et al., 2007; Gopinath, Moosa, et al., 2013; Lawrence 
et al., 2018). However, the findings presented here suggest that the transport of 
cobamides might be tightly controlled in M. smegmatis. Possibly due to this regulation, 
the quantities of the metE transcript were only slightly decreased the presence of 
CNCbl, even though the exogenous co-factor was provided at high concentration 
(Figure 5.5). Similarly, the suppression of the growth of a double mutant deficient in 
cobalamin and lacking MetH (cobKmetH) by exogenous CNCbl, was attained only 
when a very dilute inoculum of this strain was used in culture (Figures 5.16-21). 
Technical limitations undetermined the ability to measure the minimum internal 
concentration of cobalamin that would be required to completely shut down MetE 
activity. Furthermore, attempts to do titrate metE repression using exogenous CNCbl 
were hindered by poor CNCbl uptake in M. smegmatis.  
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The combination of SULFAs and loss of MetH activity was lethal in M. smegmatis. 
Both in vitro and clinical evidence indicate the susceptibility of M. tuberculosis, 
including drug resistant strains, to cotrimoxazole, a combination of sulfamethoxazole 
and TMP (Forgacs et al., 2009; Huang et al., 2012; Ameen & Drancourt, 2013). Given 
that there are circulating clinical strains that lack metH, it will be worthwhile to 
investigate whether this susceptibility is related to the presence of an intact metH allele 
or if wild-type (e.g., H37Rv) and derivative metH-null strains have differential 
susceptibilities to SULFA drugs. In addition, if M. tuberculosis can access cobalamin 
in vivo, SULFA drug testing in animal models might provide critical insight that will 
inform the feasibility of repurposing and reintroducing these drugs into current 
antimycobacterial regimens.  
Naturally occurring mutations affecting MetH activity have been reported in clinical 
M. tuberculosis isolates, but the implications of these alleles remain unclear. The ns-
SNMs in the M. tuberculosis metH identified in this analysis and in other genomic 
screens (Comas et al., 2013) appear to occur in the tips of a phylogenetic tree, which 
implies their origins are recent. The fact that M. tuberculosis strains lacking MetH are 
circulating in populations presents an exciting opportunity for further research on the 
global prevalence of these strains and their relevance for M. tuberculosis physiology, 
TB epidemiology and treatment. Further WGS analyses are planned to confirm 
whether these mutations confer any selective advantages.  
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6 Concluding remarks 
Cobamide acquisition and related metabolism in mycobacteria has been a subject of 
study for many years, especially in light of the obligate lifestyle adopted by M. 
tuberculosis, which is incapable of de novo cobmide biosynthesis despite requiring the 
co-factor for three known cobamide-dependent metabolic pathways (Gopinath, 
Moosa, et al., 2013; Young, Comas & de Carvalho, 2015). Like other mycobacteria, 
M. tuberculosis utilizes cobamide in several unrelated metabolic pathways including 
the biosynthesis of methionine and deoxyribonucleotides and the metabolism of 
propionate, a by-product of cholesterol and fatty acid metabolism (Young, Comas & 
de Carvalho, 2015). This thesis focused only on the methionine biosynthesis pathway. 
The overall goal of the thesis was to describe cobamide biosynthesis and cobamide-
dependent regulation of methionine biosynthesis in mycobacteria. As the best 
characterised saprophytic mycobacterium, M. smegmatis was chosen as the model for 
cobamide biosynthesis, transport, assimilation and function in this study. The data 
described in this thesis show that the cobamide form produced by this organism is 
cobalamin, having DMB as the lower base. The data described in this thesis also show 
that methionine biosynthesis in M. smegmatis is under the control of a cobalamin 
riboswitch upstream of the metE gene. Since this riboswitch contains the “B12 
element,” an evolutionarily conserved RNA structure typical of AdoCbl-sensing 
riboswitches (Vitreschak et al., 2003), the functionality of this riboswitch suggests that 
M. smegmatis produces AdoCbl. More work is needed to verify whether this organism 
produces other cobamide forms. The data further demonstrate that both the de novo 
and salvage pathways to cobalamin biosynthesis are functional in M. smegmatis. 
The phylogenomic approach used to evaluate the genetic capacity for de novo 
cobamide production in mycobacteria indicated that environmental mycobacteria 
mostly have the potential for cobamide biosynthesis via the de novo aerobic pathway 
or via corrinoid salvage. However, host-associated mycobacterial species appeared to 
have partial genetic capacity for de novo cobamide biosynthesis but encoded intact 
pathways for corrinoid salvage. The differences in cobamide biosynthesis between 
pathogenic and non-pathogenic mycobacteria correspond to a major point of departure 
in their evolution.  
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The genetic capacity of mycobacteria to acquire exogenous cobamides via the ABC-
type transporter, BacA, was reinforced in the work conducted here. This protein, which 
is also involved in antibiotic resistance (Domenech et al., 2009), was found in all 1069 
mycobacterial genomes that were analysed in this thesis (chapter 3). In addition to 
encoding two paralogous genes encoding a putative BacA, M. smegmatis also contains 
two operons containing paralogous genes encoding putative homologues of BtuFCD, 
which are involved in the canonical cobamide transporter complex with BtuB and 
TonB-ExBD (Noinaj et al., 2010). It was found that BtuF and BtuF2 (MSMEG_4561) 
proteins were sensitive to exogenous CNCbl, presumably due to repression via 
putative riboswitches in the 5’ UTRs of their genes. As these genes are the first in the 
btuFCD and btuF2C2D2 operons, respectively, their repression likely have knock-on 
effects on the expression of their downstream operonic partners. Since all the work 
conducted in this thesis was performed in M. smegmatis and in vitro, the question of 
whether pathogenic mycobacteria can access cobamides in vivo remains unresolved. 
The organisation of cobamide transport in mycobacteria is the subject of an ongoing 
study in the MMRU. Toward this end, cobalamin-based chemical probes are being 
utilized to track cobamide uptake in both M. smegmatis and M. tuberculosis and 
identify cobamide binding proteins in these two mycobacteria. A surprising finding in 
this thesis was that, despite the presence of these multiple putative transporters, the 
uptake exogenous CNCbl was poor in M. smegmatis. However, corrinoid salvage was 
demonstrably more efficient in a cobalamin/methionine auxotroph (Figure 4.9; 
Figure 4.10), which was dependent on exogenous CNCbl for growth. It is hereby 
proposed that cobamide transport and assimilation in M. smegmatis are modulated by 
a fine-tuning process whereby enhanced corrinoid salvage is triggered when 
endogenous cobalamin is missing; i.e., when cells have an absolute requirement for 
the co-factor. 
The control of mycobacterial methionine biosynthesis via a cobalamin riboswitch was 
first demonstrated in M. tuberculosis more than a decade ago (Warner et al., 2007). 
This early work demonstrated that in M. tuberculosis, the gene encoding MetE was 
transcriptionally repressed by cobalamin. In the present work, metE was found to be 
under constitutive transcriptional repression in M. smegmatis via the cobalamin 
riboswitch. The riboswitch-mediated regulation of metE was also identified as being 
responsible for the essentiality of the M. smegmatis metH, a finding that mirrored Tn-
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seq and CRISPRi-seq predictions of the essentiality of this gene (de Wet et al., 2018). 
Given the lack of cobamide biosynthesis in M. tuberculosis, the demonstration of 
constitutive riboswitch regulation of metE in M. smegmatis lays the foundation for 
planned future work to determine the structure and riboswitch mechanism of the 
ligand-on or ligand-off riboswitch states represented by M. smegmatis and M. 
tuberculosis, respectively. 
The role of the mycobacterial MetH in mediating intrinsic resistance to SULFAs as 
recently proposed by Guzzo et al. (Guzzo et al., 2016) was also confirmed in this work. 
Specifically, the activity of SULFAs was potentiated when MetH activity, but not 
MetE activity, was missing (Table 5.4; Table 5.5). Considering potentially 
inactivating metH mutations discovered in several M. tuberculosis clinical isolates 
have uncovered, the potential for SULFAs to effectively target metH-null bacilli 
should be investigated. Advancements in sequencing technologies and increased 
application in routine TB diagnosis (Quan et al., 2018; Zignol et al., 2018) should 
make the rapid detection of metH mutations in the clinical context feasible, enabling 
targeted therapies.  
In summary, this thesis provided direct evidence that mycobacteria can synthesise 
cobalamin either via the de novo pathway or via the salvage pathway, if corrinoid 
precursors can be accessed. Moreover, it appears that environmental and pathogenic 
mycobacteria differentially regulate cobamide uptake. The precise factors underlying 
these differences remain uncharacterized, as are many other aspects of M. tuberculosis 
physiology and metabolism, which poses significant barriers to the development of 
improved drugs and effective vaccines. New insights into the metabolic mechanisms 
that underlie pathogenesis and long-term survival of M. tuberculosis in infected 
individuals are required. Mycobacterial RNA-regulators (e.g., cobalamin 
riboswitches), represent an emerging research focus with the potential to uncover 
novel drug targets. This thesis presents the idea that the outcomes of cobamide-
dependent regulation might have implications for mycobacterial evolution, 
physiology, pathogenesis and drug discovery. Drawing from this idea, three key focus 
areas for future studies are proposed: (1) the complete characterization of 
mycobacterial cobamide biosynthesis and transport; (2) the determination of the 
structure and mechanism of action of the mycobacterial cobalamin riboswitch; and (3) 
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the evaluation of the prevalence of mutations affecting genes involved in cobamide-
related metabolism in M. tuberculosis clinical isolates.  
  
 135 
 
7 Supplementary information online 
Table S1: https://uct.figshare.com/s/3881705f0809898c96e0 
 
Table S2: https://uct.figshare.com/s/76e15301fe6dec848c00 
 
Supplementary Movies 1–5: https://uct.figshare.com/s/65105b9914196c4b4654 
 
  
 136 
 
 
8 References 
Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W. & 
Lipman, D.J. 1997. Gapped BLAST and PSI-BLAST: A new generation of protein 
database search programs. Nucleic Acids Research. 25(17):3389–3402. DOI: 
10.1093/nar/25.17.3389. 
Ameen, S.M. & Drancourt, M. 2013. In Vitro Susceptibility of Mycobacterium 
tuberculosis to Trimethoprim and Sulfonamides in France. Antimicrobial Agents and 
Chemotherapy. 57(12):6370–6371. DOI: 10.1128/AAC.01683-13. 
Asmar, S., Rascovan, N., Robert, C. & Drancourt, M. 2015. Draft Genome Sequence 
of Mycobacterium mucogenicum Strain CSUR P2099. Genome Announcement. 
3(6):10–11. DOI: 10.1128/genomeA.01369-15.Copyright. 
Baker, J.L., Sudarsan, N., Weinberg, Z., Roth, A., Stockbridge, R.B. & Breaker, R.R. 
2012. Widespread Genetic Switches and Toxicity Resistance Proteins for Fluoride. 
Science. 335(6065):233–235. DOI: 10.1126/science.1215063. 
Banerjee, R. 2006. B12 trafficking in mammals: A case for coenzyme escort service. 
ACS Chemical Biology. 1(3):149–159. doi:10.1021/cb6001174 
Banerjee, R., Gherasim, C., Padovani, D. 2009. The tinker, tailor, soldier in 
intracellular B12 trafficking. Current Opinion in Chemical Biology. 13:484–491 
Barberis, I., Bragazzi, N.L., Galluzzo, L. & Martini, M. 2017. The History of 
Tuberculosis: from the First Historical Records to the Isolation of Koch’s bacillus. 
Journal of Preventive Medicine and Hygiene. 58(1): E9–E12. DOI: 10.15167/2421-
4248/jpmh2017.58.1.728. 
Barry, C.E. 2001. Mycobacterium smegmatis: An Absurd Model for Tuberculosis? 
Response from Barry, III. Trends in Microbiology. 9(10):473–474. DOI: 
10.1016/S0966-842X(01)02169-2. 
Berney, M., Berney-Meyer, L., Wong, K.-W., Chen, B., Chen, M., Kim, J., Wang, J., 
Harris, D., et al. 2015. Essential Roles of Methionine and S-Adenosylmethionine in 
the Autarkic Lifestyle of Mycobacterium tuberculosis. Proceedings of the National 
Academy of Sciences of the United States of America. 112(32):10008–13. DOI: 
10.1073/pnas.1513033112. 
Beste, D.J. V, Nöh, K., Niedenführ, S., Mendum, T.A., Hawkins, N.D., Ward, J.L., 
Beale, M.H., Wiechert, W., et al. 2013. 13C-Flux Spectral Analysis of Host-Pathogen 
Metabolism Reveals A Mixed Diet for Intracellular Mycobacterium tuberculosis. 
Chemistry and Biology. 20(8):1012–1021. DOI: 10.1016/j.chembiol.2013.06.012. 
 137 
 
Blanche, F., Cameron, B., Crouzet, J., Debussche, L., Thibaut, D., Vuilhorgne, M., 
Leeper, F. J., Battersby, A. R. 1995. Vitamin B₁₂: How the Problem of Its Biosynthesis 
Was Solved. Angewandte Chemie International Edition in English. 34(4): 383-411. 
DOI: 10.1002/anie.199503831 
Blanco, J., Coque, J.J.R. & Martin, J.F. 1998. The Folate Branch of the Methionine 
Biosynthesis Pathway in Streptomyces lividans: Disruption of the 5,10-
Methylenetetrahydrofolate Reductase Gene Leads to Methionine Auxotrophy. Journal 
of Bacteriology. 180(6):1586–1591. 
Bloom, B.R., Atun, R., Cohen, T., Dye, C., Fraser, H., Gomez, G.B., Knight, G., 
Murray, M., et al. 2017. Tuberculosis. In: Major Infectious Diseases. 3rd ed. K.K. 
Holmes, S. Bertozzi, B.R. Bloom, & P. Jha, Eds. Washington (DC): The International 
Bank for Recons. 233–313. DOI: 10.1596/978-1-4648-0524-0/ch11. 
Blouin, Y., Cazajous, G., Dehan, C., Soler, C., Vong, R., Hassan, M.O., Hauck, Y., 
Boulais, C., et al. 2014. Progenitor “Mycobacterium canettii” Clone Responsible for 
Lymph Node Tuberculosis Epidemic, Djibouti. Emerging Infectious Diseases. 
20(1):21–28. DOI: 10.3201/eid2001.130652. 
Bolger, A.M., Lohse, M. & Usadel, B. 2014. Trimmomatic: A Flexible Trimmer for 
Illumina Sequence Data. Bioinformatics. 30(15):2114–2120. DOI: 
10.1093/bioinformatics/btu170. 
Boot, M., Sparrius, M., Jim, K.K., Commandeur, S., Speer, A., Van De Weerd, R. & 
Bitter, W. 2016. iniBAC Induction is Vitamin B12- and MutAB-Dependent in 
Mycobacterium marinum. Journal of Biological Chemistry. 291(38):19800–19812. 
DOI: 10.1074/jbc.M116.724088. 
Boritsch, E.V.A.C. & Brosch, R. 2016. Evolution of Mycobacterium tuberculosis: 
New Insights into Pathogenicity and Drug Resistance. Microbiology Spectrum. 4(5):1–
20. DOI: 10.1128/microbiolspec.TBTB2-0020-2016. 
Boritsch, E.C., Supply, P., Honoré, N., Seeman, T., Stinear, T.P. & Brosch, R. 2014. 
A Glimpse into the Past and Predictions for the Future: The Molecular Evolution of 
the Tuberculosis Agent. Molecular Microbiology. 93(5):835–852. DOI: 
10.1111/mmi.12720. 
Boritsch, E.C., Frigui, W., Cascioferro, A., Malaga, W., Etienne, G., Laval, F., Pawlik, 
A., Le Chevalier, F., et al. 2016. Pks5-Recombination-Mediated Surface Remodelling 
in Mycobacterium tuberculosis Emergence. Nature Microbiology. 1(2). DOI: 
10.1038/nmicrobiol.2015.19. 
Boritsch, E.C., Khanna, V., Pawlik, A., Honoré, N., Navas, V.H., Ma, L., Bouchier, 
C., Seemann, T., et al. 2016. Key Experimental Evidence of Chromosomal DNA 
Transfer Among Selected Tuberculosis-Causing Mycobacteria. Proceedings of the 
National Academy of Sciences. 113(35):9876–9881. DOI: 10.1073/pnas.1604921113. 
Bos, K.I., Harkins, K.M., Herbig, A., Coscolla, M., Weber, N., Comas, I., Forrest, 
S.A., Bryant, J.M., et al. 2014. Pre-Columbian Mycobacterial Genomes Reveal Seals 
 138 
 
as A Source of New World Human Tuberculosis. Nature. 514(7253):494–497. DOI: 
10.1038/nature13591. 
Bottai, D. & Brosch, R. 2009. Mycobacterial PE, PPE And ESX Clusters: Novel 
Insights into The Secretion of These Most Unusual Protein Families. Molecular 
Microbiology. 73(3):325–328. DOI: 10.1111/j.1365-2958.2009.06784.x. 
Breaker, R.R. 2012. Riboswitches and The RNA World. Cold Spring Harbor 
Perspectives in Biology. 4(2):1–15. DOI: 10.1101/cshperspect.a003566. 
Brennan, M.J. 2017. The Enigmatic PE/PPE Multigene Family of Mycobacteria and 
Tuberculosis Vaccination. Infection and Immunity. 85(6):1–8. DOI: 
10.1128/IAI.00969-16. 
Bridwell-Rabb, J., Grell, T.A.J. & Drennan, C.L. 2018. A Rich Man, Poor Man Story 
of S -Adenosylmethionine and Cobalamin Revisited. Annual Review of Biochemistry. 
87:555–584. DOI: 10.1146/annurev-biochem-062917-012500. 
Brosch, R., Gordon, S. V., Marmiesse, M., Brodin, P., Buchrieser, C., Eiglmeier, K., 
Garnier, T., Gutierrez, C., et al. 2002. A New Evolutionary Scenario for The 
Mycobacterium tuberculosis Complex. Proceedings of the National Academy of 
Sciences. 99(6):3684–3689. DOI: 10.1073/pnas.052548299. 
Brynildsrud, O.B., Pepperell, C.S., Suffys, P., Grandjean, L., Monteserin, J., Debech, 
N., Bohlin, J., Alfsnes, K., et al. 2018. Global Expansion of Mycobacterium 
tuberculosis Lineage 4 Shaped by Colonial Migration and Local Adaptation. Science 
Advances. 4(10):eaat5869. DOI: 10.1126/sciadv.aat5869. 
Cadieux, N., Bradbeer, C., Reeger-Schneider, E., Köster, W., Mohanty, A.K., Wiener, 
M.C. & Kadner, R.J. 2002. Identification of The Periplasmic Cobalamin-Binding 
Protein BtuF of Escherichia coli. Journal of Bacteriology. 184(3):706–717. DOI: 
10.1128/JB.184.3.706-717.2002. 
Cambau, E. & Drancourt, M. 2014. Steps Towards the Discovery of Mycobacterium 
tuberculosis by Robert Koch, 1882. Clinical Microbiology and Infection. 20(3):196–
201. DOI: 10.1111/1469-0691.12555. 
Cingolani, P., Platts, A., Wang, L.L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, 
X., et al. 2012. A Program for Annotating and Predicting the Effects of Single 
Nucleotide Polymorphisms, SnpEff: SNPs in the Genome of Drosophila melanogaster 
strain w1118; iso-2; iso-3. Fly. 6(2):80–92. DOI: http://dx.doi.org/10.4161/fly.19695. 
Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. 
V, Eiglmeier, K., et al. 1998. Deciphering the Biology of Mycobacterium tuberculosis 
From the Complete Genome Sequence. Nature. 393(6685):537–544. DOI: 
10.1038/31159. 
Cole, S.T., Eiglmeier, K., Parkhill, J., James, K.D., Thomson, N.R., Wheeler, P.R., 
Honoré, N., Garnier, T., et al. 2001. Massive Gene Decay in The Leprosy Bacillus. 
Nature. 409:1007–1011. DOI: 10.1038/35059006. 
 139 
 
Comas, I., Coscolla, M., Luo, T., Borrell, S., Holt, K.E., Parkhill, J., Malla, B., Berg, 
S., et al. 2013. Out-Of-Africa Migration and Neolithic Co-Expansion of 
Mycobacterium tuberculosis With Modern Humans. Nature Genetics. 45(10):1176–
1182. DOI: 10.1038/ng.2744. 
Comas, I., Hailu, E., Kiros, T., Bekele, S., Mekonnen, W., Gumi, B., Tschopp, R., 
Ameni, G., et al. 2015. Population Genomics of Mycobacterium tuberculosis in 
Ethiopia Contradicts the Virgin Soil Hypothesis for Human Tuberculosis in Sub-
Saharan Africa. Current Biology. 25(24):3260–3266. DOI: 
10.1016/j.cub.2015.10.061. 
Coscolla, M. & Gagneux, S. 2014. Consequences of genomic diversity in 
Mycobacterium tuberculosis. Seminars in Immunology. 26(6):431–444. DOI: 
10.1016/j.smim.2014.09.012. 
Coscolla, M., Lewin, A., Metzger, S., Maetz-Rennsing, K., Calvignac-Spencer, S., 
Nitsche, A., Dabrowski, P.W., Radonic, A., et al. 2013. Novel Mycobacterium 
tuberculosis Complex Isolate from A Wild Chimpanzee. Emerging Infectious 
Diseases. 19(6):969–976. DOI: 10.3201/eid1906.121012. 
Crespo, A., Blanco-Cabra, N. & Torrents, E. 2018. Aerobic Vitamin B12 Biosynthesis 
Is Essential for Pseudomonas aeruginosa Class II Ribonucleotide Reductase Activity 
During Planktonic and Biofilm Growth. Frontiers in Microbiology. 9(May):986. DOI: 
10.3389/fmicb.2018.00986. 
Croft, M.T., Lawrence, A.D., Raux-Deery, E., Warren, M.J. & Smith, A.G. 2005. 
Algae Acquire Vitamin B12 Through A Symbiotic Relationship with Bacteria. Nature. 
438(7064):90–93. DOI: 10.1038/nature04056. 
Daniel, T.M. 2015. Jean-Antoine Villemin And the Infectious Nature of Tuberculosis. 
International Journal of Tuberculosis and Lung Disease. 19(3):267–268. 
Daniel, J., Maamar, H., Deb, C., Sirakova, T.D. & Kolattukudy, P.E. 2011. 
Mycobacterium tuberculosis Uses Host Triacylglycerol to Accumulate Lipid Droplets 
and Acquires A Dormancy-Like Phenotype in Lipid-Loaded Macrophages. PLoS 
Pathogens. 7(6). DOI: 10.1371/journal.ppat.1002093. 
Danilchanka, O., Sun, J., Pavlenok, M., Maueroder, C., Speer, A., Siroy, A., Marrero, 
J., Trujillo, C., et al. 2014. An Outer Membrane Channel Protein of Mycobacterium 
tuberculosis With Exotoxin Activity. Proceedings of the National Academy of 
Sciences. 111(18):6750–6755. DOI: 10.1073/pnas.1400136111. 
Danilchanka, O., Pires, D., Anes, E. & Niederweis, M. 2015. The Mycobacterium 
tuberculosis Outer Membrane Channel Protein CpnT Confers Susceptibility to Toxic 
Molecules. Antimicrobial Agents and Chemotherapy. 59(4):2328–2336. DOI: 
10.1128/AAC.04222-14. 
Dassanayake, R.S., Cabelli, D.E. & Brasch, N.E. 2013. Pulse Radiolysis Studies on 
The Reaction of The Reduced Vitamin B12 Complex Cob(II)Alamin With Superoxide. 
ChemBioChem. 14(9):1081–1083. DOI: 10.1002/cbic.201300229. 
 140 
 
DeJesus, M.A., Gerrick, E.R., Xu, W., Park, S.W., Long, J.E., Boutte, C.C., Rubin, 
E.J., Schnappinger, D., et al. 2017. Comprehensive Essentiality Analysis of The 
Mycobacterium tuberculosis Genome Via Saturating Transposon Mutagenesis. mBio. 
8(1):1–2. DOI: 10.1128/mBio.02133-16. 
DeJesus, M.A., Ambadipudi, C., Baker, R., Sassetti, C. & Ioerger, T.R. 2015. 
TRANSIT – A Software Tool for Himar1 Tn-seq Analysis. PLoS Computational 
Biology. 11(10):1–17. DOI: 10.1371/journal.pcbi.1004401. 
Delogu G, Cole ST, B.R. 2008. The PE And PPE Protein Families of Mycobacterium 
tuberculosis. Handbook of tuberculosis. 131–150. 
Dixon, M.M., Huang, S., Matthews, R.G. & Ludwig, M. 1996. The Structure of the C-
Terminal Domain of Methionine Synthase: Presenting S-Adenosylmethionine for 
Reductive Methylation of B12. Structure. 4(11):1263–1275. DOI: 10.1016/S0969-
2126(96)00135-9. 
Domenech, P., Kobayashi, H., Levier, K., Walker, G.C. & Barry, C.E. 2009. Baca, An 
ABC Transporter Involved in Maintenance of Chronic Murine Infections with 
Mycobacterium tuberculosis. Journal of Bacteriology. 191(2):477–485. DOI: 
10.1128/JB.01132-08. 
Dowling, D.P., Miles, Z.D., Köhrer, C., Maiocco, S.J., Elliott, S.J., Bandarian, V. & 
Drennan, C.L. 2016. Molecular Basis of Cobalamin-Dependent RNA Modification. 
Nucleic Acids Research. 44(20):9965–9976. DOI: 10.1093/nar/gkw806. 
Doxey, A.C., Kurtz, D.A., Lynch, M.D., Sauder, L.A. & Neufeld, J.D. 2015. Aquatic 
Metagenomes Implicate Thaumarchaeota in Global Cobalamin Production. The ISME 
Journal. 9:461–471. DOI: 10.1038/ismej.2014.142. 
Drain, P.K., Bajema, K.L., Dowdy, D., Dheda, K., Naidoo, K., Schumacher, S.G., Ma, 
S., Meermeier, E., et al. 2018. Incipient and Subclinical Tuberculosis: A Clinical 
Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews. 
31(4):1–24. DOI: 10.1128/CMR.00021-18. 
Drennan, C.L., Huang, S., Drummond, J.T., Matthews, R.G. & Ludwig, M.L. 1994. 
How A Protein Binds B12: A 3.0A X-Ray Structure of B12-Binding Domains of 
Methionine Synthase. Science. 266(10):1660–1674. 
Ehrt, S. & Schnappinger, D. 2009. Mycobacterial Survival Strategies in the 
Phagosome: Defense Against Host Stresses. Cell Microbiology. 11(8):1170–1178. 
DOI: 10.1111/j.1462-5822.2009.01335.x. 
El-Gebali, S., Mistry, J., Bateman, A., Eddy, S.R., Luciani, A., Potter, S.C., Qureshi, 
M., Richardson, L.J., et al. 2018. The Pfam Protein Families Database In 2019. Nucleic 
Acids Research. DOI: 10.1093/nar/gky995. 
Eoh, H. & Rhee, K.Y. 2014. Methylcitrate Cycle Defines the Bactericidal Essentiality 
of Isocitrate Lyase for Survival of Mycobacterium tuberculosis on Fatty Acids. 
 141 
 
Proceedings of the National Academy of Sciences. 111(13):4976–4981. DOI: 
10.1073/pnas.1400390111. 
Escalante-Semerena, J. C., Suh, S. J., Roth, J. R. 1990. cobA Function is required for 
both de novo cobalamin biosynthesis and assimilation of exogenous corrinoids in 
Salmonella typhimurium. Journal of Bacteriology. 172: 273-280. DOI: 
10.1128/jb.172.1.273-280.1990 
Esmail, A., Sabur, N.F., Okpechi, I. & Dheda, K. 2018. Management of Drug-
Resistant Tuberculosis in Special Subpopulations Including Those with HIV Co-
Infection, Pregnancy, Diabetes, Organ-Specific Dysfunction, and in the Critically Ill. 
Journal of Thoracic Disease. 10(5):3102–3118. DOI: 10.21037/jtd.2018.05.11. 
Fang, H., Kang, J. & Zhang, D. 2017. Microbial Production of Vitamin B12: A Review 
and Future Perspectives. Microbial Cell Factories. 16(1):15. DOI: 10.1186/s12934-
017-0631-y. 
Ferguson, S.J. 2016. SAM – A Helping Hand in Many Places. FEBS Letters. 
590(June):2536–2537. DOI: 10.1002/1873-3468.12249/. 
Ferla, M.P. & Patrick, W.M. 2014. Bacterial Methionine Biosynthesis. Microbiology 
(United Kingdom). 160(PART 8):1571–1584. DOI: 10.1099/mic.0.077826-0. 
Ferrer, J.L., Ravanel, S., Robert, M. & Dumas, R. 2004. Crystal Structures of 
Cobalamin-Independent Methionine Synthase Complexed with Zinc, Homocysteine, 
and Methyltetrahydrofolate. Journal of Biological Chemistry. 279(43):44235–44238. 
DOI: 10.1074/jbc.C400325200. 
Fleischmann, R.D., Dodson, R.J., Haft, D.H., Merkel, J.S., Nelson, W.C. & Fraser, 
C.M. 2006. Direct submission. Bethesda, MD: National Center for Biotechnology 
Information, NIH. 
Forgacs, P., Wengenack, N.L., Hall, L., Zimmerman, S.K., Silverman, M.L. & 
Roberts, G.D. 2009. Tuberculosis and Trimethoprim-Sulfamethoxazole. 
Antimicrobial Agents and Chemotherapy. 53(11):4789–4793. DOI: 
10.1128/AAC.01658-08. 
Fu, T.M., Almqvist, J., Liang, Y.H., Li, L., Huang, Y. & Su, X.D. 2011. Crystal 
Structures of Cobalamin-Independent Methionine Synthase (MetE) from 
Streptococcus mutans: A Dynamic Zinc-Inversion Model. Journal of Molecular 
Biology. 412(4):688–697. DOI: 10.1016/j.jmb.2011.08.005. 
Furukawa, K., Ramesh, A., Zhou, Z., Weinberg, Z., Vallery, T., Winkler, W.C. & 
Breaker, R.R. 2015. Bacterial Riboswitches Cooperatively Bind Ni2+ or Co2+ Ions and 
Control Expression of Heavy Metal Transporters. Molecular Cell. 57(6):1088–1098. 
DOI: 10.1016/j.molcel.2015.02.009. 
Gagneux, S. 2018. Ecology and Evolution of Mycobacterium tuberculosis. Nature 
Reviews Microbiology. 16(4):202–213. DOI: 10.1038/nrmicro.2018.8. 
 142 
 
Galagan, J.E. 2014. Genomic Insights into Tuberculosis. Nature Reviews Genetics. 
15(5):307–320. DOI: 10.1038/nrg3664. 
Van der Geize, R., Yam, K., Heuser, T., Wilbrink, M.H., Hara, H., Anderton, M.C., 
Sim, E., Dijkhuizen, L., et al. 2007. A Gene Cluster Encoding Cholesterol Catabolism 
in A Soil Actinomycete Provides Insight into Mycobacterium tuberculosis Survival in 
Macrophages. Proceedings of the National Academy of Sciences. 104(6):1947–1952. 
DOI: 10.1073/pnas.0605728104. 
Gey van Pittius, N.C., Sampson, S.L., Lee, H., Kim, Y., Van Helden, P.D. & Warren, 
R.M. 2006. Evolution and Expansion of the Mycobacterium tuberculosis PE And PPE 
Multigene Families and Their Association with the Duplication of the ESAT-6 (ESX) 
Gene Cluster Regions. BMC Evolutionary Biology. 6(95). DOI: 10.1186/1471-2148-
6-95. 
Giedyk, M., Goliszewska, K. & Gryko, D. 2015. Vitamin B12 Catalysed Reactions. 
Chem. Soc. Rev. 44(11):3391–3404. DOI: 10.1039/C5CS00165J. 
Gonzalez, J.C., Banerjee, R. V., Huang, S., Sumner, J.S. & Matthews, R.G. 1992. 
Comparison of Cobalamin-independent and Cobalamin-dependent Methionine 
Synthases from Escherichia coli: Two Solutions to the Same Chemical Problem. 
Biochemistry. 31(26):6045–6056. DOI: 10.1021/bi00141a013. 
Gonzalo-Asensio, J., Malaga, W., Pawlik, A., Astarie-Dequeker, C., Passemar, C., 
Moreau, F., Laval, F., Daffe, M., et al. 2014. Evolutionary History of Tuberculosis 
Shaped by Conserved Mutations in the PhoPR Virulence Regulator. Proceedings of 
the National Academy of Sciences. 111(31):11491–11496. DOI: 
10.1073/pnas.1406693111. 
Gopinath, K., Venclovas, C., Ioerger, T.R., Sacchettini, J.C., McKinney, J.D., Mizrahi, 
V. & Warner, D.F. 2013. A vitamin B₁₂ Transporter in Mycobacterium tuberculosis. 
Open Biology. 3(2):120175. DOI: 10.1098/rsob.120175. 
Gopinath, K., Moosa, A., Mizrahi, V. & Warner, D.F. 2013. Vitamin B12 metabolism 
in Mycobacterium tuberculosis. Future Microbiology. 8(11):1405–1418. 
Gopinath, K., Warner, D.F. & Mizrahi, V. 2015. Targeted Gene Knockout and 
Essentiality Testing by Homologous Recombination. In: Mycobacteria Protocols: 
Third Edition. V. 1285. T. Parish & D.M. Roberts, Eds. 131–149. DOI: 10.1007/978-
1-4939-2450-9. 
Goulding, C.W., Postigo, D. & Matthews, R.G. 1997. Cobalamin-dependent 
Methionine Synthase Is a Modular Protein with Distinct Regions for Binding 
Homocysteine, Methyltetrahydrofolate, Cobalamin, and Adenosylmethionine. 
Biochemistry. 36:8082–8091. DOI: 10.1021/BI9705164. 
Gouzy, A., Larrouy-Maumus, G., Bottai, D., Levillain, F., Dumas, A., Wallach, J.B., 
Caire-Brandli, I., de Chastellier, C., et al. 2014. Mycobacterium tuberculosis Exploits 
Asparagine to Assimilate Nitrogen and Resist Acid Stress during Infection. PLoS 
Pathogens. 10(2). DOI: 10.1371/journal.ppat.1003928. 
 143 
 
Greenhalgh, I. & Butler, A.R. 2017. Sanatoria Revisited: Sunlight and Health. Journal 
of the Royal College of Physicians of Edinburgh. 47(3):276–280. DOI: 
10.4997/JRCPE.2017.314. 
Griffin, J.E., Gawronski, J.D., DeJesus, M.A., Ioerger, T.R., Akerley, B.J. & Sassetti, 
C.M. 2011. High-resolution Phenotypic Profiling Defines Genes Essential for 
Mycobacterial Growth and Cholesterol Catabolism. PLoS Pathogens. 7(9):1–9. DOI: 
10.1371/journal.ppat.1002251. 
Griffin, J.E., Pandey, A.K., Gilmore, S.A., Mizrahi, V., McKinney, J.D., Bertozzi, 
C.R. & Sassetti, C.M. 2012. Cholesterol Catabolism by Mycobacterium tuberculosis 
Requires Transcriptional and Metabolic Adaptations. Chemistry and Biology. 
19(2):218–227. DOI: 10.1016/j.chembiol.2011.12.016. 
Gröschel, M.I., Sayes, F., Simeone, R., Majlessi, L. & Brosch, R. 2016. ESX Secretion 
Systems: Mycobacterial Evolution to Counter Host Immunity. Nature Reviews 
Microbiology. 14(11):677–691. DOI: 10.1038/nrmicro.2016.131. 
Gryko, D., Giedyk, M., Jackowska, A., Równicki, M., Kolanowska, M. & Trylska, J. 
2018. Vitamin B12 Transports Modified RNA into E. coli and S. Typhimurium Cells. 
Chemical Communications. 12:10–13. DOI: 10.1039/C8CC05064C. 
Guirado, E. & Schlesinger, L.S. 2013. Modeling the Mycobacterium tuberculosis 
Granuloma – the Critical Battlefield in Host Immunity and Disease. Frontiers in 
Immunology. 4(APR):1–7. DOI: 10.3389/fimmu.2013.00098. 
Gutierrez, M.C., Brisse, S., Brosch, R., Fabre, M., Omaïs, B., Marmiesse, M., Supply, 
P. & Vincent, V. 2005. Ancient Origin and Gene Mosaicism of the Progenitor of 
Mycobacterium tuberculosis. PLoS Pathogens. 1(1):0055–0061. DOI: 
10.1371/journal.ppat.0010005. 
Guzzo, M.B., Nguyen, H.T., Pham, T.H., Wyszczelska-Rokiel, M., Jakubowski, H., 
Wolff, K.A., Ogwang, S., Timpona, J.L., et al. 2016. Methylfolate Trap Promotes 
Bacterial Thymineless Death by Sulfa Drugs. PLoS Pathogens. 12(10):1–28. DOI: 
10.1371/journal.ppat.1005949. 
Haller, A., Soulière, M.F. & Micura, R. 2011. The Dynamic Nature of RNA as Key to 
Understanding Riboswitch Mechanisms. Accounts of Chemical Research. 
44(12):1339–1348. DOI: 10.1021/ar200035g. 
Halpern, J. 1985. Mechanisms of coenzyme B12-dependent rearrangements. Science. 
227(4689):869–875. doi:10.1126/science.2857503 
Hamada, M., Shibata, C., Sakurai, K., Hosoyama, A., Oji, S., Teramoto, K. & Tamura, 
T. 2016. Reclassification of Amycolicicoccus subflavus as Hoyosella subflava comb. 
nov. and Emended Descriptions of the Genus Hoyosella and Hoyosella altamirensis. 
International Journal of Systematic and Evolutionary Microbiology. 66(11):4711–
4715. DOI: 10.1099/ijsem.0.001415. 
 144 
 
Hazra, A.B., Han, A.W., Mehta, A.P., Mok, K.C., Osadchiy, V., Begley, T.P. & Taga, 
M.E. 2015. Anaerobic Biosynthesis of the Lower Ligand of Vitamin B12. Proceedings 
of the National Academy of Sciences. 112(34):10792–10797. DOI: 
10.1073/pnas.1509132112. 
van Helden, P.D., Victor, T.C., Warren, R.M. & Helden, E.G. Van. 2001. Isolation of 
DNA from Mycobacterium tuberculosis. Methods in Molecular Medicine. 54(15):19–
29. DOI: 10.1385/1-59259-147-7:019. 
Hermann, C., Giddey, A.D., Nel, A.J.M., Soares, N.C. & Blackburn, J.M. 2019. Cell 
Wall Enrichment Unveils Proteomic Changes in the Cell Wall During Treatment of 
Mycobacterium smegmatis with Sub-lethal Concentrations of Rifampicin. Journal of 
Proteomics. 191:166–179. DOI: 10.1016/j.jprot.2018.02.019. 
Hershberg, R., Lipatov, M., Small, P.M., Sheffer, H., Niemann, S., Homolka, S., 
Roach, J.C., Kremer, K., et al. 2008. High Functional Diversity in Mycobacterium 
tuberculosis Driven by Genetic Drift and Human Demography. PLoS Biology. 
6(12):2658–2671. DOI: 10.1371/journal.pbio.0060311. 
Horswill, A. R., Dudding, Andrea R., Escalante-Semerena, J. C. 2001. Studies of 
Propionate Toxicity in Salmonella enterica Identify 2-Methylcitrate as a Potent 
Inhibitor of Cell Growth. Journal of Biological Chemistry. 276(22):19094-19101. 
DOI: 10.1074/jbc.M100244200 
Houben, R.M.G.J. & Dodd, P.J. 2016. The Global Burden of Latent Tuberculosis 
Infection: A Re-estimation Using Mathematical Modelling. PLOS Medicine. 
13(10):e1002152. DOI: 10.1371/journal.pmed.1002152. 
Huang, L., Nazarova, E. V, Tan, S., Liu, Y. & Russell, D.G. 2018. Growth of 
Mycobacterium tuberculosis in vivo Segregates with Host Macrophage Metabolism 
and Ontogeny. Journal of Experimental Medicine. 215(4):1135–1152. DOI: 
10.1084/jem.20172020. 
Huang, T.S., Kunin, C.M., Yan, B.S., Chen, Y.S., Lee, S.S.J. & Syu, W. 2012. 
Susceptibility of Mycobacterium tuberculosis to Sulfamethoxazole, Trimethoprim and 
Their Combination Over A 12 Year Period in Taiwan. Journal of Antimicrobial 
Chemotherapy. 67(3):633–637. DOI: 10.1093/jac/dkr501. 
Hunter, R.L. 2018. The Pathogenesis of Tuberculosis: The Early Infiltrate of Post-
primary (Adult Pulmonary) Tuberculosis: A Distinct Disease Entity. Frontiers in 
Immunology. 9(2108):1–9. DOI: 10.3389/fimmu.2018.02108. 
Ignatov, D. & Johansson, J. 2017. RNA-mediated Signal Perception in Pathogenic 
Bacteria. Wiley Interdisciplinary Reviews: RNA. 8(6):1–25. DOI: 10.1002/wrna.1429. 
Imperiale, B.R., Moyano, R.D., Di Giulio, A.B., Romero, M.A., Alvarado Pinedo, 
M.F., Santangelo, M.P., Travería, G.E., Morcillo, N.S., et al. 2017. Genetic Diversity 
of Mycobacterium avium Complex Strains Isolated in Argentina by MIRU-VNTR. 
Epidemiology and Infection. 145(7):1382–1391. DOI: 10.1017/S0950268817000139. 
 145 
 
James, B.W., Williams, A. & Marsh, P.D. 2000. The Physiology and Pathogenicity of 
Mycobacterium tuberculosis Grown Under Controlled Conditions in A Defined 
Medium. Journal of Applied Microbiology. 88(4):669–677. DOI: 10.1046/j.1365-
2672.2000.01020.x. 
Johnson, C. L. V., Pechonick, E., Park, S. D., Havemann, G. D., Leal, N. A., Bobik, 
T. A. 2001. Functional Genomic, Biochemical, and Genetic Characterization of the 
Salmonella pduO Gene, an ATP:Cob(I)alamin Adenosyltransferase Gene. Journal of 
Bacteriology. 183(5): 1577-1584. DOI: 10.1128/JB.183.5.1577 
Johnson Jr, J.E., Reyes, F.E., Polaski, J.T. & Batey, R.T. 2012. B12 Cofactors Directly 
Stabilize An mRNA Regulatory Switch. Nature. 492(7427):133–137. DOI: 
10.1038/nature11607. 
Jones, A.R. 2017. The Photochemistry and Photobiology of Vitamin B12. Photochem. 
Photobiol. Sci. 16(6):820–834. DOI: 10.1039/C7PP00054E. 
Jones, P., Binns, D., Chang, H.Y., Fraser, M., Li, W., McAnulla, C., McWilliam, H., 
Maslen, J., et al. 2014. InterProScan 5: Genome-scale Protein Function Classification. 
Bioinformatics. 30(9):1236–1240. DOI: 10.1093/bioinformatics/btu031. 
Kang, Z., Zhang, J., Zhou, J., Qi, Q., Du, G. & Chen, J. 2012. Recent Advances in 
Microbial Production of δ-aminolevulinic Acid and Vitamin B12. Biotechnology 
Advances. 30(6):1533–1542. DOI: 10.1016/j.biotechadv.2012.04.003. 
Kapopoulou, A., Lew, J.M. & Cole, S.T. 2011. The MycoBrowser Portal: A 
Comprehensive and Manually Annotated Resource for Mycobacterial Genomes. 
Tuberculosis. 91(1):8–13. DOI: 10.1016/j.tube.2010.09.006. 
Karasseva, V., Weiszfeiler, J.G. & Lengyel, Z. 1977. Synthesis of Vitamin B12 by 
Various Species of Mycobacteria. Zentralblatt für Bakteriologie, Parasitenkunde, 
Infektionskrankheiten und Hygiene. Erste Abte (Reihe A: Medizinische Mikrobiologie 
und Parasitologie 239):514–520. 
Kaufmann, S.H. 2001. How Can Immunology Contribute to the Control of 
Tuberculosis? Nature Reviews Immunology. 1(1):20–30. DOI: 10.1038/35095558. 
Keck, B., Munder, M. & Renz, P. 1998. Biosynthesis of Cobalamin in Salmonella 
typhimurium: Transformation of Riboflavin into the 5,6-dimethylbenzimidazole 
Moiety. Archives of Microbiology. 171(1):66–68. DOI: 10.1007/s002030050679. 
Koch, A.S., Brites, D., Stucki, D., Evans, J.C., Seldon, R., Heekes, A., Mulder, N., 
Nicol, M., et al. 2017. The Influence of HIV on the Evolution of Mycobacterium 
tuberculosis. Molecular Biology and Evolution. 34(7):1654–1668. DOI: 
10.1093/molbev/msx107. 
Koeck, J.L., Fabre, M., Simon, F., Daffé, M., Garnotel, É., Matan, A.B., Gérôme, P., 
Bernatas, J.J., et al. 2011. Clinical Characteristics of the Smooth Tubercle Bacilli 
“Mycobacterium canettii” Infection Suggest the Existence of An Environmental 
 146 
 
Reservoir. Clinical Microbiology and Infection. 17(7):1013–1019. DOI: 
10.1111/j.1469-0691.2010.03347.x. 
Korkhov, V.M., Mireku, S.A., Veprintsev, D.B. & Locher, K.P. 2014. Structure of 
AMP-PNP-bound BtuCD and Mechanism of ATP-powered Vitamin B12 Transport by 
BtuCD-F. Nature Structural and Molecular Biology. 21(12):1097–1099. DOI: 
10.1038/nsmb.2918. 
Koutmos, M., Pejchal, R., Bomer, T.M., Matthews, R.G., Smith, J.L. & Ludwig, M.L. 
2008. Metal Active Site Elasticity Linked to Activation of Homocysteine in 
Methionine Synthases. Proceedings of the National Academy of Sciences of the United 
States of America. 105(9):3286–91. DOI: 10.1073/pnas.0709960105. 
Koutmos, M., Datta, S., Pattridge, K. A., Smith, J. L., Matthews, R. G. 2009. Insights 
into the reactivation of cobalamin-dependent methionine synthase. Proceedings of the 
National Academy of Sciences. 106(14): 18527-18532. DOI: 
10.1073/pnas.0906132106 
Krebs, H., Hems, R. & Tyler, B. 1976. The Regulation of Folate and Methionine 
Metabolism. The Biochemical Journal. 158(2):341–353. 
Kucukyildirim, S., Long, H., Sung, W., Miller, S.F., Doak, T.G. & Lynch, M. 2016. 
The Rate and Spectrum of Spontaneous Mutations in Mycobacterium smegmatis, a 
Bacterium Naturally Devoid of the Postreplicative Mismatch Repair Pathway. G3: 
Genes, Genomes, Genetics. 6(7):2157–2163. DOI: 10.1534/g3.116.030130. 
Lawrence, A. D., Deery, E., McLean, K. J., Munro, A. W., Pickersgill, R. W., Rigby, 
S. E. J., Warren, M. J. 2008. Identification, characterization, and structure/function 
analysis of a corrin reductase involved in adenosylcobalamin biosynthesis. Journal of 
Biological Chemistry. 283(16):10813-10821. DOI: 10.1074/jbc.M710431200 
Lawrence, A.D., Nemoto-smith, E., Deery, E., Baker, J.A., Schroeder, S., Brown, 
D.G., Tullet, J.M.A., Howard, M.J., et al. 2018. Construction of Fluorescent Analogs 
to Follow the Uptake and Distribution of Cobalamin (Vitamin B12) in Bacteria, 
Worms, and Plants. Cell Chemical Biology. 25(8):941–951. DOI: 
10.1016/j.chembiol.2018.04.012. 
Lawrence, J.G., Roth, J.R., Lawrence, J.G. & Roth, J.R. 1995. The Cobalamin 
(Coenzyme B12) Biosynthetic Genes of Escherichia coli. Journal of Bacteriology. 
177(22):6371–6380. 
Lee, W., VanderVen, B.C., Fahey, R.J. & Russell, D.G. 2013. Intracellular 
Mycobacterium tuberculosis Exploits Host-derived Fatty Acids to Limit Metabolic 
Stress. Journal of Biological Chemistry. 288(10):6788–6800. DOI: 
10.1074/jbc.M112.445056. 
Lewinson, O., Lee, A.T., Locher, K.P. & Rees, D.C. 2010. A Distinct Mechanism for 
the ABC Transporter BtuCD-BtuF Revealed by the Dynamics of Complex Formation. 
Nature Structural and Molecular Biology. 17(3):332–338. DOI: 10.1038/nsmb.1770. 
 147 
 
Li, H. & Durbin, R. 2009. Fast and Accurate Short Read Alignment with Burrows-
Wheeler Transform. Bioinformatics. 25(14):1754–1760. DOI: 
10.1093/bioinformatics/btp324. 
Li, H. & Durbin, R. 2010. Fast and Accurate Long-read Alignment with Burrows-
Wheeler Transform. Bioinformatics. 26(5):589–595. DOI: 
10.1093/bioinformatics/btp698. 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., 
Abecasis, G., et al. 2009. The Sequence Alignment/Map Format and SAMtools. 
Bioinformatics. 25(16):2078–2079. DOI: 10.1093/bioinformatics/btp352. 
Li, K., Li, G., Bradbury, L.M.T., Hanson, A.D. & Bruner, S.D. 2016. Crystal Structure 
of the Homocysteine Methyltransferase MmuM from Escherichia coli. Biochemical 
Journal. 473(3):277–284. DOI: 10.1042/BJ20150980. 
Libecco, J.A. & Powell, K.R. 2004. Trimethoprim/Sulfamethoxazole: Clinical Update. 
Pediatrics in Review. 25(11):375–380. 
Lin, P.L. & Flynn, J.L. 2018. The End of the Binary Era: Revisiting the Spectrum of 
Tuberculosis. The Journal of Immunology. 201(9):2541–2548. DOI: 
10.4049/jimmunol.1800993. 
Lin, P.L., Ford, C.B., Coleman, M.T., Myers, A.J., Gawande, R., Ioerger, T., 
Sacchettini, J., Fortune, S.M., et al. 2014. Sterilization of Granulomas isCcommon in 
Active and Latent Tuberculosis Despite Within-host Variability in Bacterial Killing. 
Nature Medicine. 20(1):75–9. DOI: 10.1038/nm.3412. 
Locher, K.P., Lee, A.T. & Rees, D.C. 2002. The E. coli BtuCD Structure: A 
Framework for ABC Transporter Architecture and Mechanism. Science. 
296(5570):1091–1098. DOI: 10.1126/science.1071142. 
Lopez, B., Aguilar, D., Orozco, H., Burger, M., Espitia, C., Ritacco, V., Barrera, L., 
Kremer, K., et al. 2003. A Marked Difference in Pathogenesis and Immune Response 
Induced by Different Mycobacterium tuberculosis Genotypes. Clinical and 
Experimental Immunology. 133:30–37. 
Lovewell, R.R., Sassetti, C.M. & VanderVen, B.C. 2016. Chewing the Fat: Lipid 
Metabolism and Homeostasis During M. tuberculosis Infection. Current Opinion in 
Microbiology. 29:30–36. DOI: 10.1016/j.mib.2015.10.002. 
Lussier, A., Bastet, L., Chauvier, A. & Lafontaine, D.A. 2015. A Kissing Loop Is 
Important for BtuB Riboswitch Ligand Sensing and Regulatory Control. Journal of 
Biological Chemistry. 290(44):26739–26751. DOI: 10.1074/jbc.M115.684134. 
Markowitz, V.M., Chen, I.M.A., Palaniappan, K., Chu, K., Szeto, E., Grechkin, Y., 
Ratner, A., Jacob, B., et al. 2012. IMG: The Integrated Microbial Genomes Database 
and Comparative Analysis System. Nucleic Acids Research. 40(D1):115–122. DOI: 
10.1093/nar/gkr1044. 
 148 
 
Marrero, J., Rhee, K.Y., Schnappinger, D., Pethe, K. & Ehrt, S. 2010. Gluconeogenic 
Carbon Flow of Tricarboxylic Acid Cycle Intermediates Is Critical for Mycobacterium 
tuberculosis to Establish and Maintain Infection. Proceedings of the National 
Academy of Sciences. 107(21):9819–9824. DOI: 10.1073/pnas.1000715107. 
Mattes, T. A., Deery, E., Warren, M. J., Escalante-Semerena, J. C. 2017. Cobalamin 
Biosynthesis and Insertion. In Encyclopedia of Inorganic and Bioinorganic Chemistry. 
Scott, R.A. (ed.) Chichester: John Wiley & Sons Ltd, pp. 1–24. DOI: 
10.1002/9781119951438.eibc2489 
Matthews, R.G. & Goulding, C.W. 1997. Enzyme-catalyzed Methyl Transfers to 
Thiols: The Role of Zinc. Current Opinion in Chemical Biology. 1(3):332–339. DOI: 
10.1016/S1367-5931(97)80070-1. 
McKinney, J.D., Höner zu Bentrup, K., Muñoz-Elías, E.J., Miczak, a, Chen, B., Chan, 
W.T., Swenson, D., Sacchettini, J.C., et al. 2000. Persistence of Mycobacterium 
tuberculosis in Macrophages and Mice Requires the Glyoxylate Shunt Enzyme 
Isocitrate Lyase. Nature. 406(6797):735–738. DOI: 10.1038/35021074. 
Merker, M., Blin, C., Mona, S., Duforet-Frebourg, N., Lecher, S., Willery, E., Blum, 
M.G.B., Rüsch-Gerdes, S., et al. 2015. Evolutionary History and Global Spread of the 
Mycobacterium tuberculosis Beijing Lineage. Nature Genetics. 47(3):242–249. DOI: 
10.1038/ng.3195. 
Minias, A., Minias, P. & Dziadek, J. 2018. Purifying Selective Pressure Suggests the 
Functionality of a Vitamin B12 Biosynthesis Pathway in a Global Population of 
Mycobacterium tuberculosis. Genome Biology and Evolution. 10(9):2326–2337. DOI: 
10.1093/gbe/evy153/5061319. 
Mokrousov, I. 2013. Insights into the Origin, Emergence, and Current Spread of a 
Successful Russian Clone of Mycobacterium tuberculosis. Clinical Microbiology 
Reviews. 26(2):342–360. DOI: 10.1128/CMR.00087-12. 
Moore, S.J. & Warren, M.J. 2012. The Anaerobic Biosynthesis of Vitamin B12. 
Biochemical Society Transactions. 40(3):581–586. DOI: 10.1042/BST20120066. 
Mostowy, S., Cousins, D., Brinkman, J., Aranaz, A. & Behr, M.A. 2002. Genomic 
Deletions Suggest a Phylogeny for the Mycobacterium tuberculosis Complex. The 
Journal of Infectious Diseases. 186(1):74–80. DOI: 10.1086/341068. 
Muñoz-Elías, E.J., Upton, A.M., Cherian, J. & McKinney, J.D. 2006. Role of the 
Methylcitrate Cycle in Mycobacterium tuberculosis Metabolism, Intracellular Growth, 
and Virulence. Molecular Microbiology. 60(5):1109–1122. DOI: 10.1111/j.1365-
2958.2006.05155.x. 
Nahvi, A., Barrick, J.E. & Breaker, R.R. 2004. Coenzyme B12 Riboswitches are 
Widespread Genetic Control Elements in Prokaryotes. Nucleic Acids Research. 
32(1):143–150. DOI: 10.1093/nar/gkh167. 
 149 
 
Nebenzahl-Guimaraes, H., Yimer, S.A., van Soolingen, D., Brosch, R., Holm-Hansen, 
C. & de Beer, J. 2016. Genomic Characterization of Mycobacterium tuberculosis 
Lineage 7 and a Proposed Name: ‘Aethiops vetus’. Microbial Genomics. 2(6):1–8. 
DOI: 10.1099/mgen.0.000063. 
Nechooshtan, G., Elgrably-Weiss, M., Sheaffer, A., Westhof, E. & Altuvia, S. 2009. 
A pH-Responsive Riboregulator. Genes and Development. 23(22):2650–2662. DOI: 
10.1101/gad.552209. 
Neyrolles, O., Wolschendorf, F., Mitra, A. & Niederweis, M. 2015. Mycobacteria, 
Metals, and the Macrophage. Immunological Reviews. 364:249–263. 
Niederweis, M., Danilchanka, O., Huff, J., Hoffmann, C. & Engelhardt, H. 2010. 
Mycobacterial Outer Membranes: In Search of Proteins. Trends in Microbiology. 
18(3):109–116. DOI: 10.1016/j.tim.2009.12.005. 
Nielsen, M.J., Rasmussen, M.R., Andersen, C.B.F., Nexø, E. & Moestrup, S.K. 2012. 
Vitamin B12 Transport from Food to the Body’s Cells – a Sophisticated, Multistep 
Pathway. Nature Reviews Gastroenterology & Hepatology. 9(6):345–54. DOI: 
10.1038/nrgastro.2012.76. 
Noinaj, N., Guillier, M., Barnard, T.J. & Buchanan, S.K. 2010. TonB-dependent 
Transporters: Regulation, Structure, and Function. Annual Review of Microbiology. 
64(1):43–60. DOI: 10.1146/annurev.micro.112408.134247. 
Nou, X. & Kadner, R. J. 2000. Adenosylcobalamin inhibits ribosome binding to btuB 
RNA. Proceedings of the National Academy of Sciences. 97(13): 7190-7195. DOI: 
10.1073/pnas.130013897 
Novichkov, P.S., Kazakov, A.E., Ravcheev, D.A., Leyn, S.A., Kovaleva, G.Y., 
Sutormin, R.A., Kazanov, M.D., Riehl, W., et al. 2013. RegPrecise 3.0--a Resource 
for Genome-scale Exploration of Transcriptional Regulation in Bacteria. BMC 
Genomics. 14(1):745. DOI: 10.1186/1471-2164-14-745. 
O’Neill, M.B., Kitchen, A., Zarley, A., Aylward, W., Eldholm, V. & Pepperell, C.S. 
2017. Lineage Specific Histories of Mycobacterium tuberculosis Dispersal in Africa 
and Eurasia. bioRxiv 210161. DOI: 10.1128/JB.00935-15.Editor. 
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H. & Kanehisa, M. 1999. KEGG: 
Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research. 27(1):29–34. 
DOI: 10.1093/nar/27.1.29. 
Oh-hama, T., Stolowich, N.J. & Scott, A.I. 1988. 5-Aminolevulinic Acid Formation 
from Glutamate via the C5 Pathway in Clostridium thermoaceticum. FEBS letters. 
228(1):89–93. DOI: 10.1016/0014-5793(88)80591-X. 
Orgeur, M. & Brosch, R. 2018. Evolution of Virulence in the Mycobacterium 
tuberculosis Complex. Current Opinion in Microbiology. 41:68–75. DOI: 
10.1016/j.mib.2017.11.021. 
 150 
 
Padmanabhan, S., Jost, M., Drennan, C.L. & Elías-Arnanz, M. 2017. A New Facet of 
Vitamin B12: Gene Regulation by Cobalamin-based Photoreceptors. Annual Review of 
Biochemistry. 86:485–514. DOI: 10.1146/annurev-biochem-061516-044500. 
Padovani, D., Labunska, T., Palfey, B. A., Ballou, D. P., Banerjee, R. 2008. 
Adenosyltransferase tailors and delivers coenzyme B12. Nature Chemical Biology. 
4(3):194–196. DOI:10.1038/nchembio.67  
Palmer, A.M., Kamynina, E., Field, M.S. & Stover, P.J. 2017. Folate rescues vitamin 
B12 Depletion-induced Inhibition of Nuclear Thymidylate Biosynthesis and Genome 
Instability. Proceedings of the National Academy of Sciences. 114(20):e4095–E4102. 
DOI: 10.1073/pnas.1619582114. 
Parish, T. & Stoker, N.G. 2000. Use of a Flexible Cassette Method to Generate a 
Double Unmarked Mycobacterium tuberculosis tlyA plcABC Mutant by Gene 
Replacement. Microbiology. 146(8):1969–1975. DOI: 10.1099/00221287-146-8-
1969. 
Parks, J.M., Johs, A., Podar, M., Bridou, R., Hurt, R. a., Smith, S.D., Tomanicek, S.J., 
Qian, Y., et al. 2013. The Genetic Basis for Bacterial Mercury Methylation. Science. 
339(6125):1332–5. DOI: 10.1126/science.1230667. 
Payne, K. A.P., Quezada, C. P., Fisher, K., Dunstan, M. S., Collins, F. A., Sjuts, H., 
Levy, C., Hay, S., Rigby, S.E.J.. Leys, D. 2015. Reductive dehalogenase structure 
suggests a mechanism for B12-dependent dehalogenation. 517(7535): 513-516. DOI: 
10.1038/nature13901 
Pejchal, R. & Ludwig, M.L. 2005. Cobalamin-independent Methionine Synthase 
(MetE): A Face-to-face Double Barrel That Evolved by Gene Duplication. PLoS 
Biology. 3(2):0254–0265. DOI: 10.1371/journal.pbio.0030031. 
Perdrizet, G.A., Artsimovitch, I., Furman, R., Sosnick, T.R. & Pan, T. 2012. 
Transcriptional Pausing Coordinates Folding of the Aptamer Domain and the 
Expression Platform of a Riboswitch. Proceedings of the National Academy of 
Sciences. 109(9):3323–3328. DOI: 10.1073/pnas.1113086109. 
Peselis, A. & Serganov, A. 2012. Structural Insights into Ligand Binding and Gene 
Expression Control by an Adenosylcobalamin Riboswitch. Nature Structural & 
Molecular Biology. 19(11):1182–1184. DOI: 10.1038/nsmb.2405. 
Peyron, P., Vaubourgeix, J., Poquet, Y., Levillain, F., Botanch, C., Bardou, F., Daffé, 
M., Emile, J.F., et al. 2008. Foamy Macrophages from Tuberculous Patients’ 
Granulomas Constitute a Nutrient-rich Reservoir for M. tuberculosis Persistence. 
PLoS Pathogens. 4(11):1–14. DOI: 10.1371/journal.ppat.1000204. 
Polaski, J.T., Webster, S.M., Johnson, J.E. & Batey, R.T. 2017. Cobalamin 
Riboswitches Exhibit a Broad Range of Ability to Discriminate Between 
Methylcobalamin and Adenosylcobalamin. Journal of Biological Chemistry. 
292(28):11650–11658. DOI: 10.1074/jbc.M117.787176. 
 151 
 
Pym, A.S., Brodin, P., Brosch, R., Huerre, M. & Cole, S.T. 2002. Loss of RD1 
Contributed to the Attenuation of the Live Tuberculosis Vaccines Mycobacterium 
bovis BCG and Mycobacterium microti. Molecular Microbiology. 46(3):709–717. 
DOI: 10.1046/j.1365-2958.2002.03237.x. 
Quadri, L.E.N. 2014. Biosynthesis of Mycobacterial Lipids by Polyketide Synthases 
and Beyond. Critical Reviews in Biochemistry and Molecular Biology. 49(3):179–211. 
DOI: 10.3109/10409238.2014.896859. 
Quan, T.P., Bawa, Z., Foster, D., Walker, T., Elias, C. del O., Rathod, P., MMM 
Informatics Group, Iqbal, Z., et al. 2018. Evaluation of Whole-Genome Sequencing 
for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical 
Setting: A Large-Scale Prospective Assessment of Performance against Line Probe 
Assays and Phenotyping. Journal of Clinical Microbiology. 56(e01480-17):1–14. 
DOI: 10.1128/JCM.01480-17. 
Rad, M.E., Bifani, P., Martin, C., Kremer, K., Samper, S., Rauzier, J., Kreiswirth, B., 
Blazquez, J., et al. 2003. Mutations in Putative Mutator Genes of Mycobacterium 
tuberculosis Strains of the W-Beijing Family. Emerging Infectious Diseases. 
9(7):838–845. DOI: 10.3201/eid0907.020589. 
Ramagopalan, S. V., Goldacre, R., Skingsley, A., Conlon, C. & Goldacre, M.J. 2013. 
Associations Between Selected Immune-mediated Diseases and Tuberculosis: Record-
linkage Studies. BMC Medicine. 11(1). DOI: 10.1186/1741-7015-11-97. 
Randall, P.J., Hsu, N.-J., Quesniaux, V., Ryffel, B. & Jacobs, M. 2015. Mycobacterium 
tuberculosis Infection of the ‘Non-classical Immune Cell’. Immunology and Cell 
Biology. 93(9):789–795. DOI: 10.1038/icb.2015.43. 
Raux, E., Lanois, A., Warren, M. J., Rambach, A., Thermes, C. 1998. Cobalamin 
(vitamin B12) biosynthesis: identification and characterization of a Bacillus 
megaterium cobI operon. The Biochemical Journal. 335:159–166. 
Ravnum, S. & Andersson, D. I. 1997. Vitamin B12 repression of the btuB gene in 
Salmonella typhimurium is mediated via a translational control which requires leader 
and coding sequences. Molecular Microbiology. 23:35-42. DOI: 10.1046/j.1365-
2958.1997.1761543.x 
Rempel, S., Colucci, E., Gier, J.W. de, Guskov, A. & Slotboom, D.J. 2018. Cysteine-
mediated Decyanation of Vitamin B12 by the Predicted Membrane Transporter BtuM. 
Nature Communications. 9(3038):1–8. DOI: 10.1038/s41467-018-05441-9. 
Renz, P. 1970. Riboflavin as Precursor in the Biosynthesis of 5,6-
dimethylbenzimidazole Moiety of Vitamin B12. FEBS Letters. 6(3):187–189. 
Reyrat, J.-M. & Kahn, D. 2001. Mycobacterium smegmatis: An Absurd Model for 
Tuberculosis? Trends in Microbiology. 9(10):472–473. DOI: 10.1016/S0966-
842X(01)02169-2. 
 152 
 
Rhee, K.Y., Carvalho, L.P.S. de, Bryk, R., Ehrt, S., Marrero, J., Park, S.W., 
Schnappinger, D., Venugopal, A., et al. 2011. Central Carbon Metabolism in 
Mycobacterium tuberculosis: An Unexpected Frontier. Trends in Microbiology. 
19(7):307–314. DOI: 10.1016/j.tim.2011.03.008. 
Rindi, L. & Garzelli, C. 2014. Genetic Diversity and Phylogeny of Mycobacterium 
avium. Infection, Genetics and Evolution. 21:375–383. DOI: 
10.1016/j.meegid.2013.12.007. 
Rocco, C. J., Escalante-Semerena, J. C. 2010. In Salmonella enterica, 2-methylcitrate 
blocks gluconeogenesis. Journal of Bacteriology. 192(3):771-778 
Rock, J.M., Hopkins, F.F., Chavez, A., Diallo, M., Chase, M.R., Gerrick, E.R., 
Pritchard, J.R., Church, G.M., et al. 2017. Programmable Transcriptional Repression 
in Mycobacteria Using an Orthogonal CRISPR Interference Platform. Nature 
Microbiology. 2(16274). DOI: 10.1038/nmicrobiol.2016.274. 
Rodionov, D.A., Vitreschak, A.G., Mironov, A.A. & Gelfand, M.S. 2003. 
Comparative Genomics of the Vitamin B12 Metabolism and Regulation in Prokaryotes. 
Journal of Biological Chemistry. 278(42):41148–41159. DOI: 
10.1074/jbc.M305837200. 
Romine, M.F., Rodionov, D.A., Maezato, Y., Anderson, L.N., Nandhikonda, P., 
Rodionova, I.A., Carre, A., Li, X., et al. 2017. Elucidation of Roles for Vitamin B12 in 
Regulation of Folate, Ubiquinone, and Methionine Metabolism. Proceedings of the 
National Academy of Sciences. 114(7):E1205–E1214. DOI: 
10.1073/PNAS.1612360114. 
Russell, D.G. 2011. Mycobacterium tuberculosis and the Intimate Discourse of a 
Chronic Infection. Immunological Reviews. 240(1):252–268. DOI: 10.1111/j.1600-
065X.2010.00984.x. 
Russell, D.G., VanderVen, B.C., Lee, W., Abramovitch, R.B., Kim, M.J., Homolka, 
S., Niemann, S. & Rohde, K.H. 2010. Mycobacterium tuberculosis Wears What It 
Eats. Cell Host and Microbe. 8(1):68–76. DOI: 10.1016/j.chom.2010.06.002. 
Sampson, S.L. 2011. Mycobacterial PE/PPE proteins at the Host-pathogen Interface. 
Clinical and Developmental Immunology. 2011(497203). DOI: 10.1155/2011/497203. 
Sasaki, S., Takeshita, F., Okuda, K. & Ishii, N. 2001. Mycobacterium leprae and 
Leprosy: A Compendium. Microbiology and Immunology. 45(11):729–736. DOI: 
10.1111/j.1348-0421.2001.tb01308.x. 
Savvi, S., Warner, D.F., Kana, B.D., McKinney, J.D., Mizrahi, V. & Dawes, S.S. 2008. 
Functional Characterization of a Vitamin B12-Dependent Methylmalonyl Pathway in 
Mycobacterium tuberculosis: Implications for Propionate Metabolism During Growth 
on Fatty Acids. Journal of Bacteriology. 190(11):3886–3895. DOI: 
10.1128/JB.01767-07. 
 153 
 
Schroeder, J.W., Yeesin, P., Simmons, L.A. & Wang, J.D. 2018. Sources of 
Spontaneous Mutagenesis in Bacteria. Critical Reviews in Biochemistry and 
Molecular Biology. 53(1):29–48. DOI: 10.1080/10409238.2017.1394262. 
Serganov, A., Yuan, Y.R., Pikovskaya, O., Polonskaia, A., Malinina, L., Phan, A.T., 
Hobartner, C., Micura, R., et al. 2004. Structural Basis for Discriminative Regulation 
of Gene Expression by Adenine- and Guanine-sensing mRNAs. Chemistry and 
Biology. 11(12):1729–1741. DOI: 10.1016/j.chembiol.2004.11.018. 
Shelton, A.N., Seth, E.C., Mok, K.C., Han, A.W., Jackson, S.N., Haft, D.R. & Taga, 
M.E. 2018. Uneven Distribution of Cobamide Biosynthesis and Dependence in 
Bacteria Predicted by Comparative Genomics. The ISME Journal. DOI: doi: 
http://dx.doi.org/10.1101/342006. 
Shepard, C.C. 1960. The Experimental Disease That Follows the Injection of Human 
Leprosy Bacilli into Foot-pads of Mice. Journal of Experimental Medicine. 112:445–
454. 
Sherwood, A. V & Henkin, T.M. 2016. Riboswitch-mediated Gene Regulation: Novel 
RNA Architectures Dictate Gene Expression Responses. Annual Review of 
Microbiology. 70:361–374. DOI: 10.1146/annurev-micro-091014-104306. 
Shiloh, M.U. & DiGiuseppe Champion, P.A. 2010. To Catch a Killer. What Can 
Mycobacterial Models Teach Us About Mycobacterium tuberculosis Pathogenesis? 
Current Opinion in Microbiology. 13(1):86–92. DOI: 10.1016/j.mib.2009.11.006. 
Singh, V., Brecik, M., Mukherjee, R., Evans, J.C., Svetlíková, Z., Blaško, J., Surade, 
S., Blackburn, J., et al. 2015. The Complex Mechanism of Antimycobacterial Action 
of 5-fluorouracil. Chemistry and Biology. 22(1):63–75. DOI: 
10.1016/j.chembiol.2014.11.006. 
Smith, A.D., Warren, M.J. & Refsum, H. 2018. Vitamin B12. Advances in Food and 
Nutrition Research. 83:215–279. DOI: 10.1016/bs.afnr.2017.11.005. 
Snapper, S.B., Melton, R.E., Mustafa, S., Kieser, T. & Jr, W.R.J. 1990. Isolation and 
Characterization of Efficient Plasmid Transformation Mutants of Mycobacterium 
smegmatis. Molecular Microbiology. 4(11):1911–1919. DOI: 10.1111/j.1365-
2958.1990.tb02040.x. 
van Soolingen, D., Hoogenboezem, T., De Haas, P.E.W., Hermans, P.W.M., Koedam, 
M.A., Teppema, K.S., Brennan, P.J., Besra, G.S., et al. 1997. A Novel Pathogenic 
Taxon of the Mycobacterium tuberculosis Complex, Canetti: Characterization of an 
Exceptional Isolate from Africa. International Journal of Systematic Bacteriology. 
47(4):1236–1245. DOI: 10.1099/00207713-47-4-1236. 
Soulière, M.F., Haller, A., Santner, T. & Micura, R. 2013. New Insights into Gene 
Regulation – High-Resolution Structures of Cobalamin Riboswitches. Angewandte 
Chemie – International Edition. 52(7):1874–1877. DOI: 10.1002/anie.201208167. 
 154 
 
Springer, B., Bottger, E.C., Kirschner, P. & Richard J. Wallace, J. 1995. Phylogeny of 
the Mycobacterium chelonae-Like Organism Based on Partial Sequencing of the 16S 
rRNA Gene and Proposal of Mycobacterium mucogenicum sp. nov. International 
Journal of Systematic Bacteriology. 45(2):262–267. 
Srivastava, S., Ernst, J.D. & Desvignes, L. 2014. Beyond Macrophages: The Diversity 
of Mononuclear Cells in Tuberculosis. Immunological Reviews. 262(1):179–192. DOI: 
10.1111/imr.12217. 
Sun, J., Siroy, A., Lokareddy, R.K., Speer, A., Doornbos, K.S., Cingolani, P. & 
Niederweis, M. 2015. The Tuberculosis Necrotizing Toxin Kills Macrophages by 
Hydrolyzing NAD. Nature Structural & Molecular Biology. 22(9):672–678. DOI: 
10.1038/nsmb.3064. 
Supply, P. & Brosch, R. 2017. The Biology and Epidemiology of Mycobacterium 
canettii. In: Advances in Experimental Medicine and Biology. V. 1019. S. Gagneux, 
Ed. Springer International Publishing. 27–41. DOI: 10.1007/978-3-319-64371-7. 
Supply, P., Marceau, M., Mangenot, S., Roche, D., Rouanet, C., Khanna, V., Majlessi, 
L., Criscuolo, A., et al. 2013. Genomic Analysis of Smooth Tubercle Bacilli Provides 
Insights into Ancestry and Pathoadaptation of Mycobacterium tuberculosis. Nature 
Genetics. 45(2):172–179. DOI: 10.1038/ng.2517. 
Tailleux, L., Waddell, S.J., Pelizzola, M., Mortellaro, A., Withers, M., Tanne, A., 
Castagnoli, P.R., Gicquel, B., et al. 2008. Probing Host Pathogen Cross-talk by 
Transcriptional Profiling of Both Mycobacterium tuberculosis and Infected Human 
Dendritic Cells and Macrophages. PloS One. 3(1):e1403. DOI: 
10.1371/journal.pone.0001403. 
Thanbichler, M., Neuhierl, B. & Böck, A. 1999. S-Methylmethionine Metabolism in 
Escherichia coli. Journal of Bacteriology. 181(2):662–665. 
Tientcheu, L.D., Koch, A., Ndengane, M., Andoseh, G., Kampmann, B. & Wilkinson, 
R.J. 2017. Immunological Consequences of Strain Variation Within the 
Mycobacterium tuberculosis Complex. European Journal of Immunology. 47(3):432–
445. DOI: 10.1002/eji.201646562. 
Turner, R.D., Chiu, C., Churchyard, G.J., Esmail, H., Lewinsohn, D.M., Gandhi, N.R. 
& Fennelly, K.P. 2017. Tuberculosis Infectiousness and Host Susceptibility. Journal 
of Infectious Diseases. 216(suppl_6):S636–S643. DOI: 10.1093/infdis/jix361. 
Ubhi, D.K. & Robertus, J.D. 2015. The Cobalamin-independent Methionine Synthase 
Enzyme Captured in a Substrate-induced Closed Conformation. Journal of Molecular 
Biology. 427(4):901–909. DOI: 10.1016/j.jmb.2014.12.014. 
Ubhi, D., Kago, G., Monzingo, A.F. & Robertus, J.D. 2014. Structural Analysis of a 
Fungal Methionine Synthase with Substrates and Inhibitors. Journal of Molecular 
Biology. 426(8):1839–1847. DOI: 10.1016/j.jmb.2014.02.006. 
 155 
 
Upton, A.M. & McKinney, J.D. 2007. Role of the Methylcitrate Cycle in Propionate 
Metabolism and Detoxification in Mycobacterium smegmatis. Microbiology. 
153(12):3973–3982. DOI: 10.1099/mic.0.2007/011726-0. 
Uribe-Querol, E. & Rosales, C. 2017. Control of Phagocytosis by Microbial 
Pathogens. Frontiers in Immunology. 8(1368). DOI: 10.3389/fimmu.2017.01368. 
Vanderven, B.C., Huang, L.U., Rohde, K.H. & Russell, D.G. 2016. The Minimal Unit 
of Infection: Mycobacterium tuberculosis in the Macrophage. Microbiology Spectrum. 
4(6):1–18. DOI: 10.1128/microbiolspec.TBTB2-0025-2016. 
Vasava, M.S., Bhoi, M.N., Rathwa, S.K., Borad, M.A., Nair, S.G. & Patel, H.D. 2017. 
Drug Development Against Tuberculosis: Past, Present and Future. Indian Journal of 
Tuberculosis. 64(4):252–275. DOI: 10.1016/j.ijtb.2017.03.002. 
Vergne, I., Chua, J., Lee, H.-H., Lucas, M., Belisle, J. & Deretic, V. 2005. Mechanism 
of Phagolysosome Biogenesis Block by Viable Mycobacterium tuberculosis. 
Proceedings of the National Academy of Sciences. 102(11):4033–4038. DOI: 
10.1073/pnas.0409716102. 
Vitreschak, A.G., Rodionov, D.A., Mironov, A.A. & Gelfand, M.S. 2003. Regulation 
of the Vitamin B12 Metabolism and Transport in Bacteria by a Conserved RNA 
Structural Element. RNA. 9:1084–1097. DOI: 10.1261/rna.5710303.conserved. 
Vordermeier, H.M., Hewinson, R.G., Wilkinson, R.J., Wilkinson, K.A., Gideon, H.P., 
Young, D.B. & Sampson, S.L. 2012. Conserved Immune Recognition Hierarchy of 
Mycobacterial PE/PPE Proteins During Infection in Natural Hosts. PLoS One. 7(8). 
DOI: 10.1371/journal.pone.0040890. 
Voss, G., Casimiro, D., Neyrolles, O., Williams, A., Kaufmann, S.H.E., McShane, H., 
Hatherill, M. & Fletcher, H.A. 2018. Progress and Challenges in TB Vaccine 
Development. F1000Research. 7(Mvi):199. DOI: 10.12688/f1000research.13588.1. 
Warner, D.F., Savvi, S., Mizrahi, V. & Dawes, S.S. 2007. A Riboswitch Regulates 
Expression of the Coenzyme B12-independent Methionine Synthase in Mycobacterium 
tuberculosis: Implications for Differential Methionine Synthase Function in Strains 
H37Rv and CDC1551. Journal of Bacteriology. 189(9):3655–3659. DOI: 
10.1128/JB.00040-07. 
Warren, M.J., Raux, E., Schubert, H.L. & Escalante-Semerena, J.C. 2002. The 
Biosynthesis of Adenosylcobalamin (vitamin B12). Natural Product Reports. 19:390–
412. DOI: 10.1039/b108967f. 
Weerdenburg, E.M., Abdallah, A.M., Rangkuti, F., El Ghany, M.A., Otto, T.D., 
Adroub, S.A., Molenaar, D., Ummels, R., et al. 2015. Genome-wide Transposon 
Mutagenesis Indicates That Mycobacterium marinum Customizes Its Virulence 
Mechanisms for Survival and Replication in Different Hosts. Infection and Immunity. 
83(5):1778–1788. DOI: 10.1128/IAI.03050-14. 
 156 
 
Weissbach, H., Ladd, J. N., Volcani, B. E., Smyth, R. D., Barker, H. A. 1960. Structure 
of the Adenylcobamide Coenzyme: Degradation by Cyanide, Acid, and Light. The 
Journal of Biological Chemistry. 235(5): 1462-1473 
de Wet, T.J., Gobe, I., Mhlanga, M.M. & Warner, D.F. 2018. CRISPRi-Seq for 
Improved Identification, Targeting and Phenotyping of Essential Mycobacterial 
Genes. bioRxiv 358275. DOI: https://doi.org/10.1101/358275. 
Wheatley, R.W., Ng, K.K.S. & Kapoor, M. 2016. Fungal Cobalamin-independent 
Methionine Synthase: Insights from the Model Organism, Neurospora crassa. 
Archives of Biochemistry and Biophysics. 590:125–137. DOI: 
10.1016/j.abb.2015.11.037. 
WHO Tuberculosis Programme. 1994. WHO Tuberculosis Programme: Framework 
for Effective Tuberculosis Control. Geneva. Available: 
http://www.who.int/iris/handle/10665/58717.  
Wirth, T., Hildebrand, F., Allix-Béguec, C., Wölbeling, F., Kubica, T., Kremer, K., 
Van Soolingen, D., Rüsch-Gerdes, S., et al. 2008. Origin Spread and Demography of 
the Mycobacterium tuberculosis Complex. PLoS Pathogens. 4(9). DOI: 
10.1371/journal.ppat.1000160. 
Woodson, J. D., Escalante-Semerena, J. C. 2003. CbiZ, an amidohydrolase enzyme 
required for salvaging the coenzyme B12 precursor cobinamide in archaea. 
Proceedings of the National Academy of Sciences. 101(10): 3591-3596. DOI: 
10.1073/pnas.0305939101 
World Health Organization. 2018. Global tuberculosis report 2018. Geneva. 
Available: http://www.who.int/iris/handle/10665/274453. 
Ying, J., Wang, H., Bao, B., Zhang, Y., Zhang, J., Zhang, C., Li, A., Lu, J., et al. 2015. 
Molecular Variation and Horizontal Gene Transfer of the Homocysteine 
Methyltransferase Gene mmuM and its Distribution in Clinical Pathogens. 
International Journal of Biological Sciences. 11(1):11–21. DOI: 10.7150/ijbs.10320. 
Young, D.B., Comas, I. & de Carvalho, L.P.S. 2015. Phylogenetic Analysis of Vitamin 
B12-related Metabolism in Mycobacterium tuberculosis. Frontiers in Molecular 
Biosciences. 2(6):1–14. DOI: 10.3389/fmolb.2015.00006. 
Zhang, Y., Rodionov, D.A., Gelfand, M.S. & Gladyshev, V.N. 2009. Comparative 
Genomic Analyses of Nickel, Cobalt and Vitamin B12 Utilization. BMC Genomics. 
10:78. DOI: 10.1186/1471-2164-10-78. 
Zignol, M., Cabibbe, A.M., Dean, A.S., Glaziou, P., Alikhanova, N., Ama, C., Andres, 
S., Barbova, A., et al. 2018. Genetic Sequencing for Surveillance of Drug Resistance 
in Tuberculosis in Highly Endemic Countries: A Multi-Country Population-Based 
Surveillance Study. The Lancet Infectious Diseases. 18(6):675–683. DOI: 
10.1016/S1473-3099(18)30073-2. 
 157 
 
Zumbo, A., Palucci, I., Cascioferro, A., Sali, M., Ventura, M., D’Alfonso, P., 
Iantomasi, R., Di Sante, G., et al. 2013. Functional Dissection of Protein Domains 
Involved in the Immunomodulatory Properties of PE_PGRS33 of Mycobacterium 
tuberculosis. Pathogens and Disease. 69(3):232–239. DOI: 10.1111/2049-
632X.12096. 
